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Leucine modulates the effects of the Walker tumour’s proteolysis-
inducing factor on gene expression and cells activity in C2C12
myotubes
Estela M. Gonçalves, Emilianne M. Salomão, Maria Cristina C. Gomes-
Marcondes (Nutrition and Cancer Laboratory, Department of Physiology
and Biophysics, IB, UNICAMP, Campinas, SP, Brazil)
Cancer cachexia involves a severe weight lost, particularly from waste of
skeletal muscle, which can arise from the increase on protein catabolism
and/or the decrease on protein synthesis. The protein degradation in
skeletal muscle of cancer patients is mediated by the cytokine proteolysis-
inducing factor (PIF), produced by tumour, which increases the expression
of the ubiquitin–proteasome pathway, and the skeletal muscle protein
synthesis in these patients can be affected by several agents, including
nutrient signalling. Some nutrients, such as branched-chain amino acid
leucine, can decrease the expression of the ubiquitin–proteasome pathway
and improve the protein content in skeletal muscle of cachectic animals. In
this study, we investigated the effects of leucine on cell viability,
morphology, functional proteasome activity, enzymatic activities, and
protein synthesis and degradation in C2C12 skeletal muscle cells exposed
to the PIF-like protein, purified from the Walker tumour-bearing rat. The
Walker factor (WF), immunologically identical to PIF and with the same
molecular weight, presented no cytotoxic effect in myotube cells, which
had no alterations in their morphological characteristics in the presence of
WF and/or leucine. However, increased phosphatase alkaline activity was
observed, especially at low WF concentrations. At higher WF concen-
trations, chymotrypsin-like activity and also the 20S proteasome gene
expression were increased, as well as the cathepsin B activity trended to
increase. Adding leucine previously to WF-treated myotubes cells,
proteasome activity decreased and phosphatase alkaline activity increased.
Total protein synthesis was decreased in WF-treated cells in parallel to
increase in protein degradation. These changes were minimized or reverted
after leucine exposure. Taken together, these results suggested an important
modulatory effect of leucine under the WF actions in C2C12 myotube cells.
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Habitual skeletal muscle protein fractional synthetic rate in healthy
individuals as determined by a novel oral tracer technique
Alisdair J. MacDonald
1, Carolyn A. Greig
2, Holger Husi
1, Nathan A.
Stephens
1, Jim Ross
1, Alexandra C. Small
3, Kenneth C.H. Fearon
1,T o m
Preston
3 (
1Tissue Injury and Repair Group, University of Edinburgh,
Edinburgh, UK;
2Department of Clinical and Surgical Sciences, University
of Edinburgh, Edinburgh, UK;
3Stable Isotope Biochemistry Laboratory,
Scottish Universities Environmental Research Centre, East Kilbride, UK)
Background/aims: Using current methodology skeletal muscle fractional
synthetic rate (FSR) is measured over short time periods in response to
specific stimuli (e.g. feeding/exercise) resulting in wide variation in FSRs.
In clinical studies, interventions occur over weeks or months and measures
over longer periods may be more representative. We aimed to develop a
novel method to determine skeletal muscle protein FSR to estimate
habitual FSR in healthy individuals, over timescales comparable with
clinical interventions, avoiding intravenous amino acid tracer.
Method: Four healthy males, median (range) age: 37 years (32–52), height
179 cm (177–185), weight 80 kg (71–87) were given 100 g water enriched
to 70 atom% with 2H2O as a single oral bolus. Vastus lateralis biopsies
were performed using a Bergstrom needle at intervals 4–12 days post-dose.
Serum was collected at baseline and three time-points between 3 and
14 days, measuring body water enrichment and analysis of plasma alanine
enrichment (GC–pyrolysis–IRMS). Myofibrillar protein was isolated, acid
hydrolysed and 2H-alanine enrichment measured. Skeletal muscle protein
FSR was calculated (% day−1) both using free 2H-alanine and body water
to predict precursor enrichment.
Results: Body water 2H increased to 1520 ppm excess (1,435–1,582).
Elimination half time was 8 days (7–10). The r2 for the natural log of 2H
enrichment against time was >0.999 in each individual. Plasma alanine
was labelled in a predictable manner (in theory, four atoms become
labelled; 3.1–4.2 were measured). Skeletal muscle FSR was calculated
from six biopsies in four individuals as 1.18% day−1 (0.94–1.59). For the
two individuals with two biopsies each at different times, the differences in
estimates of FSR were 14.3% and 20%.
Conclusions: This is the first study to describe skeletal muscle protein FSR
in free-living healthy individuals over 4–12 days. Using a single oral
2H2O bolus, endogenous labelling of alanine occurs in a predictable
manner giving estimates of FSR comparable with published values.
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Environmental conditions in musclet i s s u ec u l t u r ea l t e rr e s p o n s e s
to atrophy signals
Elodie Archer-Lahlou
1, Cathy Lan
1, Robert T. Jagoe
2 (
1Segal Cancer
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Hospital, Montreal, Quebec, Canada,
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J Cachexia Sarcopenia Muscle (2011) 2:209–261
DOI 10.1007/s13539-011-0045-3Muscle atrophy is a powerful determinant of poor prognosis, impaired
physical function, and debility in all chronic diseases, including cancer.
Laboratory models of muscle wasting have suggested a number of different
mechanisms which can contribute to cancer-related muscle atrophy.
However, paradoxically, very little progress has been made in developing
therapies which are clinically effective in treating muscle wasting in cancer
patients. Muscle tissue culture still has huge potential to help develop new
treatments but the factors which have impeded the effective translation of
basic research into clinical treatments need to be identified and addressed.
For this reason, we studied the effects of using tissue culture conditions
that reproduce the in vivo physiological environment of muscles. We first
established two highly defined and reproducible muscle tissue culture
systems using C2C12 myotubes under standard and modified conditions.
These modified conditions have been chosen to attempt to mimic certain
key aspects of the in vivo environment experienced by muscle in cancer
patients, on the assumption that this may promote more representative
adaptive responses. We then assessed whether such modified conditions
alter the responses of mature myotubes to distinct atrophy-inducing
treatments. After 3 days of treatment, we observed a 20–30% reduction
in protein and myotube diameter but a 46% increase in myotube number in
modified conditions compared to standard culture conditions. Only small
differences in most atrophy-related gene expression or protein levels for
markers of muscle growth and phenotype were observed but modified
conditions did induce a 70% reduction in IGF-1 mRNA levels. However,
surprisingly, the modified culture conditions offered partial or complete
protection against further atrophy due to added atrophy-inducing treat-
ments. This protection was observed despite similar changes in the
transcript levels of selected atrophy-related genes. These studies confirm
the potential for environmental conditions to modulate muscle responses to
atrophy-inducing conditions in vivo.
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During early recovery the worsening of immobilization-induced rat
tibialis anterior muscle atrophy is associated with sustained activation
of proteolytic and apoptotic pathways
LamiaSlimani
1,2, Anabelle Dubost
2,B r u n oM e u n i e r
2, Dominique Dardevet
1,
Anne Listrat
2,L y d i eC o m b a r e t
1, Didier Attaix
1 (
1Clermont Université,
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Clermont-Ferrand;
2INRA, UMR 1213, URH, F-63122 Saint Genès
Champanelle)
Background and aims: Muscle atrophy induced by immobilization
stabilized in the shortened gastrocnemius muscle (GA), but worsened in
the lengthened tibialis anterior muscle (TA) after 10 days of recovery.
Thus, important remodeling within the TA following immobilization could
condition the initial steps of recovery and may depend on the position of
immobilization. The ubiquitin–proteasome system (UPS) and the
mitochondria-associated apoptosis being involved in GA atrophy their
role in muscle remodeling were studied during the very early stages of
recovery in both the TA and GA.
Methods: Adult rats were subjected to unilateral hindlimb immobiliza-
tion and the contralateral non-immobilized leg served as the control.
After 8 days of immobilization (I8), casts were removed and animals
were allowed to recover for 1 (R1) to 10 (R10) days. UPS-dependent
proteolysis and apoptosis were evaluated in both the TA and GA.
Results: Muscle atrophy rapidly worsened after cast removal as soon as R1
and up to R6 in the TA previously immobilized, but stabilized in the GA
from R1. In addition, a more pronounced and sustained activation of
proteasome and apoptosome activities prevailed in the immobilized TA
from I8 until R10, but was normalized at R6 in the previously immobilized
GA.
Conclusions: Altogether, the data suggest that UPS-dependent proteolysis
and mitochondria-associated apoptosis are involved in the muscle
remodeling during recovery and may be responsible for the worsening
of muscle atrophy observed in the TA. Alterations of connective tissue
being differentially altered upon stretching during immobilization
(Mattiello-Sverzut et al. Histol Histopathol 2006; 21:957–964), we
hypothesized that this may impact muscle proteolytic signaling
pathways.
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Msy-3/Csda coordinatesrepression of myogenic genes in muscle
wasting
Alessandra Feraco
1, Georgi Marinov
3, Luciana De Angelis
2, Elisabetta
Ferraro
1,G i l b e r t oH e r n a n d e z
3, Barbara J. Wold
3, Libera Berghella
1
(
1IRCCS San RaffaelePisana Institute, Roma, Italy;
2University La
Sapienza, Dept. of Hystology and Medical Embryology, Roma, Italy;
3California Institute of Technology, Pasadena, USA)
Background and aims: The Y-box protein MSY-3/Csda regulates
postnatal repression of the myogenic transcription factor myogenin.
In postnatal muscle, myogenin plays a key role in regulating pathways
involved in muscle maturation, degeneration and eventually cachexia.
MSY-3 binds a highly conserved DNA cis-acting element located
upstream of the myogenin promoter. We wanted to find other possible
targets of MSY-3 regulated in concert during muscle maturation and
atrophy.
Methods: ByChIP assay, we analyzed MSY3/Csda binding in vivo in
adult muscle and in C2C12. We tested the MSY-3/MyoD conserved
site transcriptional activity by luciferase assay and in vivo electro-
poration. By high-throughput technology, we genome-wide analyzed
MSY-3 DNA binding in adult muscle and expression profile of wt and
MSY-3 knockout mice and denervated muscle.
Results: We found a conserved regulative cis-element in the MyoD locus,
that matches with the myogenincis-motif and by ChIP assays we verified
that both MyoD and MSY-3/Csda bind to it in vivo. Luciferase assays
show that the MYOD site, is sufficient for high levels of expression in
C2C12 and MSY-3 acts as a repressor. In vivo muscle electroporation
demonstrates that the MYOD site is required for MyoD postnatal
repression. Furthermore, in combined genome-wide analysis of MSY-3
DNA binding and global RNA expression, we found other candidate genes
possibly repressed by MSY-3 during adult muscle maturation, as well as
myogenin, MYOD, AChRs and HDAC4.
Conclusions: This study suggests that both MyoD and myogenin are
controlled by the same repressor complex (MSY-3/Csda), recognizable by
a similar cis-motif. This motif is responsible for MYOD auto activation/
maintenance during muscle differentiation and its repression MSY-3-
mediated in postnatal muscle, suggesting a developmental stage depending
competition for the two transcription factors at the same site. This strongly
suggests that MSY-3 regulates in concert MYOD and myogenin
expression. Moreover, the genome-wide analysis highlights a group of
genes possibly modulated by the same regulatory complex during muscle
maturation and degeneration. These findings indicate MSY3/Csda as a
potential target for muscle wasting caused by neurogenic atrophy,
sarcopenia, and cachexia.
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Resveratrol blocks glucocorticoid-induced muscle wasting in L6
cultured myotubes through a SIRT1-dependent mechanism
Nima Alamdari, Zaira Aversa, Estibaliz Castillero, Aniket Gurav, Sreven
Tizio, Per-Olof Hasselgren (Department of Surgery, Beth Israel Deaconess
Medical Center, Harvard Medical School, Boston, MA, USA)
210 J Cachexia Sarcopenia Muscle (2011) 2:209–261Background and aims: Muscle proteolysis during sepsis and other catabolic
conditions is, at least in part, regulated by glucocorticoids. Dexamethasone-
treated myotubes are a commonly used in vitro model of muscle wasting. We
reportedrecentlythatdecreasedexpressionandactivityofhistonedeacetylases
(HDACs) including sirtuin (SIRT) 1 are involved in the development of
muscle wasting. Here, we tested the hypothesis that treatment with the SIRT1
activator resveratrol would prevent glucocorticoid-induced protein degrada-
tion and muscle atrophy, and that glucocorticoid-induced expression of
atrogin-1 and MuRF1 is, at least in part, regulated by SIRT1.
Methods: L6 myotubes were treated for 24 h with 1 μM dexamethasone in
the absence or presence of resveratrol (100 μM). After treatment for 24 h,
myotubes were harvested for determination of atrogin-1 and MuRF1
mRNA and protein levels, protein degradation, and myotube diameter. In
additional experiments, the effects of resveratrol treatment were tested in
myotubes transfected with non-targeting or SIRT1 siRNA.
Results: Treatment with dexamethasone increased atrogin-1 and
MuRF1 expression and protein degradation and reduced myotube
diameter. Resveratrol treatment inhibited the dexamethasone-induced
increase in atrogin-1 and MuRF1 expression and protein degradation
as well as the reduction in myotube size. SIRT1 siRNA abolished the
effect of resveratrol on atrogin-1 and MuRF1 expression.
Conclusions: Results suggest that resveratrol treatment may prevent
glucocorticoid-induced muscle wasting through a SIRT1-dependant mech-
anism. SIRT1 activation may be a novel therapeutic approach in combating
muscle wasting conditions. Supported by R01 DK37908 from the NIH.
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Decreased NADPH oxidase expression and antioxidant activity
in cachectic skeletal muscle
Melanie J. Sullivan-Gunn, Paul A. Lewandowski (Deakin University,
Medical School, Geelong, Australia)
Background: Cancer cachexia is the progressive loss of skeletal
muscle protein that contributes significantly to cancer morbidity and
mortality. Evidence of antioxidant attenuation and the presence of
oxidised proteins in patients with cancer cachexia indicate a role for
oxidative stress. This study aimed to investigate the superoxide
generating NADPH oxidase (NOX) enzyme and antioxidant enzyme
systems in murine adenocarcinoma tumour-bearing cachectic mice.
Method: Superoxide levels, mRNA levels of NOX enzyme subunits, and the
antioxidantenzymesweremeasuredintheskeletalmuscleofmicewithcancer
and cancer cachexia. Protein expression levels of NOX enzyme subunits and
antioxidant enzyme activity were also measured in these samples.
Results: Superoxide levels increased 1.4-fold in the muscle of mice with
cancer cachexia, and this was associated with a decrease in mRNA of NOX
enzyme subunits, NOX2, p40phox, and p67phox along with the antioxidant
enzymes SOD1, SOD2, and GPx. Cancer cachexia was also associated with a
1.3-fold decrease in SOD1 and 2.0-fold decrease in GPx enzyme activity.
Conclusion: Despiteincreasedsuperoxide levelsincachecticskeletalmuscle,
NOX enzyme subunits, NOX2, p40phox, and p67phox, were downregulated
along with the expression and activity of the antioxidant enzymes. Therefore,
the increased superoxide levels in cachectic skeletal muscle may be attributed
to the reduction in the activity of endogenous antioxidant enzymes.
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Differential adaptation of glycolytic and oxidative muscle to hypoxia
Chiel C. de Theije
1, Ramon C.J. Langen
2, Eleonore S. Kohler
1, Wouter H.
Lamers
1, Annemie M. W. J. Schols
2 (
1Department of Anatomy &
Embryology, NUTRIM, Maastricht University, Maastricht, The Netherlands;
2Department of Respiratory Medicine, NUTRIM, Maastricht University,
Maastricht, The Netherlands)
Background: Hypoxia may be a trigger of skeletal muscle atrophy in
acute and chronic respiratory disease. In chronic obstructive pulmo-
nary disease patients, muscle fiber atrophy is most pronounced in
glycolytic compared to oxidative muscle fibers. Therefore, we
hypothesized that hypoxia preferentially affects glycolytic muscles.
Methods: Mice were maintained under normoxia or hypoxia. During
48 h, oxygen levels were reduced stepwise to 8%, which was
maintained for 21 days. Food intake was monitored daily and mice
were sacrificed at days 4 and 21.
Results: Pair-feeding experiments revealed that the reduction in
oxidative (Soleus) muscle weight was solely attributable to hypoxia-
induced reduced food intake (hypophagia), whereas hypoxia caused a
greater decrease of the glycolytic muscle weight, which was not
accounted for by hypophagia. Furthermore, cross-sectional area (CSA)
of the individual fibers revealed reduced CSA in glycolytic muscle,
whereas no reduction was seen in the oxidative muscle. Expression
levels of genes involved in proteasomal protein degradation (Atrogin-
1), lysosomal protein degradation (Lc3B, Atg5), endoplasmic reticu-
lum (ER) stress signaling (Atf4 and Gadd34), and glucocorticoid
receptor (GR) signaling (Glul and GR) were increased by hypoxia in
both muscles. Interestingly, only in glycolytic muscle, the upregulation
involved a hypoxia-specific component and was not merely explained by
hypophagia. Furthermore, capillary contacts per muscle fiber CSA,
increased in both muscles in response to hypoxia. In the oxidative
muscle, this was the result of a reduction in interstitial space, whereas
this adaptation was accounted for by decreased fiber CSA in the
glycolytic muscle.
Conclusions: Muscle mass, proteolysis, ER stress, and GR signaling in
the glycolytic muscle are more affected than in the oxidative muscle by
hypoxia. In addition, in oxidative, but not in the glycolytic muscle,
these alterations are accounted for by hypophagia, indicative of an
intrinsic sensitivity of glycolytic muscle to hypoxia, which may involve
a differential adaptive capacity of the vascular bed.
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The incidence of sarcopenia and its effects on body composition,
physiological function, nutrition, and fatigue in patients before
allogeneic hematopoietic stem cell transplantation
Shinichiro Morishita
1,K a t s u j iK a i d a
2, Shinya Yamauchi
1, Tatsushi
Wakasugi
1, Kazuhiro Ikegame
2, Norihiko Kodama
3, Hiroyasu Ogawa
2,
Kazuhisa Domen
3 (
1Department of Rehabilitation, Hyogo College of
Medicine Hospital, Nishinomiya, Hyōgo, Japan;
2Division of Hematology,
Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya,
Hyōgo, Japan;
3Department of Rehabilitation Medicine, Hyogo College of
Medicine, Nishinomiya, Hyōgo, Japan)
Background and aims: Cachexia in patients with haematological
malignancies is often related to sarcopenia. We believe that allogeneic
hematopoietic stem cell transplant (allo-hematopoietic stem cell
transplantation (HSCT)) patients are often stricken by sarcopenia prior
to transplantation. The aim of this study is to investigate the incidence
of sarcopenia and the relationship of sarcopenia with body composi-
tion and physiological function, nutrition, and fatigue in patients
before allo-HSCT.
Methods: Study participants included patients who had undergone
allo-HSCT from May 2007 to July 2011. One hundred and sixty-four
patients were included in this study (median 50 years). Body
composition was evaluated using bioelectrical impedance analysis.
Evidence of sarcopenia was calculated using the male (<8.87 kg of
skeletal muscle mass/m
2) and female (<6.42 kg of skeletal muscle mass/
m
2). Physiological functions were evaluated by handgrip, knee extensor
strength, and 6-min walk test (6MWT).
J Cachexia Sarcopenia Muscle (2011) 2:209–261 211Results: Eighty-three patients (50.6%) enrolled in our study had sarcopenia
prior to allo-HSCT. Lean body mass (LBM) strongly correlated with handgrip
and knee extensor strength (r=0.72∼0.75, p<0.01) and weakly correlated
with 6MWT (r=0.34, p<0.01). Body weight and fat body mass correlated
with fatigue (r=−0.15 and r=−0.2, respectively, p<0.05). Patients with
sarcopenia experienced decreased muscular strength and increased fatigue
compared with patients without sarcopenia (handgrip=−12%, knee extensor
strength=−12%, fatigue=+22%, p<0.05).
Conclusion: Sarcopenia has been reported to occur at a rate of 5% (2 SD)
in the elderly. In this study, roughly half of the patients had sarcopenia
before allo-HSCT. Therefore, patients may have decreased muscle mass
prior to allo-HSCT. In the evaluation of body composition, we discovered
that muscle strength and LBM showed a high correlation. Patients with
sarcopenia also have decreased muscle strength due to muscle atrophy and
we believe that this causes increased fatigue in these patients.
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Oleic acid accelerates myogenic differentiation through modulation
of Notch and beta-catenin pathways in muscle stem cells
Carlos Hermano J. Pinheiro, Kaio F. Vitzel, Renato T. Nachbar, Hilton K.
Takahashi, Marco Aurélio R. Vinolo, Haroldo Fujiwara, Rui Curi
(Department of Physiology and Biophysics, Institute of Biomedical
Sciences, University of São Paulo, São Paulo, Brazil)
Background and aims: Marked changes in fatty acid composition occur
during myogenic differentiation of muscle stem cells. In the present study, we
demonstrated an increase in content of unsaturated fatty acids (as oleic acid)
and delta-9-desaturase activity suggesting synthesis of oleic acid during
myogenesis. The effects of oleic acid in muscle stem cell proliferation and
myogenesis were investigated.
Methods: The effect of oleic acid in muscle stem cell proliferation
was evaluated by 14C-thymidine incorporation. The content of
markers of notch and beta-catenin pathways in undifferentiated muscle
stem cells and expression of myogenic regulator factors (MyoD,
myogenin, and myf-6) in differentiating myotubes were evaluated by
western blotting.
Results: The addition of oleic acid to myogenic differentiation medium led
to an increase in myoblast fusion, myotube diameter, and length and in
expression of MyoD, myogenin, and myf-6. At 8 days of culture in
myogenic differentiation medium, increased diameter of skeletal muscle
cells and content of myosin heavy chain were also observed due to oleic
acid addition. The treatment of undifferentiated muscle stem cells with
oleic acid decreased expression of HES-1 and cell proliferation and raised
p38-MAPkinase phosphorylation, NF-kappaB activity, and the content of
phospho(Ser9)-GSK3beta and beta-catenin.
Conclusion: These results support the proposition that oleic acid accelerates
myogenesis by mechanism associated to increased p38-MAPkinase/NF-
kappaB pathway, beta-catenin stabilization, and decrease in Notch signaling.
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Oleic acid accelerates myogenic differentiation through modulation
of Notch and alpha-catenin pathways in muscle stem cells
Carlos Hermano J. Pinheiro, Kaio F. Vitzel, Renato T. Nachbar, Hilton K.
Takahashi, Marco Aurélio R. Vinolo, Haroldo Fujiwara, Rui Curi
(Department of Physiology and Biophysics, Institute of Biomedical
Sciences, University of São Paulo, São Paulo, Brazil)
Marked changes in fatty acid composition occur during myogenic
differentiation of muscle stem cells. Increased content of unsaturated fatty
acids (as oleic acid) and delta-9-desaturase activity were observed
suggesting synthesis of oleic acid during myogenesis. The addition of
oleic acid to myogenic differentiation medium led to an increase in
myoblast fusion, myotube diameter, and length and expression of
myogenic regulator factors (MyoD, myogenin and myf-6). At 8 days of
culture in myogenic differentiation medium, increased diameter of skeletal
muscle cells and content of myosin heavy chain were also observed due to
oleic acid addition. The treatment of undifferentiated muscle stem cells
with oleic acid decreased expression of HES-1 and cell proliferation and
raised p38-MAPkinase phosphorylation, NF-kappaB activity and the
content of phospho(Ser9)-GSK3beta and alpha-catenin. These results
support the proposition that oleic acid accelerates myogenesis by
mechanism associated to increased p38-MAPkinase/NF-kappaB pathway,
alpha-catenin stabilization and decrease in Notch signaling.
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Dexamethasone-induced increase in FOXO1 activity and expression
of atrogin-1 and MuRF1 in cultured muscle cells is PPARβ/δ-dependent
Estibaliz Castillero, Zaira Aversa, Nima Alamdari, Aniket Gurav, Per-Olof
Hasselgren (Department of Surgery, Beth Israel Deaconess Medical Center,
Harvard Medical School, Boston, MA, USA)
Background and aims: Muscle wasting during various catabolic
conditions is at least in part mediated by glucocorticoids. Corticosteroids
upregulate FOXO1 activity, expression of atrogin-1 and MuRF1, and
muscle proteolysis. Recent studies suggest that activation of the transcrip-
tion factor PPARβ/δ upregulates the expression and activity of FOXO1
and the expression of atrogin-1 and MuRF1. The role of PPARβ/δ in
glucocorticoid-regulated muscle wasting, however, is not known. We
hypothesized that activation of PPARβ/δ results in increased protein
degradation and muscle atrophy and that glucocorticoid-induced FOXO1
activation, expression of atrogin-1 and MuRF1, and protein degradation
are at least in part regulated by PPARβ/δ.
Methods: Cultured L6 myotubes (a rat skeletal muscle cell line) were treated
for 24 h with the PPARβ/δ agonist GW0742 (0.1 μM) or dexamethasone
(1 μM) in the absence or presence of the PPARβ/δ antagonist GSK0660
(0.1μM) followed by measurement of FOXO1 DNA-binding activity, mRNA
andproteinlevelsforatrogin-1andMuRF1,proteindegradation,andmyotube
diameter. In additional experiments, the effects of dexamethasone were tested
in myotubes transfected with non-targeting or PPARβ/δ siRNA.
Results: Treatment of the myotubes with GW0742 increased FOXO1
DNA-binding activity, atrogin-1 and MuRF1 mRNA and protein
expression, and protein degradation, and reduced myotube diameter.
Dexamethasone stimulated PPARβ/δ and FOXO1 activity, atrogin-1
and MuRF1 expression, and protein degradation, and reduced myotube
diameter. The effects of dexamethasone were blocked by GSK0660 or
PPARβ/δ siRNA.
Conclusions: Results suggest that PPARβ/δ activates the atrophy program
in skeletal muscle and that glucocortiocid-induced muscle wasting is at
least in part regulated by PPARβ/δ. The transcription factor PPARβ/δ may
be a target for the treatment and prevention of muscle wasting.
This work was supported by NIH R01 DK37908 (POH) and by a
postdoctoral fellowship from Gobierno Vasco BFI2010-240 (EC).
1-13
Bed rest-induced muscle wasting is associated with modulation
of myogenic markers
Fabrizio Pin
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1,
Maurizio Muscaritoli
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212 J Cachexia Sarcopenia Muscle (2011) 2:209–261Background/aims: Bed rest is associated with loss of skeletal muscle mass
and strength, mainly due to protein hypercatabolism. In addition, inactivity
has been shown to be associated with inflammation and oxidative stress
that may lead to modulation of transcriptional factors that regulate
myogenesis. In the present study, we investigated the relationship between
prolonged muscle immobilization and gene expression of factors involved
in myogenesis, such as MyoG, MyoD, Myf5 and Pax7.
Methods: Twenty healthy young male volunteers were recruited for a
period of strict bed rest (33 days). All daily activities were performed in
horizontal clinostatic conditions. For each volunteer, three biopsies were
performed in the vastus lateralis muscle; the first, 1 day before bed rest
(control), the second and the third after 7 and 33 days from the
beginning of immobilization, respectively. Muscle biopsies were used to
assess gene expression of MyoG, MyoD, Myf5 and Pax7 by real-time
PCR.
Results: Pax7 and Myf5 expression is reduced of about 20–25% at both
days 7 and 33 of immobilization. As for Myf5, at day 33, there is a
tendency to restore control values. MyoD gene expression increases of
about 50% after 7 days of bed rest, and returns to basal levels at day 33.
Finally, MyoG expression is increased, though not significantly, due to
sample variability, after both 7 and 33 days of immobilization.
Conclusions: Our results show that bed rest-induced muscle wasting is
associated with downregulation of Pax7 and Myf5 mRNA levels. This
could indicate a reduced satellite cell population, resulting either from
enhanced differentiation, as suggested by increased MyoG expression,
or by satellite cell death, due to inflammation and oxidative stress
associated with inactivity. Further studies are in progress to clarify
this point.
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Muscle actin is polyubiquitinated in C2C12 myotubes and human
muscle biopsies and targeted for breakdown by the E3 ligase MuRF1
Cécile Polge
1, Anne-Elisabeth Heng
1, Daniel Béchet
1, Lydie Combaret
1,
Bernard Monsarrat
2, Daniel Taillandier
1, Didier Attaix
1 (
1INRA, UMR
1019, Unité de Nutrition Humaine, CRNH Auvergne, F-63000 Clermont-
Ferrand, France;
2CNRS, Institut de Pharmacologie et de Biologie
Structurale, 205 route de Narbonne, F-31077, Toulouse, France)
Background and aims: Elaborating new strategies to prevent muscle
wasting requires information on the precise mechanisms of the breakdown
of contractile proteins. Experiments were performed (1) to demonstrate that
actin is polyubiquitinated in muscle cells and human biopsies and thus
degraded by the 26S proteasome and (2) to identify the ubiquitin (Ub)
protein ligase E3 responsible for actin recognition and polyubiquitination.
Methods: Chimeric flag-actin was stably transfected in C2C12 myotubes
treated or not with 1 μM dexamethasone (Dex). Poly-Ub conjugates in
C2C12 cells and human muscle biopsies were purified using an affinity
matrix and deubiquitination as described (Ventadour et al. J. Biol. Chem.
2007, 282:5302–9). We used glutathione S-transferase pulldown and
ubiquitination assays to detect MuRF1-actin interaction and MuRF1-
dependent actin polyubiquitination. mRNA levels of E3 ligases were
measured by qRT-PCR analysis in C2C12 myotubes treated or not with
Dex. C2C12 myotubes were transfected with siRNAs to induce MuRF1
knockout.
Results: Chimeric flag-actin was destabilized and polyubiquitinated in
stably transfected and Dex-treated C2C12 myotubes and only proteasome
inhibitors blocked its breakdown. Poly-Ub actin was also detected in
human muscle biopsies from control and cancer patients. An increase in
MAFbx/atrogin1, Trim32 and Ozz mRNAs was observed in Dex-treated
C2C12 cells, while Nedd4, E4b, MuRF1 and MuRF3 mRNAs did not
change significantly. However, MuRF1 protein content increased in Dex
and Dex+MG132 treated C2C12 cells and in muscles from early-stage
cancer patients. Actin was polyubiquitinated by MuRF1 in an in vitro
ubiquitination assay. Accordingly, MuRF1 siRNA stabilized the break-
down of flag-actin.
Conclusions: These data demonstrate that actin is polyubiquitinated in
muscle cells and human biopsies, and that MuRF1 is implicated in
this process. This further supports the need for new strategies
blocking specifically the activation of the UPS and/or MuRF1 in
wasting diseases.
Work supported by the Association Française contre les Myopathies.
1-15
Role of ubiquitin E3 ligases in sarcopenia: towards an integrative
understanding of their roles in muscle wasting
Julius Bogomolovas, Dittmar Labeit, Alexander Gasch, Siegfried Labeit
(Dept. for Integrative Pathophysiology, Medical Faculty Mannheim,
Theordor-Kutzer-Ufer 1–3, Mannheim, Germany)
Background and aims: Progressive loss of sarcomeres, leading
ultimately to a state referred to as sarcopenia, is induced by a variety
of atrophy-inducing signals, including physical inactivity, cytokines
and inflammation, and metabolic disorders. It has been postulated that
the induction of E3-type ubiquitin ligases represents an initial and rate
limiting step in the degradation of muscle proteins, thereby providing
attractive targets for atrophy attenuation.
Methods: Here, we have studied mice that were either deficient for the E3
ligase MuRF1 (MuR1-KO), or that overexpressed MuRF1 under the
control of a CK promoter (MuRF1-CK-TG).
Results: We characterized their responses to a variety of atrophy
inducing stimuli, including denervation, hindlimb suspension, and
injection of TNF-alpha. Our results indicate that inactivation of
MuRF1 leads to potent protection from muscle atrophy, and that
protection occurred preferentially in fast fiber types. Intriguingly, we
also noted a protection of force-bearing bones from demineralization
in MuRF1-KO mice and thus in a context were MuRF1 is not known
to be expressed. Consistent with systemic regulatory effects of MuRF1
during atrophy, we noted metabolic effects on lipid and glucose
oxidation, and circulating amino acid levels.
Conclusions: Future studies are warranted if additional humoral pathways
regulated by MuRF1 may contribute to sarcopenia protection in addition to
the known intra-muscular pathways involved in the degradation of
structural muscle proteins.
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Mice lacking the USP19 deubiquitinating enzyme show less muscle
wasting in response to several catabolic conditions due to suppression
of ubiquitin ligases and autophagic genes and enhanced rates
of protein synthesis
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Background and aims: Although many enzymes involved in ubiquiti-
nation are activated in atrophying muscle, little is known about the
role of deubiquitinating enzymes (DUBs). We previously showed that
the USP19 DUB is induced in various conditions of muscle atrophy
including cancer and that silencing of USP19 in muscle cells increases
expression of myofibrillar proteins. To test the relevance of this in
vivo, we inactivated USP19 in mice and characterized the wasting
response induced by denervation, fasting, and cancer.
J Cachexia Sarcopenia Muscle (2011) 2:209–261 213Methods: USP19 KO or WT mice were subjected to the above
catabolic conditions. Muscle mass, myofiber area, protein synthesis
(flooding dose method), mRNAs encoding ubiquitin ligases MuRF1,
atrogin-1, and autophagy genes Bnip3, Atg4, Gabarap and LC3 were
measured.
Results: USP19 KO mice showed 26–39% less muscle wasting than
WT mice. Myofiber area measurements in the denervation studies
confirmed that this was due to less myofiber atrophy in the KO
mice. In the fed state, fractional rates of muscle protein synthesis
were similar in WT, KO. However, in fasting, fractional synthesis
rates were 260% and 135% higher in the KO in the sarcoplasmic
and myofibrillar fractions respectively. In all conditions, WT, KO
muscle showed levels of expression of MuRF1, Atrogin1 and
autophagy genes that were similar in basal state. However, in the
catabolic states, MuRF1 and Atrogin-1 and some autophagy genes in
the KO were <50% that in WT. This regulation by USP19 appeared to
be muscle intrinsic as silencing of USP19 in muscle cells also
abrogated the increase in MuRF1 induced by dexamethasone.
Conclusions: USP19 is essential for the full catabolic response to
diverse wasting conditions including cancer cachexia. USP19 sup-
presses protein synthesis and enhances protein degradation (ubiquitin
proteasome system and autophagy) suggesting that it acts on an
upstream signalling pathway(s). These results identify USP19 as a
potential drug target in cachexia.
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IL-6 receptor signaling antagonism maintains muscle oxidative
capacity during the progression of cachexia in the ApcMin/mouse: a
role for exercise
James P. White, Suichi Sato, Melissa Puppa, James A. Carson (Applied
Physiology Division, Exercise Science, University of South Carolina,
Columbia, South Carolina, USA)
Background and aims: Cancer cachexia is associated with the loss of
skeletal muscle. Muscle mitochondria function and content have been
suggested to be as key regulators of muscle protein turnover, and we
have demonstrated that muscle oxidative capacity is reduced in severely
cachectic ApcMin/mice. Exercise and anti-cytokine therapies have been
shown to be effective in preventing the progress of cachexia tumor-
bearing mice. However, limited studies have explored the effect of these
therapies on alterations in muscle oxidative capacity. Therefore, the
purpose of this study is to determine regulation of muscle oxidative
capacity during the progression of cachexia and whether IL-6 inhibition
or exercise can preserve muscle mass through the maintenance of
muscle oxidative capacity.
Methods: Three experiments were conducted using ApcMin/mice.
Experiment 1 stratified mice by body weight loss. Experiment 2
administered IL-6 receptor antibody for 2 weeks after the onset of
cachexia. Experiment 3 examined if moderate intensity treadmill
training could attenuate changes induced by systemic IL-6 over-
expression.
Results: Muscle mitochondrial content was not reduced during the onset of
cachexia, while protein expression related to biogenesis and fusion was
repressed. As cachexia progressed, mitochondrial content decreased and
biogenesis- and fusion-related proteins were further repressed, while fission
protein expression increased. IL-6 receptor antibody administration attenuated
mitochondrial content loss, rescued the repression of biogenesis and fusion
proteins, and prevented the induction on fission proteins. Exercise training
prevented the onset of cachexia due to IL-6 over-expression, and was
associated with an increase in mitochondrial biogenesis and fusion protein
expression, while repressing fission protein expression.
Conclusions: The loss of muscle oxidative capacity occurs during late
stages of cachexia, while repressed expression of proteins regulating
mitochondrial biogenesis and dynamics occur early in the development of
cachexia. Attenuation of Il-6 receptor signing or exercise training can
reverse these changes.
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Optimization of macrophage-secreted myogenic factors and promotion
of muscle regrowth
Nicolas Dumont, Jérôme Frenette (Université Laval, CHUL research
center, Quebec, QC, Canada)
Background and aims: Muscle wasting is a common side effect of
many pathologies and conditions such as AIDS, cancers, chronic heart
diseases, aging, prolonged bed rest, space flight, etc. Using an animal
model of hypogravity, we previously showed that regrowth of
atrophied muscles is associated with an inflammatory reaction and
that the presence of macrophages is necessary for an optimal recovery.
A growing body of evidence indicates that macrophages possess
important myogenic capacities raising the question of whether the
activity of macrophages can be optimized to promote muscle repair
and regrowth. The objective of this study was thus to determine the
effect of modulating the concentration and activation of macrophages
on muscle regrowth from atrophy.
Methods: Mice were hindlimb unloaded for a period of 10 days,
which induces a 50% decrease in soleus muscle force and mass,
followed by 3, 7, or 14 days of reloading. At the day of reloading,
mice were injected with macrophage-colony stimulating factor (M-
CSF, 10 μg/ml) or phosphate-buffered saline (PBS) directly into the
right and left soleus muscles, respectively. In addition, we developed an
in vitro co-culture system in which myotubes atrophied by dexametha-
sone (1 μg/ml) were exposed or not to bone marrow-derived macro-
phages (BMDM, 25,000 cells/ml) and/or M-CSF (100 ng/ml).
Results: Compared to PBS injection, M-CSF induces a twofold
increase in macrophage concentration in soleus muscles, which is
associated with a 20% increase in muscle force and a 10% increase in
muscle fiber diameter at day 7 of reloading (p<0.05). In vitro, our data
indicate that contrary to BMDM or M-CSF alone, the combination of
BMDM and M-CSF increased myotube diameters by 20% and decreased
the expression of the catabolic protein MuRF-1 by 25% (p<0.05) relative
to control.
Conclusion: Together, these results suggest that the myogenic capacities of
macrophages can be optimized through M-CSF to promote muscle regrowth.
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SOCS3 overexpression counteracts the IL-6/STAT3 signaling pathway
and improves muscle wasting in experimental cachexia
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Background and aims: Elevated serum interleukin (IL)-6 correlates
with muscle wasting and mortality in both cancer and severe burn
injury. Systemic administration of IL-6 induces wasting, while its
214 J Cachexia Sarcopenia Muscle (2011) 2:209–261inhibition can partially rescue muscle mass. The signaling pathways
responsible for muscle wasting downstream of IL-6 are not completely
known. IL-6 binds to its receptor, thus inducing the recruitment of
gp130 and, in turn, the activation of STAT3. We recently reported that
STAT3 is associated with tumor-induced muscle wasting. Since
SOCS3 is one of the inhibitors of the IL-6/STAT3 signaling, here
we aim at investigating whether SOCS3 can antagonize the IL-6/
STAT3 pathway, thus improving muscle wasting in cancer- and burn-
associated cachexia.
Methods: C2C12 myotubes were used to investigate the IL-6/STAT3
pathway in vitro. MLC-SOCS3 C57BL/6 transgenic mice served to isolate
the effects of SOCS3 on the skeletal muscle. CD2F1 mice were injected
with the Colon-26 (C26) adenocarcinoma to study cancer-associated
cachexia, while C57BL/6 wild-type were burned to evaluate burn-
induced cachexia. SOCS3 was overexpressed by means of in vitro
adenoviral infection or in vivo electroporation.
Results: C2C12 overexpressing Ad-GFP-SOCS3 proved resistant to
IL-6 induced wasting, while SOCS3 alone induced hypertrophy in
control myotubes. Muscle weight was increased in female MLC-
SOCS3 transgenics only, thus suggesting a gender-specific function of
SOCS3. STAT3 nuclear translocation was reduced in gastrocnemius
muscle of MLC-SOCS3 mice, consistent with decreased p-STAT3
levels. Both C26 tumor-bearers and burned mice exhibited reduced
muscle CSA and wasting, associated with increased levels of p-
STAT3. Localized overexpression of SOCS3 in the tibialis muscle
inhibited STAT3 activation and prevented muscle wasting in C26 and
burn cachexia.
Conclusions: These data support the use of SOCS3 manipulation as a
therapeutic approach in cachexia of high IL-6, enhancing both muscle
mass and fiber size. Among the likely targets of SOCS3 activity is
STAT3.
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Serum creatinine is a biomarker of skeletal muscle mass in chronic
hemodialysis patients
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Background: Skeletal muscle mass is a major component of lean body mass
(LBM) and an important nutritional measure in people with chronic kidney
disease including those who undergo maintenance hemodialysis (MHD)
treatment. We hypothesized that serum creatinine concentration in stable
MHD patients with adequate dialysis represents skeletal muscle mass.
Methods:I nt h e“Nutritional and InflammatoryEvaluation in Dialysis” Study
cohort, we examined 725 randomly selected patients receiving MHD at eight
DaVita dialysis clinics in the Los Angeles South Bay area. Near-infrared
interactance (NIR) in all patients and dual energy X-ray absorptiometry
(DEXA) in a subset of randomly selected 118 patients were used as the
reference standards for LBM measurements over a 5-year period. The index
test was 3-month averaged serum concentrations of creatinine (SCr). The
reference test was LBM measured via the difference between body mass and
body fat assessed by NIR in the main cohort and by DEXA in the subcohort.
Results: Both DEXA and NIR measured LBM correlated significantly
with SCr (r=0.65 to 0.71, p<0.001). SCr in women had even stronger
correlation with LBM. Across increments of 10 kg from <40 to >70 kg
LBM, an incremental increase in SCr was observed which can be
expressed by a polynomial equation (r=0.99):
Conclusions: Three-month averaged SCr is a good correlate of LBM, as
determined from DEXA or NIR measured LBM, in MHD patients.
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Total-body creatine pool size and skeletal muscle mass determination
by D3-creatine dilution in rats
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Background and aims: There is currently no direct, facile, and inexpensive
method to determine total-body skeletal muscle mass for the routine diagnosis
and treatment of skeletal muscle wasting conditions such as sarcopenia,
cachexia, and disuse. We sought to validate in rats the hypothesis that the
enrichment of creatinine-(methyl-d3) (D3-creatinine) in a spot urine sample
after a single defined oral tracer dose of D3-creatine can be used to determine
total-body creatine pool size and skeletal muscle mass.
Methods: We determined (a) an oral tracer dose of D3-creatine that
was completely bioavailable with minimal urinary spillage and
sufficient enrichment in the body creatine pool for detection of D3-
creatine in muscle and D3-creatinine in urine, and (b) the time to
isotopic steady state. We then used cross-sectional studies in growing
(9–22 weeks of age) rats to compare creatine pool size determined by
the D3-creatine dilution method to lean body mass determined by
quantitative magnetic resonance.
Results: D3-creatine (1 mg/kg) was 103±14% bioavailable, and the
specific dose used in these studies (0.475 mg/rat) averaged <0.5% urinary
spillage. Isotopic steady state was achieved 24–48 h after giving D3-
creatine. Creatine pool size, calculated from urinary enrichment of D3-
creatinine 72 h after D3-creatine administration, significantly increased
with muscle accrual during rat growth, significantly decreased in response
to dexamethasone-induced skeletal muscle atrophy and was highly
correlated with lean body mass (r=0.9517; p<0.0001). Enrichment of
D3-creatine in muscle was greater in muscle with predominantly oxidative
Lean body mass (kg) <40 (n=97) 40 to <50 (n=226) 50 to <60 (n=234) 60 to <70 (n=115) ≥70 (n=75) p Value
Creatinine (mg/dL) 8.5±2.4 9.6±2.8 10.8±3.3 11.3±3.3 11.7±3.9 <0.001
J Cachexia Sarcopenia Muscle (2011) 2:209–261 215versus glycolytic fibers. Creatine pool size calculated from muscle D3-
creatine enrichment and converted to skeletal muscle mass based on
muscle creatine content yielded expected skeletal muscle composition.
Conclusions: A novel, facile, direct, noninvasive D3-creatine dilution
method has been validated in rats for the determination of total-body
creatine pool size and skeletal muscle mass, and holds promise for routine
clinical application.
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An investigation of potential skeletal muscle protein biomarkers
of cancer cachexia
Nathan A. Stephens, Richard J.E. Skipworth, Carolyn A. Greig, James A.
Ross, Kenneth C.H. Fearon (Department of Clinical and Surgical Sciences,
University of Edinburgh, Edinburgh, EH16 4SB, UK)
Background and aims: There remains an unmet clinical need for
diagnostic biomarkers/therapeutic targets in cancer cachexia. This study
evaluated several skeletal muscle biomarkers (selected from previous
animal/human studies) in a cohort of cachectic upper gastrointestinal
cancer (UGIC) patients.
Methods: One hundred twenty patients (18 controls, 102 UGIC patients)
were recruited. Mean (SD) weight loss of UGIC patients was 7.7 (9.2)%.
Cachexia was defined as weight loss ≥5%. Immunoblotting of protein
homogenates of rectus abdominis muscle biopsies obtained at surgery was
performed probing for Akt (n=52), phosphorylated-Akt (n=52), FOXO1
(n=59), FOXO3a (n=59), LC3 (n=32), beta-dystroglycan (BDG, n=52),
beta-sarcoglycan (BSG, n=52), calmodulin-kinase II (CAMKII, n=59),
phosphorylated-CAMKII (n=59), and myosin heavy chain (n=47). ImageJ
was used to calculate densitometry and results analysed using SPSS v15.0.
Follow-up of UGIC patients was for a median of 663 days (range, 450–
1,955 days). Candidate biomarkers were assessed for: (1) differences
between controls and UGIC patients, (2) diagnostic biomarkers of cancer
cachexia, and (3) prognostic biomarkers of survival (lower vs. upper third).
Results: Compared with controls, UGIC patients had lower Akt levels
(0.49 (0.31) vs. 0.89 (0.17), p=0.001), lower total/phosphorylated-Akt
ratio (1.73 (1.77) vs. 4.38 (2.62), p=0.002) and a trend towards higher
CAMKII levels (0.77 (0.25) vs. 0.56 (0.30), p=0.053). Compared with
noncachectic patients, cachectic patients had higher BDG levels (1.01
(0.16) vs. 0.87 (0.20), p=0.007) and a trend towards higher BSG levels
(0.63 (0.28) vs. 0.55 (0.55), p=0.052). Survival was reduced in UGIC
patients with lower vs. higher ratio of total/phosphorylated-Akt (median
survival 483 vs. 640 days, p=0.020).
Conclusions: We suggest that Akt is suppressed and CAMKII is increased in
skeletal muscle of UGIC patients. Few other potential diagnostic/prognostic
biomarkers were revealed. This may reflect lack of sensitivity using
immunoblotting, broad diagnostic criteria, or a heterogeneous patient group
including individuals at different timepoints during the cachexia journey.
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Altered skeletal muscle ultrastructure and myocyte enhancer factor
(MEF) 2 C gene expression in the colon 26 carcinoma model
of cachexia: a potential link?
Angie M. Y. Shum
1,2,3, Ryland J. Taylor
3, Arran B. Painter
3, Melissa M.
Moore
3, Maria Tsoli
3, Stephen J. Clarke
3, Graham R. Robertson
3 and
Patsie Polly
1,2,3 (
1Inflammation and Infection Research Centre, School of
Medical Sciences, Faculty of Medicine, University of New South Wales,
NSW, 2052, Australia;
2Department of Pathology, School of Medical
Sciences, Faculty of Medicine, University of New South Wales, NSW,
2052, Australia;
3Cancer Pharmacology Unit, ANZAC Research Institute,
University of Sydney at Concord Repatriation and General Hospital, NSW,
2139, Australia.)
Background and aims: Cachexia is a highly debilitating paraneoplastic
disease observed in more than 50% patients with advanced cancers and
directly contributes to 20–30% of cancer deaths. Loss of skeletal muscle is
a defining and often fatal characteristic of patients with cancer cachexia.
Pathological mechanisms of cachexia are complex and multifactorial,
which limits the development of an effective means of predicting,
preventing, or treating it. This study aims to identify transcriptional
regulators underlying cancer-induced skeletal muscle wasting.
Methods: The colon 26 (C26) carcinoma mouse model of cachexia was
established and skeletal muscle was isolated for gene and protein
expression studies by real-time qPCR and Western blotting; ultrastructural
studies were performed using transmission electron microscopy.
Results: The present study has identified a potential novel role for MEF2C
as a regulator of skeletal muscle wasting in C26-bearing mice. MEF2C, an
important transcription factor in controlling skeletal muscle maintenance
and regeneration, was found to be downregulated at both transcript and
protein levels during cancer-induced skeletal muscle wasting. Myogenic
genes including myoglobin and myomesin, also displayed reduced
expression due to cachexia; suggesting a potential link to MEF2C. These
altered molecular effects imply compromised oxygen transport capacity in
addition to distorted structural integrity. Changes in mitochondrial integrity
were also evident in electron micrographs showing ultrastructural
alterations.
Conclusion: Together, these effects may limit sarcomeric contractile ability
and lead to skeletal muscle weakness and fatigue in cancer patients.
Moreover, these may also predispose to structural instability in skeletal
muscle and thus promote degradation along the course of disease
progression. We believe that the identification of MEF2C is important as
it appears to be a potential regulator of skeletal muscle loss in cancer
cachexia. Targeting MEF2C could better direct intervention strategies at
early stage disease and thus minimise or delay skeletal muscle wasting in
cancer patients.
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Effect of plasminogen activator inhibitor 1 (PAI-1) in rodent cancer
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The plasminogen activator (PA) system has been shown to play an
important role in various diseases including muscle wasting condi-
tions. In particular, plasminogen activator 1 (PAI-1), a serine protease
inhibitor (aka serpin E1) that targets urokinase-type (uPA) and tissue-
type plasminogen activator (tPA), was shown to play an important role
in muscle regeneration and hypertrophy. For example, PAI-1 knockout
mice show improved muscle regeneration in cardiotoxin-induced
injury model (Koh et al. 2005) and PAI-1 is upregulated during acute
resistance exercise (Chen et al. 2002) as well as cancer, cardiovascular
diseases, and diabetes. Moreover, PAI-1 expression is modulated by a
variety of pathways known to be involved in muscle growth and
regeneration such as pro-inflammatory cytokines, corticosteroids, IGF-
I, and TGF-β proteins. We have further studied PAI-1’sr o l ea n d
mode of action in a human skeletal muscle assay system (HuSKmC)
as well as in rodent cancer cachexia and sarcopenia models. We show
here that HuSKmC cells increase during differentiation PAI-1 mRNA
expression and secrete active PAI-1 measured by enzyme-linked
immunosorbent assay. Treatment with TGF-β proteins further increase
PAI-1 expression and secretion. Inhibition of PAI-1 by pharmacologic
216 J Cachexia Sarcopenia Muscle (2011) 2:209–261and genetic tools increased HuSKmC differentiation indicating a tonic
effect of secreted PAI-1. On differentiated myotubes, both PAI-1
targets uPA and tPA concentration-dependently induce increase in
myotube diameter. Increased PAI-1 levels were detected in circulation
of the mouse cancer cachexia model; in addition, cultured cancer cell
lines, which are known to induce cachexia in vivo, actively secrete
PAI-1. Moreover, expression of PAI-1 was increased in muscles of the
cancer cachexia xenograft mouse model and sarcopenic rats. These
data revealed further insights into the role and mode of action of PAI-
1 in muscle cell differentiation and wasting conditions.
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Background and aims: Muscle wasting is an essential component of
cancer cachexia. Studies suggest that calcium/calmodulin-dependent
protein kinase II (CaMKII) is involved in the regulation of muscle
mass. A unique feature of CaMKII is its autophosphorylation after
calcium/calmodulin activation, resulting in calcium-independent autonomous
activity. The transcription factor serum response factor (SRF) is an
important substrate of autonomous CaMKII activity. Recent studies
suggest that increased autonomous CaMKII activity and phosphoryla-
tion of SRF(Ser103) result in muscle hypertrophy. Based on those
observations, we hypothesized that cancer-induced muscle atrophy is
associated with reduced autonomous CaMKII activity and SRF
(Ser103) phosphorylation.
Methods: Cancer cachexia was induced in male Wistar rats by i.p.
inoculation of AH-130 cells. Control rats were injected with corresponding
volume of saline. After 7 days, gastrocnemius muscles were harvested for
determination of phosphorylated CaMKII(Thr286/287) and SRF(Ser103)
by Western blotting and measurement of autonomous CaMKII activity
using a commercially available CaMKII kinase activity kit. In addition,
muscle weight was measured and mRNA levels for atrogin-1 and MuRF1
were determined by real-time PCR.
Results: Muscle weight was reduced by 25% and atrogin-1 and MuRF1
mRNA levels were increased three- and fourfold, respectively, in tumor-
bearing rats. Muscle levels of p-CaMKII(Thr236/237) and autonomous
CaMKII activity were reduced by 30% in tumor-bearing rats. These
changes were accompanied by a 25% decrease in nuclear levels of p-SRF
(Ser103).
Conclusions: Muscle wasting in cancer cachexia is associated with
reduced autonomous CaMKII activity and SRF(Ser103) phosphorylation.
Stimulation of autonomous CaMKII activity and SRF phosphorylation
may prevent cancer-induced muscle wasting.
Supported in part by NIH R01DK37908 to POH. ZA was supported by the
Department of Clinical Medicine, Sapienza, University of Rome, Rome, Italy
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Background: Cancer cachexia is a devastating wasting syndrome
characterized by fat and muscle loss that affects the majority of advanced
cancer patients. This syndrome, however, is poorly understood.
Objective: The objective of the study was to examine the extent to which
muscle area changes over time in pancreatic cancer patients.
Methods: Forty newly diagnosed or recurring cancer patients of all stages
(16 women (40%); age, 58 (SD: 10)years old) from McGill University
Health Center and the Jewish General Hospital, with an Eastern
Cooperative Oncology Group score of 0–3 and a life expectancy greater
than 3 months were included in the study. Muscle area was assessed from
computed tomography images, performed for clinical indications, of the
third lumbar vertebrae with Slice-O-Matic. Cytokines were measured from
plasma samples with the Bio-PlexR system and data output being analyzed
with the Bio-Plex ManagerTM software. Group-based trajectory modeling
was used to identify trajectories of muscle area over time.
Results: Twenty (50%) patients in the study were losing muscle over time,
13 (81%) women compared to seven (29%) men. Four trajectories of
muscle area were identified: one losing muscle area over time and three
with stable muscle area over time. Therefore, the losing weight group
included 13 women and 7 men, while the other three groups included a
total of 3 women and 24 men (z value 3.23, p value=0.001). Women had
differing cytokine profiles compared to men at baseline.
Conclusion: Muscle loss occurs in half of the pancreatic cancer patients in
this study, the majority of which are women. Future studies on cancer
cachexia should explore the effects of sex differences among pancreatic
cancer patients, especially in regard of the influence of cytokine profiles.
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Background: Human skeletal muscle demonstrates remarkable hetero-
geneity in capacity to adapt to external loading, such that gains in
muscle strength or mass during resistance exercise training (RET) vary
greatly between individuals. Our objective was to explore relationships
between adaptive heterogeneity and abundance of miRNAs—the key
regulators of translation of protein-coding mRNA.
Methods: Muscle biopsies were obtained from young (18–28 years
old, n=14), middle-aged (45–55 years old, n=20) and older (65–75 years
old, n=17) men and women before and after 20 weeks fully supervised
whole-body RET. Using miRNA arrays that detect ∼700 human
miRNAs, we hypothesised that miRNA abundance would differ between
the highest (n=5) and lowest (n=5) responders (in terms of muscle
strength) to RET. Results were confirmed using the entire cohort (n=51),
with TaqMan-based miRNA detection technology.
Results: Baseline physiology did not differ between high and low
responders. We provide independent validation of a previous observation
that mir-451 is specifically upregulated in young male low-responders to
RET, and extended this observation to middle-aged and older male
subjects. No such association was found in female subjects. Intriguingly,
mir-451 is not expressed in murine C2C12 cells and its expression is
absent or 10–50-fold lower in mouse/rat than in human skeletal muscle
extracts. Targets of mir-451 are limited in number (∼20) and represent
conserved protein coding genes, including Hamartin (TSC1), F-box
protein 33 (FBXO33) and calcium-binding protein 39 (CAB39) which
along with additional evidence that mir-451 can inhibit Serine/threonine-
J Cachexia Sarcopenia Muscle (2011) 2:209–261 217protein kinase 11 (LKB1), places it in a central position to interact with
numerous anabolic and catabolic related pathways.
Conclusion: We have validated a novel regulator of male human in vivo
muscle growth. The fact that miR-451 demonstrates a human-specific
expression pattern supports the notion that current preclinical murine or
rodent models of muscle growth may be unable to fully mimic the human
scenario.
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Transcriptomic and proteomic profiling of livers from cachectic mice
reveals dysfunctional metabolism
Dominic Burg
1, Ryland Taylor
1, Lucy Jankova
1, Arran Painter
1, Maria
Tsoli
1, Shiba Dolai
2, Stephen Clarke
1, Mark Molloy
2, Graham Robertson
1
(
1Cancer Pharmacology Unit, ANZAC Research Institute, Concord RG
Hospital, NSW 2139, Australia;
2Australian Proteome Analysis Facility,
Dept of Chemistry & Biomolecular Sciences, Macquarie University, NSW
Australia)
Background: Cancer cachexia is a catabolic condition characterized
by progressive weight reduction and energy imbalance associated
with systemic inflammation, elevated serum C-reactive protein and
cytokines. While muscle and fat loss are obvious manifestations of
cachexia, it is likely that the pivotal role of the liver in nutrient
uptake, metabolism, and redistribution contributes to dysregulated
metabolism of cachexia.
Methods: Utilising a multiplatform approach including microarray and
iTRAQ analysis, as well as novel ATP-binding protein enrichment
technology coupled with label-free quantitation, we have profiled gene
and protein expression patterns of livers from C26 tumor-bearing mice
displaying cachexia.
Results: The transcriptomic and proteomic datasets revealed high
correlation between the three approaches, with very few instances of
incongruity. Pathway analysis utilizing several software packages
indicated that central metabolic processes including lipid handling,
glycolysis/gluconeogenesis, amino acid metabolism, tricarboxylic acid
cycle and mitochondrial electron transport chain are reduced in
cachectic mice. Linking these metabolic pathways to upstream
regulatory events, transcriptional activation is reduced within the
RXR canonical pathway (e.g., LXR, FXR, TR, PPARα/δ/γ), associ-
ated with cytokine signaling through activated JAK/STAT pathway,
SOCS3, and IL-1/LPS-BP signaling. Repressed expression of genes
and proteins in key energy generation pathways is counter-intuitive to
the expected role of the liver in settings of food restriction/weight-loss
—i.e., to adaptively utilize amino acids, carbohydrates and fatty acids,
and activate ketone body production and gluconeogenesis. As a
counterpoint to this dramatic disruption in metabolic pathways, we
see significant acute phase protein production and a concomitant
increase in protein translation, potentially mediated through phosphorylated
4E-BP downstream of mTOR.
Conclusion: Chronic stimulation of cytokine-signaling in the liver by
distal tumours disrupts metabolic pathways responsible for maintaining
energy homeostasis. The net outcome of impaired processing and supply of
nutrients to muscle, fat, and other organs would contribute to the
devastating effects of cachexia.
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Background/aims: Prognostic assessment of cirrhotic patients remains a
challenge. Sarcopenia is defined as low levels of muscle mass; it may be
present in chronic/malignant diseases. It is not well-studied/understood in
cirrhotic and HCC patients. We aimed to establish sarcopenia frequency
and if it predicts mortality in a cohort of cirrhotic patients with and without
hepatocellular carcinoma (HCC).
Patients and methods: One hundred sixty-three patients with cirrhosis
were consecutively evaluated for liver transplant and had computed
tomography (CT) scan at the third lumbar vertebrae were selected. Skeletal
muscle cross-sectional area was measured by CT to determine the third
lumbar vertebrae (L3) skeletal muscle index (L3 SMI) defined as total
lumbar muscle cross-sectional area adjusted for stature; sarcopenia was
defined using previously published gender-specific cutoffs.
Results: One hundred eighteen patients were males (72%), mean age of 55
±1 years, 51 patients (31%) had HCC at the time of CT. Median time of
follow-up was 19±1 months. Sarcopenia was present in 61 patients (37%),
and there was no difference in the frequency of sarcopenia among patients
with and without HCC (31% vs. 40%, P=0.3). By univariate Cox analysis
the bilirubin, creatinine, albumin, Model for End-Stage Liver Disease
(MELD), Child–Pugh, sodium, L3 SMI, and sarcopenia were associated
with mortality. The presence of HCC was not associated with increased
mortality (HR 1.12, P=0.6). By multivariate Cox regression analysis, only
MELD score (HR 1.08, P=0.001), and sarcopenia (HR 2.18, P=0.001)
were independently associated with early mortality. Median survival for
sarcopenic patients was 19±5 months, compared to 30±2 months in
nonsarcopenic patients (P=0.001). There was a poor correlation
between sarcopenia and MELD score (r=−0.13, P=0.1) and sarcopenia
and Child–Pugh score (r=0.04, P=0.6).
Conclusions: Sarcopenia is present in 37% of patients with cirrhosis
and is not associated with the presence of HCC. Sarcopenia
constitutes a strong and independent predictor of mortality in cirrhotic
patients and does not correlate with degree of liver dysfunction
evaluated with conventional scoring systems. Further studies including
sarcopenia with conventional scores may allow better mortality
prediction among cirrhotic patients with and without HCC.
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Metabolic derangements in the gastrocnemius and the effect
of selective NF-κB inhibition in a murine model of cancer cachexia
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Cancer cachexia is a severe wasting syndrome characterized by the
progressive loss of lean body mass and systemic inflammation. Inhibiting
NF-κB signaling largely prevents such cancer-induced muscle wasting in
murine models. We have previously shown the utility of compound A, a
highly selective novel NF-κB inhibitor that targets the IkB kinase complex,
to provide clinical benefit in cancer-induced skeletal muscle and cardiac
atrophy. Using a metabolomics approach, we describe the changes found
between cachectic and noncachectic gastrocnemius muscles, before and
after compound A treatment. Of the 234 metabolites in the gastrocnemius,
cachexia-induced changes in gastrocnemius metabolism reset the steady-
state abundances of 42 metabolites (p<0.05). These changes, not evenly
distributed across biochemical categories, are concentrated in amino acids,
peptides, carbohydrates and energetics intermediates, and lipids. The
gastrocnemius glycolytic pathway is markedly altered—changes consistent
with tumor Warburg physiology. This is the first account of a Warburg
218 J Cachexia Sarcopenia Muscle (2011) 2:209–261effect that is not exclusively restricted to cancer cells or rapidly
proliferating nonmalignant cells. Cachectic gastrocnemius also displays
tricarboxylic acid cycle disruptions, signs of oxidative stress, and impaired
redox homeostasis. Interestingly, treatment with compound A has more
profound effects on the metabolism of the tumor itself than on the
gastrocnemius. In fact, compound A treatment has only a modest effect on
the biochemistry of the cachectic gastrocnemius, failing to restore the
gastrocnemius’ baseline metabolic profile. Conversely, the biochemical
changes in the tumor point to a direct anti-oxidant effect, but also a
potential reduction in the growth rate of the tumor—consistent with the
observation of tumor shrinking post-treatment. These changes give
significant insight into the complex pathophysiology of cancer cachexia,
shedding light on specific changes that might be avenues for targeted
therapies.
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Disrupted circadian regulation of metabolic pathways in livers
of cachectic mice associated with tumour-derived IL-6
Ryland Taylor, Arran Painter, Maria Tsoli, Stephen Clarke, Graham
Robertson (Cancer Pharmacology Unit, ANZAC Research Institute,
Concord RG Hospital, NSW 2139, Australia)
Background: Circadian patterns of gene expression are intimately
linked with control of metabolic pathways to coordinate diurnal cycles
of feeding and activity. The molecular regulation of body clocks
involves complex circuitry of negative feedback loops mediated by
transcription factors BMAL1/CLOCK entwined with CRY, PER, and
nuclear receptors RORα and REVERBα. While perturbations to these
intrinsic circadian regulators are associated with obesity, the impact of
the converse setting of cachexia on their action is unknown.
Aim: In this study, we focused on the liver and hepatic metabolic pathways
fundamental for the control of total body homeostasis. Given the integral
role of nuclear receptors in regulating metabolic pathways, we character-
ized the diurnal expression pattern of nuclear receptors and genes they
regulate in the livers of cachectic colon 26 tumour-bearing mice.
Results: Six-timepoint analysis by RT-qPCR of BMAL1, CLOCK,
CRY1, PER2 REVERBα, and RORα showed significant changes to
their normal rhythmic expression patterns, particularly at the midpoint
of the dark and light cycles. Western analysis of BMAL1 protein at six
timepoints confirmed disruption of core circadian regulation. Analysis of
liver samples by cDNA microarrays identified numerous genes that
displayed rhythmic patterns in control mice (i.e., peaking at 2 am or
2 pm) many of which lost the normal diurnal rhythm in cachectic C26
livers. PPARα/δ/γ as well as ERRα all displayed markedly altered
circadian expression patterns, along with their target genes in fatty acid
β-oxidation (PBE, HADHA, and B), fatty acid uptake (LPL),
lipogenesis (FAS, SCD1) and glucose/pyruvate metabolism (PEPCK,
PDK4). Expression profiling demonstrated decreased expression of
many other genes in key metabolic pathways indicating a profound
disruption in circadian regulation of hepatic metabolism.
Conclusion: As cachexia in C26 mice is driven by tumour-derived
factors such as IL-6, it is likely that chronic stimulation of cytokine-
signaling in the liver disrupts hepatic metabolic pathways responsible
for maintaining diurnal energy homeostasis throughout the body.
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Background: Infection due to immunosuppression following chemo-
therapy in advanced cancer is an inherent problem with cytotoxic
drugs. Cachectic cancer patients are particularly susceptible to
excessive toxicities resulting in delay or termination of treatment and
in some instances death. Systemic inflammation associated with
cachexia is also linked with repression of drug clearance pathways,
altering the pharmacokinetics of anticancer agents and thereby
enhancing the potential for adverse toxicity.
The Colon-26 carcinoma is a widely used mouse model of cachexia
mediated by tumour-derived IL-6 and a common preclinical model for
evaluation of antineoplastic pharmaceuticals. Prior to assessment of
susceptibility to myelosuppression by cytotoxic drugs, haematopoietic
and immunological cell populations of cachectic colon-26 mice were
compared with those of mice engrafted with a noncachectic variant of
the same tumour, delineating effects of cachexia vs. those of a tumour
per se. Changes attributable to anorexia were identified using pair-fed
mice.
Results: Blood of cachectic mice displayed highly elevated erythrocyte
sedimentation rate and thrombocytosis, consistent with systemic inflam-
mation. Their bone marrows indicated developing anaemia with erythro-
blast microcytosis and elevated transferrin receptor (CD71) levels.
Downregulated hepcidin and upregulated transferrin in the livers point to
iron-deficiency anaemia rather than the expected anaemia of chronic
disease. Production of new lymphocytes, both pre-B and pre-T cells, was
abrogated, with obvious implications for susceptibility to infection. Natural
killer cell populations were strongly ablated, which could affect innate
anti-tumour response, particularly surveillance and suppression of metas-
tases. Neutrophil and monocyte levels were increased in circulation and
peripheral lymphoid organs. The blood neutrophil lymphocyte ratio was
elevated 15–20-fold; high NLR in humans is strongly prognostic of poor
outcome for many tumour types.
Conclusion: The progressive changes in the immune and haemato-
logical systems of cachectic mice associated with rises in plasma IL-6
indicate that the C26 tumour provides an excellent model for studying
the links between cachexia, altered drug clearance, and bone marrow
toxicity
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Regulation of TNF/cachectin signalling
John Silke, Andrew I. Webb (The Walter and Eliza Hall Institute,
Melbourne, Victoria, Australia)
Background: It is 26 years since the hormone cachectin was identified
as tumor necrosis factor (TNF) and TNF-producing tumors injected
intramuscularly produce significant weight loss and cachectic symp-
toms. Great strides have been made in understanding how TNF
signals and studies on TNF have led to text book examples of
receptor signalling but there is still much to learn.
Methods: Using a combination of genetics, biochemistry, mass spectrom-
etry and small molecule inhibitors my lab has recently made significant
contributions to understanding how TNF signals.
Results and conclusions: We have shown that cIAPs are critical regulators
of the initial phase of TNF signalling, and identified new molecules HOIL-
1/HOIP and Sharpin (Vince et al. 2009; Haas et al. 2009; Gerlach et al.
2011; Vince et al. 2007) that together form the Linear Ubiquitin Assembley
Complex. Using multiple reaction monitoring mass spectrometry, we now
demonstrate that linear ubiquitin chains are present within the endogenous
TNF signalling complex and together with other data generated in my lab
(Wong et al. 2010) present a new model for TNF signalling that empasizes
the exquisite regulation of TNF signalling.
Gerlach, B. et al. (2011). Linear ubiquitination prevents inflammation and
regulates immune signalling. Nature 471, 591–96.
J Cachexia Sarcopenia Muscle (2011) 2:209–261 219Haas, T.L. et al. (2009). Recruitment of the linear ubiquitin chain assembly
complex stabilizes the TNF-R1 signaling complex and is required for TNF-
mediated gene induction. Mol Cell 36, 831–844.
Vince, J.E. et al. (2009). TRAF2 must bind to cellular inhibitors of
apoptosis for tumor necrosis factor (tnf) to efficiently activate nf-{kappa}b
and to prevent TNF-induced apoptosis. J Biol Chem 284, 35906–915.
Vince, J.E. et al. (2007). IAP antagonists target cIAP1 to Induce
TNFalpha-dependent apoptosis. Cell 131, 682–693.
Wong, W.W et al. (2010). RIPK1 is not essential for TNFR1-induced
activation of NF-kappaB. Cell Death Differ 17, 482–87.
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Cachexia and inflammation in patients with chronic obstructive
pulmonary disease (COPD)
Barbara Kuznar-Kaminska, Halina Batura-Gabryel (Department of
Pulmonology Allergology and Respiratory Oncology Poznan University of
medical Sciences, Poznan, Poland)
Background and aims: Chronic obstructive pulmonary disease (COPD) is
chronic inflammatory disease with specific loss of lean body mass
determined cachexia. One of causes of cachexia in COPD can be excessive
production of cytokines and molecules that are engaged in regulation of
nutritional status. Study aim was: (1) Evaluation of IL-6 level and leptin
concentration and assessment of the relation between blood level of these
molecules in COPD patients. (2) Attempt to find the connection between
IL-6 and leptin and nutritional status.
Material and methods: Fifty-five COPD patients—43 males, 12 females
(mean age 62.31±11.08) and 32 controls (mean age 57.43±8.79)
participated in the study. In study and control group, fat-free mass index
(FFMI) as indicator of cachexia was measured using analyzer of body
composition. Leptin and IL-6 concentration were measured in serum with a
specific enzyme-linked immunosorbent assay methods.
Results: Average leptin blood concentration in study group for
females and males was 358.38±66.57, 316.75±27.14, respectively;
in control group 344.99±54.98, 309.58±19.36, respectively. Significant
correlation between leptin and BMI (body mass index)–R Spearman=0.52,
and FMI (fat mass index)–R Spearman=0.60, but not for FFMI was
confirmed. Average IL-6 serum level in study and control group was
2.47±2.0, 1.30±1.51 pg/ml, respectively, and it was statistical
difference between groups. IL-6 serum level did not correlate with
leptin level as well as with indicators of nutritional status: BMI,
FFMI, FMI. It was not observed IL-6 level difference between well-
fed COPD subjects and patients with cachexia.
Conclusions: (1) COPD is an inflammatory disease with increased serum
level of IL-6 and leptin. (2) Leptin and IL-6 are not directly responsible for
state of nutrition in COPD patients. (3) It is necessary to find different new
markers, which will be the connection between inflammation and cachexia
in COPD patients
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Gene expression of the NF-κB signaling path in the subcutaneous
adipose tissue of cachectic patients
Rodolfo G. Camargo, Henrique H. T. Ribeiro, Patricia E. R. Guilherme,
Paulo S. Alcantara, Jose Pinhata, Linda F. Maximiliano, Marilia C.L.
Seelaender (Cancer Metabolism Research Group, University of Sao Paulo,
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Cachexia, a paraneoplastic syndrome is frequently underlined by
systemic inflammation, leading to dramatic wasting of lean and fat
mass and to metabolic chaos. The adipose tissue is an endocrine organ
and secretes a number of factors known as adipokines, many of which
are involved in the regulation of inflammatory processes. We have
demonstrated that this tissue contributes to systemic inflammation during
cachexia both in animal models and in patients (Machado et al., Cell Tissue
Res, 2004, Dec 503–14; Batista Jr et al., Med Sci Sports Exerc, 2008, Mar
549–56). A key point in the expression of pro-inflammatory cytokines
(including TNF-alpha) is the activation in cells of the nuclear transcription
factor kappa B (NF-kappaB), which also plays a part in modulating the
resolutionof inflammation. In orderto examine NF-kappaBgene expression
in the subcutaneous adipose tissue, cachectic patients were selected
according to the parameters described by Evans et al. (Clin Nutr, 2008,
Dec 793–9), after signing a term agreeing to donate blood and tissue
samples, both collected during surgery. Patients were divided into three
groups: control (C, n=13), tumor with cachexia (TC, n=13), and tumor
without cachexia (T, n=12). PCR real time for the NF-kappaB signaling
pathway genes was performed and the results show a significant increase
in the expression of p65/RelA (p<0.03) and Ikkβ genes (p<0.05) and also
a tendence of increased Ikkα gene expression, both in T. p50/p105, IkBα,
IkBβ and Ikkγ gene expression did not change significantly and a
pronounced variation between individuals was found. These results show
that TC individuals are probably less capable of modulation in the NFkB
pathway, what may interfere with the resolution of inflammation, as
increased cytokine content triggers this process.
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Background and aims: Hematopoietic stem cell transplant (HSCT)
patients have decreased exercise capacity and muscle strength from
before to after transplantation. However, there are no reports
evaluating body composition in adult HSCT patients. The primary
aim of this study is to investigate the change in body composition,
physiological function, nutritional status, and fatigue pre- and post-
allogeneic (allo) HSCT. Additional aims of this study include examining
gender differences in physiological function, nutritional status, and fatigue pre
and post allo-HSCT.
Methods: Study participants included patients who had undergone allo-
HSCT from July 2007 to June 2011. Ninety-eight patients were included in
this study (65 men, 33 women). The evaluation was performed up to
3 weeks before and 6 weeks after transplantation. Body composition was
evaluated using a bioelectrical impedance analysis (BIA). Physiological
functions were evaluated by handgrip, knee extensor strength, and 6-min
walk test (6MWT).
Results: Body weight (BW) and fat body mass significantly decreased
after transplantation (5% in BW and 20% in fat body mass, p<0.01).
Moreover, there was no significant decrease in lean body mass before to
after transplantation. Handgrip, knee extensor strength, 6MWT, all
decreased significantly after transplantation (20% in both handgrip and
knee extensor strength and 5% in 6MWT, p<0.01). There were no
significant differences between men and women with respect to any of the
tested parameters.
Conclusions: We found that, despite the fact that lean body mass did not
decrease, muscle strength decreased significantly in allo-HSCT patients.
Many patients receive intravenous drip therapy after transplantation. Thus,
220 J Cachexia Sarcopenia Muscle (2011) 2:209–261despite decreased muscle mass, the lack of change in lean body mass may
be a result of a corresponding increase in body water volume. Based on
these facts, the BIA method may not be ideal for accurately assessing
muscle mass in the early phases of allo-HSCT.
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Prevalence of undernutrition, sarcopenia and cachexia in patients
with inflammatory bowel diseases
Igor Khoroshilov, Sergius Ivanov (Saint-Petersburg State Medical Academy
named after I.I. Mechnikov, Saint-Petersburg, Russian Federation)
Aims: This paper aims to study the prevalence of undernutrition,
sarcopenia, and cachexia in patients with inflammatory bowel diseases in
acute phase.
Methods: Thirty patients with ulcerative colitis and 26 patients with
Crohn’s disease in acute phase had been inspected in hospital conditions.
We studied the body weight, body mass index, body composition, muscle
volume of arm, protein content in the blood, and number of lymphocytes in
the blood. Content of fat body mass and fat-free mass was determined by
methods of bioelectrical impedance and dual energy X-ray absorbtiometry.
Results: Reduction of the body weight and body mass index (<18.5) was
detected in 42% of patients with ulcerative colitis and 54% of patients with
Crohn’s disease. The diagnosis “cachexia” was installed in 10% of patients
with ulcerative colitis and 8% of patients with Crohn’s disease. Reduction
of the muscle volume of arm (sarcopenia) has been revealed in 25% of
patients with ulcerative colitis and 27% of patients with Crohn’s disease.
Hypoproteinemia and hypoalbuminemia took place in 16% of patients in
both groups, reducing of number of lymphocytes in the blood in 14% of
patients with ulcerative colitis and 27% of patients with Crohn’s disease.
Conclusions: Undernutrition was detected in 42–54% of patients with
inflammatory bowel diseases, however diagnosis of cachexia was installed
in 8–10% of patients, sarcopenia took place in 25–27% of patients with
inflammatory bowel diseases in acute phase.
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Association between body condition and survival in dogs
with naturally-occurring chronic kidney disease
Valerie J. Parker, Lisa M. Freeman (Tufts Cummings School of Veterinary
Medicine, North Grafton, USA)
Obesity in people with chronic kidney disease (CKD) is associated with
longer survival. The purpose of this study was to determine if a
relationship exists between body condition and survival in dogs with
naturally-occurring CKD, with the hypothesis that overweight and obesity
are associated with longer survival times. Data regarding initial body
weight and body condition score (BCS), clinicopathologic values and
treatments were collected retrospectively from medical records and
compared with survival times. One hundred dogs diagnosed with CKD
(International Renal Interest Society stages II, III or IV) between 2008 and
2009 were enrolled in the study. For dogs with BCS recorded (n=72), 13
were underweight (BCS=1–3; 18%), 49 were moderate (BCS=4–6; 68%),
and 10 were overweight (BCS=7–9; 14%). For dogs with at least two body
weights recorded (n=77), 21 gained weight, 47 lost weight, and 9 had no
change in weight. Dogs classified as underweight at the time of diagnosis
(median survival=25 days) had a significantly shorter survival time
compared to both moderate (median survival=190 days, P<0.001) and
overweight dogs (median survival=365 days; P<0.001). There was no
significant difference in survival between moderate and overweight dogs (P=
0.95). Higher BCS at the time of diagnosis was significantly associated with
improved survival. These results suggest that body condition is an important
consideration in dogs with naturally-occurring CKD. Further studies are
warranted to evaluate the relationship between obesity and survival in dogs
with CKD.
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Vitamin D repletion and receptor activation ameliorate cachexia
in chronic kidney disease (CKD)
Wai W. Cheung, Robert H Mak (Division of Pediatric Nephrology,
University of California San Diego)
Background and aims: Vitamin D deficiency is prevalent and may be
important in CKD-associated cachexia.
Methods: CKD was induced by 5/6 nephrectomy (N) in 8-week old
c57BL/6 J mice.
Results: Both 25-vitamin and 1,25-vitamin D levels are significantly lower
in N mice compared with sham (S) mice. N and S mice received 25-VitD
(VitD25, 80 ng/kg, i.p., 3× per week), paracalcitol (PC, 150 ng/kg, i.p., 3×
per week) or vehicle (V) for 2 weeks. N/V mice were fed ad libitum
whereas N/VitD25, N/PC, S/V, S/VitD25, and S/PC mice were pair-fed to
N/V mice. Serum BUN and creatinine was significantly higher in N/V, N/
VitD25, and N/PC compared with S/V, S/VitD25, and S/PC mice (p<0.01).
N/VitD25 and N/PC mice gained more weight than N/V mice (1.4±0.2 and
1.2±0.3 vs. 0.7±0.3 g, p<0.01). Basal metabolic rate was higher in N/V
compared with N/VitD25 and N/PC mice (3,895.8±234.7 vs. 3415.2±
224.6 and 3,216.5±124.4, p<0.01). N/V mice lost lean and fat mass
whereas N/VitD25 and N-PC mice gained lean and fat mass. Muscle
strength, assessed by rotarod activity and grip strength, showed significant
improvement in N/VitD25 (117.4±183.5 s, 1,653.5±126.4 g/100 g) and
N/PC (121.4±21.5 s, 1,624.5±125.6 g/100 g) compared with N/V
mice (68.8±12.6 s, 1,243.2±129.0/100 g, p<0.001). mRNA of
uncoupling proteins 1 and 2, which regulate energy expenditure, and
proinflammatory cytokine IL-6 were upregulated in skeletal muscle and
adipose tissue in N/V but normalized in N/VitD25 andN/PC mice.
mRNA of myogenic pathway genes, IGF-I, MyoD, and PAX3 were all
downregulated in the skeletal muscles in N/V but normalized in N/
VitD25 and N/PC mice.
Conclusions: 25-Vitamin repletion and vitamin D receptor activation
ameliorated cachexia as well as reversed cytokine over-expression in a
mouse model of CKD-associated cachexia. Vitamin D deficiency may be
an important factor in the pathogenesis of cachexia and inflammation in
CKD.
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Introduction: Oxidative stress and chronic inflammation are striking
features in chronic heart failure (CHF). Both may cause an impaired
selenium (Se) metabolism characterized by decreased biosynthesis of
selenoprotein-P (SEPP), a protein involved in Se transport and antioxidant
defence in the blood. Concentrations of Se and SepP have not yet been
studied in CHF.
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noncachectic (LVEF 31±2%, peak VO2 15±1 mL/kg/min, NYHA class
2.5±0.1) and 10 cachectic (LVEF 28±3%, peak VO2 13±1 mL/kg/min,
NYHA class 2.9±0.1) and 30 control subjects (peak VO2 25±1 mL/kg/
min, LVEF 66±2%). Blood concentrations of Se, SEPP, pro-
inflammatory interleukin-22 (IL-22), and high sensitive C-reactive
protein (hsCrP) were assessed by spectroscopy and enzyme-linked
immunosorbent assay (ELISA), respectively. We measured in a subgroup
of 17 patients and 12 controls interleukin-10 (IL-10) and tumor necrosis
factor (TNF) blood cytokine excretion upon lipopolysaccharide (LPS)
s t i m u l a t i o nb yE L I S A .
Results: In CHF, we found lower blood concentration of both Se and SEPP
comparedtocontrols(70.4±2.6vs.80.3±2.4μg/L[p<0.008] and 2.7±0.9 vs.
3.0±0.8 mg/L [p<0.05], respectively). Cachectic patients showed lowest
blood concentration of Se compared to noncachectic patients and controls
(66.4±5.5 vs. 73.5±3.2 vs. 79.9±2.3 μg/L, analysis of variance, p<0.03).
Furthermore, cachectic patients had lowest SEPP blood concentration
indicating a lack in antioxidant capacity in cardiac cachexia (2.4±0.1 vs.
2.9±0.1 vs. 2.9±0.1, p<0.02). Cachectic patients had highest blood
concentration of IL-22 and hsCrP compared to noncachectic patients and
controls (23.9±9.4 vs. 7.5±2.1 vs. 3.1±0.8 pg/mL [p<0.0003] and 0.8±0.2
vs. 0.3±0.1 vs. 0.2±0.1 pg/mL [p<0.03]). The concentration of IL-22, which
exerts antimicrobial properties, correlated with lower levels of SEPP (r=
0.40, p<0.03) and Se (r=0.50, p<0.03) and higher levels of anti-LPS-
Immunoglobulin-M-antibodies in CHF (r=0.65, p<0.007). Upon blood LPS
stimulation, CHF patients showed a higher IL-10 and TNF release (78±11
vs. 37±6 and 919±80 vs. 516±79 pg/mL, p<0.01). Higher hsCrP levels in
CHF correlated with lower SEPP and Se blood concentrations (r=0.47, p=
0.01 and r=0.40, p=0.055, respectively).
Conclusion: Decreased selen status (i.e., serum Se and SEPP levels) are seen
in CHF patients. The subgroup of CHF patients with cachexia displayed the
lowest blood concentrations indicating limited anti-oxidative potential. Low
selen status correlated with higher IL-22 and hsCrP levels. Chronic
inflammation may constitute a causal factor for the observed relative
deficiency in both Se and SEPPP concentrations in cardiac cachexia and
could be a therapeutic target.
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Background: The impact of endothelial dysfunction (ED) on athero-
genesis and increased cardiovascular risk is clearly established and has
important implications for blood supply to the muscle and develop-
ment of muscle wasting. Current assessment methods of ED are,
however, complicated by invasive protocols or laborious Doppler
ultrasound procedures and are often more strenuous for the elderly
fragile patients in cachexia research. The aim of the study was to
examine ED in patients with chronic heart failure (CHF) by a novel
non-invasive and easily applicable method. We aimed to assess the
relationship of ED to exercise capacity and clinical status in CHF
patients with and without cachexia.
Methods: We studied 75 patients with CHF [age 65±11 years, 24%
female, body mass index (BMI) 28.6±5.5 kg/m², New York Heart
Association (NYHA) class (I/II/III/IV, 4/41/24/3), left ventricular ejection
fraction (LVEF) 36±11%, pVO2 16.6±5.0 ml/min/kg (all mean±SD)].
Endothelial dysfunction was assessed by non-invasive arterial tonom-
etry (EndoPAT) using the reactive hyperaemia index (RHI). RHI is
defined as a ratio between the post- and pre-occlusion arterial
tonometry signal of the index finger corrected for baseline vascular
tone and for the signal of the non-occluded contra lateral arm.
Exercise capacity was assessed by symptome limited treadmill
spiroergometric exercise test (modified Bruce protocol) and six-min
walk test (6MWT). For comparison, we studied 20 healthy controls
(CON) of similar age and gender distribution.
Results: Compared to controls (RHI 2.14±0.62), endothelial function was
16% lower in CHF (RHI 1.80±0.36, p=0.007) and decreased stepwise
with advancing disease severity (NYHA I+II/III+IV 1.89±0.37/1.63±
0.33, analysis of variance, p<0.005). RHI was more reduced in CHF
patients with ischaemic aetiology than in non-ischaemic CHF (ischaemic
CHF vs. non-ischaemic CHF, 1.64±0.3 vs. 1.96±0.5; p<0.05). In linear
regression analyses, lower RHI was associated with lower pVO2 (r=+0.30,
p<0.05) as well as lower 6-min walking distance (r=+0.40, p=0.01).
6MWT distance was reduced in CHF vs. CON (414±146 vs. 556±100 m,
p<0.001). In multivariable analysis, the association between RHI and
6MWT distance was independent of age and LVEF(r=+0.50, p<0.05).
Conclusions: Endothelial dysfunction as assessed by EndoPAT is
predictive of reduced functional status and impaired exercise capacity in
patients with CHF. Endothelial dysfunction may impact on development of
poor muscle perfusion, particularly during exercise, and contribute to
skeletal muscle wasting. Assessment of endothelial function by this novel
non-invasive method using reactive hyperaemia is a simple and easily
applicable method for the use in ambulatory and clinical settings, and can
be used in patients with and without cachexia.
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Background: Overweight and obesity are established risk factors for
cardiovascular disease including stroke. In patients with established
cardiovascular disease, increasing evidence suggests an inverse relation-
ship between body mass index (BMI) on outcome, which has been termed
obesity paradox. The impact of body weight in general and presence of
cachexia specifically on outcome after stroke is not well established. We
aimed to investigate the relationship between BMI and mortality as well as
functional outcome in patients after stroke.
Patients and methods: We analysed data from of the Telemedical
Project for Integrative Stroke Care project. In 1,521 patients suffering
from an acute stroke or TIA data on BMI at time of hospital
admission and on subsequent outcomes were available. Patients were
grouped by BMI as cachectic (BMI ≤18.5), reference group (BMI
>18.5 to 25) overweight (BMI >25 to 30), mild obesity (BMI >30 to
35) and advanced obesity (BMI >35, all kg/m
2). Outcome measures
after 30 months included all-cause mortality, recurrent stroke, need for
institutional care, and dependency (institutionalisation, Barthel index
< 6 0o rm o d i f i e dR a n k i ns c o r e> 3 ) .
Results: During 30 months of follow-up, 401 patients (27%) died.
Mortality rates at 30 months were 61%, 33%, 24%, 18%, and 13% in
222 J Cachexia Sarcopenia Muscle (2011) 2:209–261the BMI subgroups ≤18.5, >18.5–25, >25–30, >30–35, and >35 kg/m
2,
respectively (P<0.001). Rates for the combined endpoint of death or
recurrent stroke were 64%, 40%, 31%, 22%, 18%, respectively (p<0.001).
Also, institutional care and dependency followed the same stepwise pattern
with lowest rates in obese subjects (all p<0.001). BMI was a significant
inverse predictor for poor outcome after multivariable adjustment for age,
sex, co-morbidity, living in partnership, and stroke severity: Compared to
BMI 18-5-25 (HR 1.0, i.e., reference group) risk for death or recurrent
stroke was higher in patients with BMI<18.5 (HR 2.74, 95%CI 1.23–
6.03), but lower in patients with overweight (HR 0.79; 95%CI 0.60–1.03,
p=0.08), mild obesity (HR 0.56, 95%CI 0.37–0.86; p<0.01) and advanced
obesity (HR 0.51, 95%CI 0.27–0.97; p<0.05). When patients’ obesity
(BMI>30) are considered as reference group, risk for death or recurrent
stroke more than five times increased in patients with BMI<18.5, and two
times increased in patients with BMI 18.5–25. Similarly, the risk for death
or institutional care or and dependency was highest in patients with
cachexia (BMI<18.5), and decreased stepwise with increasing BMI being
lowest in obese and very obese patients.
Conclusion: Patients hospitalised for stroke or TIA with low BMI (BMI<
25) and particularly with cachexia show increased subsequent morbidity
and mortality. In contrast, obese patientss have better outcome for mortality
or recurrent stroke, need for institutional care, and dependency than
patients with normal BMI. A better outcome after stroke in obese patients
is in contrast to data from primary prevention studies, but concurs with
observations of an obesity paradox in other cardiovascular diseases
including heart failure and diabetes mellitus. Treatment strategies to
increase or maintain body weight in patients with stroke or TIA should
be tested.
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Background: Weight loss is a common observation after stroke and
nutritional status contributes to post-stroke recovery and rehabilitation
progress. Weight loss due to impaired feeding and disuse atrophy are
clinically recognised. However, mechanisms of catabolic stimulation in
skeletal muscle in relation to the degree of brain damage and muscle
denervation have not been investigated in detail.
Methods: We investigated skeletal muscle apoptotic activation in a
model of acute focal cerebral ischaemia produced by temporal
occlusion of the mouse middle cerebral artery (MCAO). Caspase 3
(C3) and caspase 6 (C6) activity of the gastrocnemius muscle were
assessed 3 and 7 days after MCA occlusion of both the paretic and
non paretic legs. Global body composition (fat and lean tissue by
nuclear magnetic resonance) and gastrocnemium muscle were assessed
in relation to infarct size.
Results: Activity of caspase 3 and caspase 6 were upregulated after stroke
compared to sham in the paretic and nonparetic leg at day 3 (C3 +548%
and +454%; C6 +145% and +134%, respectively; both p<0.001) and still
increased at day 7 (C3 +194% and +248%, p<0.05). This was
accompanied by progressing wasting of the gastrocnemius muscle until
day 7 (paretic leg, −20%; nonparetic leg, −19%; both, p<0.01) and global
lean tissue loss (day 3, –17%; day 7, –12%, p<0.05 vs. baseline). Infarct
volume directly related to C3 and C6 activity only in the paretic leg
(C3, r=0.72;C6, r=0.78; p<0.01) but not in the nonparetic leg (p>0.5).
Conclusion: Increased apoptosis accounts for skeletal muscle wasting after
stroke. While global muscle degradation may result from systemic signals,
denervation may trigger local signals toward increased apoptosis in the
paretic leg that are not seen in the nonparetic leg.
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Background: Burn injury is characterized by chronic inflammation
(increased chemokines, cytokines, and acute phase proteins), hypermetab-
olism, and hypercatabolism (increased resting energy expenditure and
caloric requirements) resulting in a unique profound and prolonged loss of
lean body mass (LBM) with concurrent hepatosplenomegaly. Several
animal burn models have been developed, however no murine models have
been shown to faithfully reproduce the pathophysiological response of
human burn injury.
Methods: Adult male C57BL/J6 mice were shaved, Naired
©,a n d
subjected to full-thickness burns using heated brass plates. Tissues were
flash frozen for analysis and muscle sectioning. Piximus was used for
quantification of LBM, fat mass, bone mineral density, and bone mineral
content.
Results: Survival and weight loss were dependent upon total body surface
area (TBSA) burned and brass plate contact time, with 20% TBSA burn (5-s
contact time) resulting in 60% survival over 30 days. In burned mice, body
weight, LBM, individual muscle masses remained significantly reduced and
liver and spleen weights were significantly increased out to 30 days. Body
weightnadirinburnedmicewas14days,withsignificantlyreducedtotalbody
mass (−7.4%), LBM (−11.5%), individual muscle masses [quadriceps,
(−25.1%); gastrocnemius, (−20.3%); tibialis, (−30%)], and muscle fiber
cross-sectional area (−12%) compared to shams. At 14 days, burned mice
had significantly reduced fat mass (−18.5%), bone mineral density (−7.5%),
bone mineral content (−17.5%), and increases in spleen (+44.4%), and liver
masses (+17.5%). At 14 days, burned mice had significantly elevated
cytokine, chemokine, and acute phase proteins consistent with results in
human burn subjects. Recovery of initial body weight occurred at 35 days,
however significant hyperphagia and polydipsia persisted out to 80 days.
Discussion: This murine model accurately reproduces human pathophys-
iology following severe burn injury, providing a robust framework for
future pharmacological and genetic approaches to dissect out the molecular
mechanisms underlying burn pathophysiology.
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A hallmark of pancreatic cancer (PC) is weight loss (WL) and cachexia.
However, cachexia is difficult to define. According to the new
international consensus classification of cancer cachexia patients who
have one or more of the following three criteria should be diagnosed as
cachectic: (a)>5% loss of body weight (BW) during the past 6 months,
or (b) a body mass index (BMI)<20 kg/m
2 and ongoing WL>2%, or (c)
sarcopenia and ongoing WL>2%.
Aim: The study aims to use this new cancer cachexia definition to
diagnose cachexia in an unselected group of patients with advanced
PC referred for palliative treatment.
Methods: Thirty-nine patients with PC were consecutively recruited,
and asked to recall pre-illness stable BW and duration of WL.
Anthropometric measurements (height, BW, skinfold thickness) were
performed at inclusion and after 1 month. Sarcopenia was assessed
with anthropometry (mid-upper arm muscle area <32 cm
2 for men and
<18 cm
2 for women).
Results: Median age was 62 years and median Eastern Cooperative
Oncology Group Performance Status status was 1. Median survival was
5 months. Upon inclusion, 92% had weight loss>5%, 28% had BMI<
20 kg/m
2, and 10% had sarcopenia. Median survival among patients
meeting one criteria (n=25) or two criteria (n=9) was 7 months while
patients meeting three criteria (n=3) had a median survival of 2 months.
According to the definition, three patients did not have cachexia, and the
survival in this group was >8 months. After 1 month, 30 (88%) of the
patients were evaluated and 16 (53%) patients were found to have
cachexia.
Conclusion: Almost all patients (92%) with advanced PC were cachectic
at inclusion according to the new definition. After 1 month, about half of
the patients (53%) fulfilled the criteria for the diagnosis, probably
indicating an effect of the palliative treatment.
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Background and aims: The publication of an expert consensus on the
diagnostic criteria and classification of cancer cachexia (Fearon et al.,
Lancet Oncology, 2011) stimulated us: (1) to apply the published
classification system to real patient data; (2) to determine if the primary
tumour site influenced the proportions of patients with “precachexia” or
“cachexia”.
Methods: One hundred ninety-eight persons with a recent diagnosis
of advanced cancer of various origins from the McGill University
Health Center and the Jewish General Hospital, in Montréal, Canada
were evaluated prior to treatment. Self-reported weight loss over the
past 6 months and anorexia/associated symptoms were obtained.
Serum C-reactive protein (CRP) levels were collected and measured.
Patients were classified as normal, with precachexia or with
cachexia.
Results: We evaluated 81 women (40.9%) and 117 men (59.1%). In
our sample, 107 (54%) persons were classified as “normal”,8( 4 . 0 % )
with precachexia, and 83 (41.9%) with cachexia at the time of
diagnosis. People with pancreatic cancers had the higher rates of
cachexia (58.0%), followed by colorectal (50.0%), upper GI (42.3%),
hepatobiliary (41.2%), lung (34.5%), breast (26.3%), ENT (26.1%),
and prostate cancers (33.3%). High serum CRP levels (>10 mg/L)
were less prevalent on average in normal patients (40.0%), followed
by patients with precachexia (71.4%) and cachexia (50.8%), but this
difference was not statistically different (p=0.12).
Conclusions: The Lancet Oncology classification system enabled us to
identify patients with cachexia. However, while the <5% weight loss
criteria for precachexia is clear, factoring in the other criteria
(anorexia and catabolic change) is imprecise. We recommend that
clearer definitions for anorexia and catabolic load be established.
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Background: Many challenges exist in the design of clinical trials for
cancer cachexia particularly in patient selection and identification of
appropriate outcomes. A consensus framework for the definition and
classification of cancer cachexia was proposed in 2010; the main goal to
help improve the design of clinical trials.
Objective: To evaluate published and ongoing/unpublished clinical
trials according to patient selection (cachexia stage, oncology
treatment profile), and outcomes related to the four domains of the
consensus framework: domain I, depletion of reserves (body weight,
muscle mass, strength); domain II, limitations to nutritional intake
(food intake, nutrition impact symptoms); domain III, catabolic drive
(systemic inflammation, altered metabolism, response to chemotherapy);
domain IV, functional/psychosocial effects of cachexia (physical function,
quality of life, distress, fatigue).
Methods: A systematic literature review identified all clinical trials from
2000 to August 31, 2011. Databases searched: Medline, Embase, PsycInfo,
CINAHL (published), and www.clinicaltrials.gov (ongoing/unpublished).
A total of 3,030 citations were identified, review of titles and abstracts
excluded 2,206 citations not related to cancer, cachexia, or clinical trials.
Ninety-three full-text articles and 64 registered clinical trials were selected
and reviewed by two researchers.
Results: Sixty-five published and 34 ongoing/unpublished clinical trials
were included. Patient population—patients were included based on
criteria known to define cachexia that was inconsistently applied:
weight loss (70%), good functional status (43%), life expectancy
>3 months (25%), reduced food intake/anorexia (26%), and inflamma-
tion/altered metabolism (12%). When compared to the criteria for
cachexia stage, all studies likely included patients with cachexia but
also pre-cachexia (n=42) and refractory cachexia (n=78). The oncology
treatment profile: no treatment (31%), active treatment or no treatment
(24%), active treatment (21%), or not reported (23%). It was not clear
whether no treatment referred to a break from current active treatment or
no further treatment options were available. A description of supportive
care was reported in 25% of studies. Outcomes related to the four
domains are listed in Table 1.
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Number of Studies %
Domain I. Depletion of Reserves 86 87%
Body Weight 72 73%
Body Composition 60 61%
CT 2 2%
DEXA 9 9%
Anthropometrics 14 14%
BIA 33 33%
Muscle Strength 21 21%
upper limb hand-grip dynamometry 14 14%
lower limb extension 3 3%
Domain II. Limitations to Nutrtional Intake 72 73%
Food Intake 33 33%
Patient-reported food records (calculated) 26 26%
Subjective categorical classification 7 7%
Nutrition Impact Symptoms 53 54%
Appetite 43 43%
Domain III. Catabolic Drive 40 40%
Inflammation 32 32%
CRP 21 21%
Altered Metabolism (REE, indirect calorimetry) 13 13%
Response to chemotherapy 5 5%
Domain IV. Functional/Psychosocial Effects 73 74%
Physical Function 41 41%
Physician reported (ECOG, KPS, WHO, etc.) 27 27%
Objective measures (measured PA, exercise capacity) 12 12%
Patient-reported 8 8%
Quality of Life 53 54%
Fatigue 18 18%
Distress (depression, anxiety, mood, well being) 9 9%
Conclusion: There is a lack of consistency in defining criteria for
patient selection into clinical trials, given the variability observed.
Outcomes as proposed in the conceptual framework are unfortunately
rarely included, specifically for muscle mass and measures of physical
function. Further work in the clinical trials in the cancer cachexia
working group of SCWD will propose implementation steps based on
this review.
3-04
Diagnostic stages for cancer cachexia: are they clinically relevant?
Antonio A.L. Vigano
1, Egidio Del Fabbro
2, José A. Morais
3, Enriqueta
Lucar
1, Barbara Trutschnigg
1, Amy Pronovost
4, Robert D. Kilgour
5,
Eduardo Bruera
2, Manuel Borod
6 (
1McGill Nutrition and Performance
Laboratory (MNUPAL), McGill University Health Centre (MUHC),
Montreal, QC, Canada;
2Department of Palliative Care and Rehabiltation
Medicine, MD Anderson Cancer Centre, Houston, TX, USA;
3Division of
Geriatric Medicine, MUHC, Montreal, QC, Canada;
4Clinical Nutrition
Services, MUHC, Montreal, QC, Canada;
5Department of Exercise Science,
Concordia University, Montreal, Canada;
6Division of Palliative Care,
MUHC, Montreal, QC, Canada)
Background: Cancer cachexia stages (CCS; Fearon et al. 2011) were applied
totheHumanCancerCachexia Database via consensusamongthe co-authors.
Methods: In 208 patients with advanced nonsmall cell lung or gastroin-
testinal cancers, we tested the relationship between the noncachexia (NC),
sarcopenia (S), pre-cachexia (PC), cachexia (C), and refractory cachexia
(RC) stages with selected outcomes.
Results:
NC S PC C RC
n=50 n=10 n=29 n=49 n=70
ECOG PS*
(0-4; 4worst)
0.7±1.0^ 0.6±0.5 1.1±0.3 1.2±0.7 2.5±0.8
McGill QoL Total
Score (0-10;
0 Worst)**
7.0±1.2 7.2±1.0 5.2±1.3 5.3±1.5 4.9±1.5
# Hospital
days/follow-up
days(%)***
4.6±11.2 6.1±13.9 13.5±25.5 4.9±11.6 30.8±35.8
Chemotherapy Dose
Reduction†
4/17 (23.5%) 1/1 (100%) 3/9 (33.3%) 7/16 (43.8%) 8/16 (50%)
Total fat mass by
DXA (kg) ††
26.1±11.7 19.8±10.9 19.9±10.7 17.1±9.4 13.0±7.6
Total lean mass by
DXA (kg) ‡
10.9±2.1 7.3±2.3 10.3±2.8 8.3±1.7 9.6±2.2
Survival (wks) ‡‡ 69.4 62.8 35.0 39.4 11.1
Median (95% CI) (48.1–90.8) (42.5–83.2) (13.9–56.1) (28.4–50.4) (5.9–16.3)
^mean ± SD. * NC different from PC, C, RC; PC different from S, RC; C different
from RC; RC different from S; ** NC and S different from PC, C, RC; *** RC
different from NC, S, PC, C; ANOVA p<0.05. † Chi-square test: p<0.05. †† NC
different from C, RC; ‡ S different from NC, PC; ANOVA p<0.05. ‡‡ Log-rank test:
p<0.01.
Conclusions: The proposed CCS appears to have specific clinical
relevance. Additional studies are needed to confirm their applicability.
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Background: Cancer cachexia (CC) is frequent in advanced cancer,
associated with high morbidity and mortality. Without anticancer treatment
options, the course is usually fatal. Psychosocial effects (PSE) of CC are
recommended to be looked for and psychosocial support should be
provided.
Objectives: This study aims to review the literature on PSE of CC with the
aim of identifying misbehaviour which could be modified.
Methods: A systematic literature search in MEDLINE was performed.
Keywords for the topics “advanced cancer”, “anorexia/cachexia” and
“psychosocial effects” were used for the search string. The search was
amended by hand search.
Results: Eighteen studies were included. The analysis revealed causes
of, presentations of, and coping strategies for PSE of CC for patients
and carers. Few do not manage the effects constructively, adverse
reactions have been identified. The main causes of PSE are a lack of
knowledge CC is usually irreversible and inappropriate attempts to
increase nutritional intake. Depending on the coping strategies of
affected ones and their carers, PSE can increase or decrease.
Identification of PSE of CC offers potential for psychosocial interventions
to improve quality of life of those affected. Our analysis generated a
conceptualisation of PSE of CC. A number of suggestions for psychosocial
interventions were detected.
Conclusion: The concept of PSE in CC could help to sensitize
healthcare professionals to cachexia-related problems and inform the
management of CC.
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Background and aims: Pancreatic cancer is characterized by a high
frequency of cachexia, pain, and neural invasion (N-inv). Neural damage is
occurred by N-inv and modulates pain and muscle atrophy in the
connected spine. N-inv, thus, may affect cachexia in pancreatic cancer.
The aim of this study is to elucidate the role of N-inv in cachexia and pain
using clinical data and experimenral N-inv model of pancreatic cancer.
Methods: Radiological N-inv, body composition, and pain were assessed
using dynamic computed tomography, bioelectrical impedance analysis,
and MD Anderson symptom inventory, respectively, in 50 patients (29
women, 21 men; median age, 66.5 years; range, 44–85; primary tumor
sites in the pancreatic head/body/tail, 22/23/5) with treatment-naive
advanced pancreatic cancer who were scheduled to undergo chemotherapy
in National Cancer Center Hospital East. Patients with liver metastasis
were excluded. The relationships between radiological N-inv and other
factors were evaluated. N-inv model was made by the injection of Capan-
1, human pancreatic cancer cell, into a left sciatic nerve of severe
combined immunodeficiency mice. To investigate the effects of sham
operation and subcutaneous tumors, the PBS group and the SC group were
produced by injecting PBS into the sciatic nerve and by subcutaneous
injection of cancer cells into the left flank, respectively. Allodynia was
measured by Von-Fray test. Food intake and body weight were recorded. All
mice were euthanized at 6 weeks after surgery. Bilateral epididymal fat tissue,
right gastrocnemius muscle, and the tumor were harvested and weighed.
Results: Clinical studies in patients with pancreatic cancer have revealed
that N-inv is related to cachexia and pain. N-inv mice showed allodynia
and a loss of body weight without appetite loss, which are compatible with
an animal model of cancer cachexia.
Conclusion: This study provides the evidence that N-inv induces cachexia
and pain in pancreatic cancer.
3-07
Physical function at the time of diagnosis: the role of cancer cachexia
Ana Maria Rodriguez
1, Bruno Gagnon
2 (
1Division of Clinical Epidemiology,
McGill University Health Center, McGill University, Montreal, Canada;
2Department of Medicine and Oncology, Faculty of Medicine, McGill
University, Montreal, Canada)
Background and aims: We have recently applied the international
consensus classification system for cancer cachexia (Fearon et al. 2011)
on people with advanced cancer. Our main objective was to determine the
extent to which cachexic state predicted physical function at the time of
diagnosis. A second aim was to verify the role of systemic inflammation in
predicting physical function.
Methods: One hundred ninety-eight persons with a recent diagnosis of
advanced cancer of various origins from the McGill University Health Center
and the Jewish General Hospital (JGH) in Montreal, Canada were evaluated
prior treatment. Cachexic state was determined by applying the guidelines
suggested by Fearon et al. Physical function was measured by the 2-min walk
test (2MWT), the Timed-Up and Go (TUG), comfortable gait speed over 5 m,
and by the physical function subscale of the SF-36 (PFI). Serum C-reactive
protein (CRP) levels were collected and measured. Multiple linear regressions
were used to analyze the relationship between the variables.
Results: Cachexic state was not a significant predictor of physical function
regardless of how physical function was measured, holding age, gender, primary
tumor site, and CRP levels constant. The TUG and 2MWT (R
2=0.21 and 0.22)
were significantly predicted by age (b=0.06±0.02 and −0.89±0.33, respec-
tively) and CRP levels (b=0.02±0.01 and −0.41±0.15, respectively).
Age (b=−0.01±0.002) was the only significant predictor of comfortable
gait speed (R
2=0.28). Sex (b=11.31±5.15) and CRP levels (b=−0.23±
0.09) significantly predicted self-reported PFI (R2=0.25).
Conclusions: At the time of diagnosis, systemic inflammation seems
to be an important predictor of physical function. Although physical
function is on average lower in cachexic and precachexic patients than
in normal patients, cachexia in itself does not seem to be a significant
predictor of physical function at diagnosis. Physical function levels
during the disease progression could however be influenced by cancer
cachexia.
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The clinical management of the emotional aspects of cancer cachexia
Jane B. Hopkinson (School of Nursing and Midwifery Studies, Cardiff
University, Cardiff, Wales, UK)
Background: The prevention or alleviation of the symptoms of cancer
cachexia, such as weight loss and poor appetite, would relieve much
cachexia-related suffering. However, whilst the research community works
to achieve this goal there is another important task: to help people with
cancer cachexia to adapt and live with the symptoms. This is now
acknowledged internationally by experts in the field of cancer cachexia
research
1.
Purpose: The study aims to discuss the psychosocial support of people
affected by cancer cachexia, drawing on recent publications.
Methods: Searches were conducted of PubMed, EMBASE, PsycINFO and
CINAHL databases for publications about the clinical management of the
emotional impact of cancer cachexia. Limits were English language; 3/09
to 9/11.
Findings: Recent studies describe the problem of distress in response
to symptoms of cancer cachexia syndrome. Some authors suggest
ways of alleviating the problem and others urge the development of
psychosocial interventions. Preliminary work is now testing supportive
interventions.
Conclusion: Despite accounts over many years of cachexia-related
distress, little attention has been paid to the potential for psychosocial
support to aid patient self-management and improve emotional health
outcomes. Emergent thinking is that psychosocial support for cancer
cachexia can have benefit for both patients and their family members, but
this is yet to be demonstrated empirically in robust trials.
1Fearon et al. Definition and classification of cancer cachexia: an
international consensus. The Lancet Oncology 12(5): 489–495.
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Healthcare professionals’ response to cachexia in advanced cancer
Claire Millar, Joanne Reid, Sam Porter (Queen’s University Belfast,
Northern Ireland)
Background: Cancer cachexia is a complex metabolic syndrome charac-
terised by severe and progressive weight loss which is predominantly
muscle mass. It is a devastating complication of advanced cancer with
profound bio-psycho-social implications for patients and their families. At
present, there is no curative treatment for cachexia in advanced cancer
therefore, the most important healthcare response entails the minimisation
of the psycho-social distress associated with it. However, the literature
226 J Cachexia Sarcopenia Muscle (2011) 2:209–261suggests healthcare professionals’ are missing opportunities to respond to
the multi-dimensional needs of this population.
Aim: The objective of this study was to explore healthcare professionals’
experience, understanding and perception of need of patients with
advanced cancer who have cachexia and their families.
Methods: An interpretative qualitative approach based on symbolic
interactionism was adopted. A purposive sample of doctors, nurses,
specialist nurses, and dieticians were recruited from a cancer centre in a
large teaching hospital in Northern Ireland. Data collection consisted of
two phases: focus group interviews followed by individual semi-structured
interviews.
Results: Findings from the focus group interviews were used as a
framework for the semistructured interview schedule. Results centred on
the influence of a variable combination of knowledge, culture, and
resources on the management of cachexia in advanced cancer. Data
revealed that variation in healthcare professionals’ perceptions of cachexia
in advanced cancer, along with their professional ethos, influenced their
response to it in clinical practice.
Conclusions: This study has revealed that cancer cachexia is a complex
and challenging syndrome which needs to be addressed from a holistic
model of care to reflect the multidimensional needs of patients and their
families. Effective management will require a combination of knowledge, a
supportive culture, and adequate resources.
3-10
Energy requirement in elderly cachectic patients with cancer
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Background: Cachexia is a well-known adverse effect of cancer and is
associated with poor prognosis, impaired physical function and reduced
tolerance to anticancer treatments. Despite understanding of cachexia has
progressed, the clinical management remains complex and few data about
energy requirement is available in elderly patients with cancer cachexia
despite its implication for nutritional support.
Aims: The present study evaluated measured resting energy expenditure
(mREE) and predicted energy expenditure (pREE) in elderly patients with
cancer cachexia.
Methods: Fifty-nine elderly patients from our consultation of nutrition and
addressed by the service of oncology were consecutively included (76.88±
9.17 years). They all had weight loss >5% or BMI<20 and weight loss >2%,
over the past 6 months according to Fearon’s criteria. mREE was measured
with indirect calorimetry and pREE was calculated from the Harris and
Benedict equations.
Results: Mean weight was 57.86±12.88 kg and mean weight loss was
7.13 kg±3.46 at 6 months; mean BMI was 21.93±4.25; mean albumine-
mia: 30.71±7.19 g/l and CRP 35.96±40.07 mg/l. Mean MNA score was
17.68±4.87. mREE was 1,296.57±341.11 kcal/day and pREE was
1,135.07±199.13 kcal/day. Of the patients, 31.7% showed mREE more
than 20% pREE; while caloric intake was 1,361 kcal±572/day and
23.52 kcal/kg/day. Anorexia was present in 43% of the patients.
Conclusion: As expected, patients had inflammatory process and
malnutrition criteria. Elderly patients with cancer cachexia show rather
similar values for mREE and pREE that do not really confirm an elevated
REE in the majority of our patients as commonly held. Loss of weight
seems to be mainly explained by insufficient caloric intake since caloric
intake was largely under energy requirement that may be estimated at least
at 1.4 REE in these patients.
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Neuropeptides, metabolic disorder and inflammation in colon
cancer patients: contributing to the cachexia syndrome
Fabio Lira
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Background and aims: Cancer cachexia, a devastating wasting syndrome,
affects around 50% of all cancer patients and up to 80% of those with the
advanced form of the disease. Inflammation plays a pivotal role in
cachexia affecting the control of central energy balance, tissue metabolism
and function, and modulation of appetite. This study aimed to examine
plasma lipid profile, neuropeptides, and inflammatory marker levels in
cancer patients with and without cachexia.
Methods: Forty-five subjects (control n=15, tumour-bearing patients
without cachexia n=15, and tumour-bearing cachectic patients n=15).
Samples were obtained from male and female patients, 18–100 years with
gastrointestinal tumour, who underwent surgery at University Hospital
(University of São Paulo). Approximately 10 mL of blood were collected
in the surgical procedure within the venous access procedure of
anaesthesia. The plasma lipid profile (Triglycerides, HDL-cholesterol, total
cholesterol, NEFA), glucose, insulin, HOMA-IR, PAI-1, endotoxin, MSH,
MCH and NPY levels were determined (Kits ELISA and colorimetric
methods).
Results: Total cholesterol levels were increased in tumour-bearing (without
and with cachexia) patients (p<0.05). In addition, NEFA and PAI-1 levels
were increased in cachectic patients only (p<0.05). In contrast, all neuro-
peptides assessed (MCH, MCH, and NPY) were decreased in cachectic
tumour-bearing patients, as compared with the control group (p<0.05).
Conclusion: These results indicate that cachectic cancer patients exhibit
alterations in metabolism, inflammation and modified neurohormonal
control of food intake, favouring the aggravation of the syndrome.
3-12
Serum IGF-1 levels help detect and predict skeletal muscle loss
in cancer patients
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Background and aims: Skeletal muscle wasting is a cardinal feature of
cancer cachexia and an important prognostic sign. Unfortunately,
measurement of skeletal muscle mass for clinical purposes can be
challenging using standard bedside techniques. Effective treatment of
cachexia in cancer patients requires accurate assessment of skeletal
muscle mass to determine both the success of interventions and to
identify patients at high risk of further muscle loss. The objective of
this study was to establish whether serum markers can help in
detecting and predicting changes in skeletal muscle mass.
J Cachexia Sarcopenia Muscle (2011) 2:209–261 227Methods: Cancer patients (n=28, mean age 65.6, 11 (39%) female, 26
(90%) advanced stage) were recruited during or after chemotherapy
treatment. Each patient had measurements of skeletal muscle mass
performed by either CT image analysis or DEXA on two occasions
(mean(SD) interval: 50 (18)days) and serum samples collected at the same
time as measurement of skeletal muscle mass were analysed for cortisol,
CRP, IGF-1, myoglobin, and creatine kinase.
Results: At first visit, skeletal muscle mass corrected for height (SMI) was
weakly correlated with IGF-1 only (R=0.39, p=0.04), and IGF-1 was also
the only factor predictive of imminent change in SMI (R=0.63, p<0.001).
At the second visit, IGF-1 was the only factor correlated with SMI (R=
0.59, p=0.003) and was also highly correlated with recent change in
skeletal muscle mass (R=0.66, p<0.001). Myoglobin level was also
inversely related to recent change in SMI (R=−0.40, p=0.03). Of the factors
tested IGF-1 was most strongly related to muscle mass. Furthermore, loss of
muscle mass was most clearly seen in the 45% of patients with IGF-1 levels
<15 nmol/l (age-adjusted reference range 6.8–23.3).
Conclusion: Even low-normal IGF-1 levels are insufficient to maintain
stable skeletal muscle mass in cancer patients with advanced disease.
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Functional impairment and distinct metabolic adaptations in skeletal
muscle of pre-cachectic and cachectic patients with non-small cell lung
cancer
Anne-Marie C. Dingemans, Céline M. Op den Kamp, Frank J.
Snepvangers, Marco C. Kelders, Ramon C. Langen, Annemie M. Schols
(Department of Respiratory Medicine,MaastrichtUniversityMedicalCentre,
Maastricht, The Netherlands)
Background: A recent study demonstrated that exercise capacity is already
decreased in patients with early stages of non-small cell lung cancer
(NSCLC) cachexia, i.e. pre-cachexia. As physical performance is an
important determinant of quality of life and mortality, we further focused
on the molecular basis of this observation.
Aim: This study aims to investigate whether histochemical and
metabolic properties of skeletal muscle are altered in pre-cachectic
and cachectic patients with NSCLC.
Methods: In this prospective study, 22 healthy controls and 16 cachectic
and 10 pre-cachectic patients with NSCLC were studied. Physical
performance was assessed using quality of life (QLQ-C30) and physical
activity (SF-20) questionnaires. Quadriceps muscle biopsies were analyzed
by immunohistochemistry to distinguish muscle fibers containing type I
(oxidative), type IIa (mixed) or type IIx (glycolytic) myosin heavy chain
isoforms. Furthermore, expression and activity of an important regulator
(PGC1alpha) and enzymes (citrate synthase and 3-Hydroxyacyl-CoA
dehydrogenase) of oxidative metabolism were assessed.
Results: Although skeletal muscle mass was only significantly
decreased in patients with cachexia (p<0.001), both patients groups
showed decreased physical performance (p<0.001). Interestingly, both
patients with pre-cachexia and cachexia demonstrated a fiber type I to >II
shift compared with healthy controls. While pre-cachectic patients
showed a higher percentage of type IIx (p=0.015), cachectic patients
showed a higher percentage of type IIa (p=0.036) fibers. mRNA
expression of PGC1alpha was decreased in both patients groups and
decreased activity of oxidative enzymes was observed in muscle of
patients with cachexia.
Conclusions: The shift from types I to II fibers and alterations in
oxidative metabolism observed in both patients with pre-cachexia
and cachexia may lie at the basis of exercise intolerance in these
patient groups. The relative shift to type IIa or IIx fibers in cachexia
and pre-cachexia, respectively, implicates that metabolic adaptations
are distinct in successive stages of cachexia.
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The prevalence and prognostic value of cachexia in patients with stage
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Background and aims: Cachexia frequently occurs in patients with lung
cancer, and is associated with reduced physical function, intolerance to anti-
cancer therapy and shorter survival. Our aim was to study the prevalence and
the prognostic value of cachexia and to explore parameters associated with
cachexia in patients with stage III non-small cell lung carcinoma (NSCLC).
Methods: In 40 patients at diagnosis of stage III NSCLC, weight loss, FFM,
handgrip strength, anorexia, nutritional intake and serum biochemistry were
assessed. The ESPEN SIG and Fearon criteria were used to define pre-
cachexia and cachexia, respectively. Cachexia was also defined by the Evans
criteria. Additionally, quality of life was assessed by the EORTC-QLQC30
questionnaire. Differences between groups were analysed by independent t
tests and ANOVA, and survival by Cox regression, adjusted for sex and
tumour stage (IIIa/IIIb).
Results: According to the SIG and Fearon criteria, pre-cachexia was
present in 9 (23%), cachexia in 7 (18%), and no cachexia in 24 (60%)
patients. Survival between these groups was not significantly different, but
patients with cachexia reported a lower quality of life (p=0.03). According
to the Evans criteria, cachexia was present in 11 (28%) patients and no
cachexia in 29 (72%) patients. The cachexia group showed a significantly
shorter survival than the no-cachexia group (HR=4.4, p=0.001). Patients
with cachexia had higher levels of CRP and IL-6, and lower Hb and serum
albumin than patients without cachexia (p<0.01), and all inflammatory
parameters were significantly correlated (Pearson r: 0.5–0.7, p<0.01).
Patients with cachexia tended to report a lower quality of life (p=0.08).
Conclusions: Pre-cachexia and cachexia are prevalent at diagnosis of stage III
NSCLC, but criteria find different prevalences. Cachexia seems to be
associated with shorter survival and a lower quality of life. Further studies
are warranted to more extensively explore these new criteria in cancer patients.
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on gastrointestinal cancer patients: IL-6 as a potencial biomarker
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Background and aims: Cancercachexiagenesisanddevelopmenthavebeen
proposed to be triggered by complex network of peripheral mediators
involving IL-6, CPR and adiponectin, cytokines involved on inflammatory
and body weight homeostasis. Thus, we proposed to determine whether the
upregulation of the aforementioned cytokines, reported in gastrointestinal
cancers (GI), is associated with substantial but involuntary weight loss in
cancer patients (cachexia).We also aimedtoevaluate the relationship between
these cytokines and the clinic-pathological variables found to affect the
incidence of cachexia in cachectic GI cancer patients.
228 J Cachexia Sarcopenia Muscle (2011) 2:209–261Methods: IL-6, IL-8, TNF-α, IL-10, CPR and adiponectin were assessed by
multiplexed microsphere cytokine immunoassay (Millipore®) in 59 patients,
which were divided into four groups: stable weight control (WS, n=10) and
tumor control (T, n=12), and control cachectic (C, n=6) and tumor cachectic
(TC, n=31). All the data were related to the effect of cachexia and/or cancer.
Results: Increased levels of CRP and adiponectin were found in TC group
when compared with WS (1.4- and 7.1-fold, p<0.01, respectively),
demonstrating a cachexia effect (ANOVA, p<0.01). In T and TC patients,
IL-6 levels were also increased when compared with WS (1.3- and 11-fold,
p<0.001, respectively), demonstrating a tumor effect and interaction
between the variables (ANOVA, p<0.05). Association between adiponectin
and body weight loss showed a positive relationship (r=0.668, p<0.001), as
well as increased levels of IL-6 were found in different cancer T stages (I/
II—34±10, III—115±59, IV—215±83, p<0.001) in cachectic GI patients.
Conclusions: A novelfinding ofthisstudywas that some molecules seems to
be disrupted only during cachexia state while some others increase in both
states (tumor x cachexia). In addition, our results suggest that IL-6 may have
an important role as a biomarker during cancer cachexia development.
Financial support: FAPESP 2007/52782-1, 2008/51094-9 and 2010/51078-1.
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Low prevalence of precachexia and cachexia in patients with head and
neck cancer scheduled for treatment with primary radiotherapy
Jacqueline A.E. Langius, Susanne Buskermolen, Hinke M. Kruizenga
(Nutrition and Dietetics, Internal Medicine, VU University Medical Center,
Amsterdam, The Netherlands)
Background and aims: Recently, an international group of experts achieved
consensus on the definition, classification and staging of cancer cachexia
1.I t
has been assumed that cachexia is present in many cancer patients. The aim of
this study was to assess the prevalence of precachexia and cachexia in patients
with head and neck cancer, scheduled for treatment with primary radiotherapy.
Methods: Of all patients with head and neck cancer who were scheduled for
treatment withprimaryradiotherapy, all items neededfortheclassificationof(pre)
cachexia were assessed before start of the antitumor treatment: anorexia symptom
score with use of the EORTC QLQ C30 (symptom scale >33), C-reactive protein
(CRP; ≥8 mg/L), weight loss history in the year prior to treatment, body mass
index (BMI; <20) and fat free mass index (FFMI; <5th percentile
2).
Results: Thirty-seven patients were studied (76% men). Eighty-nine percent of
the tumours were T-stage I or II. Sixty percent of the patients had gained body
weight, 16% of the patients had lost 0–2% body weight, 11% of the patients
had lost >2–5% body weight and 14% of the patients had lost more than 5%
body weight. Median CRP was 4.0 mg/L (2–47) and 12 patients (32%) had a
high CRP according to the hospital cut-off value (≥ 8 mg/L). Prevalence rates
for precachexia were 2.7% and for cachexia 5.4%. Figure 1 shows the
classification of (pre)cachexia in this group of patients with head and neck
cancer, with use of a decision tree.
Conclusion: Prevalence of precachexia and cachexia is low in patients with
head and neck cancer, scheduled for treatment with primary radiotherapy.
References
1. Fearon K, et al. Lancet Oncol 2011; 12(5):489–495
2. Schutz Y, et al. Int J Obes Relat Metab Disord. 2002 Jul;26(7):953–60
Figure 1. Prevalence of precachexia and cachexia for head and neck cancer
patients using a decision tree
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Assessing body composition using computed tomography imaging:
findings in UK patients with thoracic cancer
Chloe Pettit, Matthew Maddocks, Kate Pointon, Andrew Wilcock
(University of Nottingham, Nottinghamshire, UK)
Background and aims: Cancer cachexia adversely affects treatment
response, quality of life and survival. Effective treatments are lacking
and progress is hindered, in part, by the lack of reliable assessments of
body composition. The use of computed tomography (CT) images for body
composition analysis is one potential way forward. This study examined
the inter- and intra-observer reliability of this technique and findings in a
UK cohort of patients with thoracic cancer.
Methods: CT scans were analysed using Slice-O-Matic software to
calculate cross-sectional area of skeletal muscle and adipose tissues at
the level of the third lumbar vertebrae, from which whole-body fat and fat-
free mass were estimated. Intra- and inter-observer reliability was assessed
in the first 10 of 100 patients examined. Intra- and inter-class correlation
coefficients and descriptive statistics were used to assess reliability and the
main cohort findings respectively.
Results: CT image analysis was found to be highly reliable both within
and between observers for the assessment of all tissue types with intra- and
inter-class correlation coefficients of 1.00 (lower 95% confidence intervals
0.98–1.00). Of 100 patients (52 female, mean (SD) age 70(9)years, BMI
25.0(4.6)kg/m
2) one fifth were sarcopenic. Of this group, only one third
were classified as malnourished using clinical criteria.
Conclusion: CT image analysis is a highly reliable method of assessing
body composition in patients with thoracic cancer. It can be used to
accurately identify patients with severe muscle wasting, who may be
overlooked by current clinical criteria, and may play an important role in
the future management of cancer cachexia.
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Exploring physical activity level in patients with thoracic cancer:
implications for use as an outcome measure
Matthew Maddocks, Andrew Wilcock (University of Nottingham,
Nottinghamshire, UK)
Background and aims: Cachexia is common in patients with thoracic
cancer impairing physical function and quality of life. New approaches
which target muscle tissue are emerging and activity monitors could
provide an objective assessment of their effect on physical function. We
have collated data from three studies involving the use of one such monitor
in order to benchmark aspects of physical activity for patients with thoracic
cancer, explore how these relate to physician-rated performance status, and
consider the implications for future studies.
Methods: Patients with thoracic cancer and an Eastern Cooperative Oncology
GroupPerformanceStatus(ECOGPS)of0–2woreanActivP AL™monitorfor
1 week. The mean time spent each day in a range of activities, e.g. standing or
stepping, or their frequency, e.g. number of sit-to-stand transitions, steps taken,
were calculated and compared according to ECOG PS using tests of difference.
Results: Data from 84 patients (54 male, mean (SD) age 66 (9)years) were
collated. Each day, patients spent a mean (SD) of 4.3 (2.0)h upright,
completed 45 (17) sit-to-stand transitions, and took 4,246 (2,983) steps.
There was wide variation in each activity examined. All but the number of
sit-to-stand transitions differed significantly between ECOG PS categories.
Conclusion: These data provide a detailed insight into how physical
activity levels change with declining PS. The wide variation in physical
activity within each ECOG PS suggests that performance scales lack
sufficient sensitivity to evaluate new cachexia treatments. Our data help
inform future work in this area.
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Background and aims: The relationship between weight loss and the
presence of inflammation has been described in patients with cancer.
Cancer cachexia is a consequence of multiple factors, including production
of cytokines due to the increased acute phase response which also leads to
higher concentration of C-reactive protein and lower albumin levels. The
presence of inflammation contributes to loss of lean mass and body fat.
Both nutritional status and severity of inflammation may be associated
with the development of complications during cancer treatment. Thus, the
assessment of nutritional status and inflammation could be used as tools to
screen patients who may benefit from early nutritional interventions.
Methods: In the present study, the relationship between nutritional status,
defined by subjective global assessment (SGA), and the severity of
inflammation as defined by the Glasgow prognostic score (GPS) and, its
relation to complications during cancer treatment (defined by common
toxicity criteria) were assessed.
Results: This study enrolled 43 patients with cancer of the esophagus and
stomach with a mean age of 64.7±12.0 years. The nutritional status,
according to the three categories of SGA was associated with the three
categories of the Glasgow prognostic score (p<0.05), and both the SGA
and the GPS were associated with the presence of complications, but the
GPS seems to be more accurate in identifying complications than the SGA
as established by the area under the curve (AUC) (GPS: AUC=0.77, p<0.05,
CI=0.580, 0.956; SGA: AUC=0.679, p<0.05, CI=0.426, 0.931).
Conclusions: GPS may potentially be used as a nutrition screening tool,
and both GPS and SGA may identify those at risk of complications
undergoing treatment, but the GPS has higher accuracy than the SGA.
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Serum interleukin-15 levels, body weight, and muscle mass in cancer
patients with cachexia at the time of diagnosis and after 8 weeks
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Background: Interleukin-15 (IL-15) has important anabolic effects on
muscle protein metabolism through a decrease in the ATP-ubiquitin-
dependent proteolytic pathway. The role of IL-15 in human cancer
cachexia is unknown.
Objective: To assess the relationship between IL-15 and body weight and
muscle mass in cancer patients with cachexia at diagnosis of malignancy
and 8 weeks later.
Design: Observational study of 21 cancer patients and eight healthy
subjects. Cancer patients were divided into those with and without
230 J Cachexia Sarcopenia Muscle (2011) 2:209–261cachexia (loss of ≥10% or <10% of the initial body weight,
respectively). Body composition was measured by leg-to-leg imped-
ance. Serum IL-15 levels were assessed at baseline and after 4 and
8 weeks.
Results: Baseline IL-15 values were similar in cancer patients and in
healthy subjects. Five patients showed an increase of 3.7 kg at the end of
the study (5.4% of body weight) and showed a mean increase of IL-15 of
1.32 pg/mL (121%) at 4 weeks and 2.32 pg/mL (197%) at 8 weeks, as
compared with mean decreases of −4.1 kg (−5.3%) and −0.09 kg (−2.5%)
and 0.6 pg/mL (40.8%) in the 13 patients who lost weight (P=0.001 and P
=0.022, respectively). Changes of IL-15 at 4 and 8 weeks as compared
with baseline were directly associated with changes in body weight, body
mass index, fat-free mass, and muscle mass (P<0.05).
Conclusions: IL-15 may have a physiopathologic role as regulator of body
weight and muscle mass in cancer patients independently of the presence
of cachexia.
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Background and aims: Already at diagnosis, head and neck cancer
patients are at risk for malnutrition. Local symptoms, such as swallowing
problems are a major cause of malnutrition in these patients. Additionally,
malnutrition may result from changes in smell and taste/aversion and loss
of appetite
1. Presence of these systemic symptoms at diagnosis may be
indicative for the cachexia syndrome. Therefore, we tested the hypothesis
that head and neck cancer patients suffer from cachexia.
Methods: Twenty-six adult patients (21 male and 5 female) with newly
diagnosed squamous cell carcinoma in the oral cavity (n=9), pharynx (n=11)
or larynx (n=6), using a solid diet, were included. Cachexia was assessed
1 week prior to start of cancer treatment, according to the criteria of Fearon et
al.
2: appendicular skeletal muscle index <7.26 kg/m² in men and <5.45 kg/m²
in women, as measured by dual energy X-ray absorptiometry, and any degree
of weight loss >2%. Additionally, inflammatory markers (CRP, IL-6 and Hb)
were assessed.
Results: Prevalence of cachexia was 31% (8/26) (95% CI: 17%; 50%). Of
the cachectic patients, six had elevated levels of serum CRP (>5 mg/l), one
had an elevated level of IL-6 (>4.0 pg/ml) and two had anemia (Hb<
8.5 mmol/l in men, <7.5 mmol/l in women). None of the cachectic patients
had disturbed levels of all inflammatory markers.
Conclusions: About one third of newly diagnosed head and neck cancer
patients suffers from cachexia. In the strategy to prevent further
deterioration of nutritional status of this patient group, treatment of
cachexia should be a specific target.
1. Jager-Wittenaar H, Dijkstra PU, Vissink A et al. Malnutrition in patients
treated for oral or oropharyngeal cancer—prevalence and relationship with
oral symptoms: an explorative study. Supp Care Cancer 2010 (in press)
2. Fearon K, Strasser F, Anker SD et al. Definition and classification of
cancer cachexia: an international consensus: Lancet Oncol 2011;12
(5):489–95.
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Background and aims: Lower-limb extensor power (LLEP) is important
for the daily performance of dynamic lower-limb activities that require
rapid rates of muscle contraction. However little is known about the
relationship between muscle power and functional ability nor the influence
of weight loss on power output in cancer cachexia. We hypothesized that
(1) LLEP would be associated with power-related functional ability and (2)
LLEP would be influenced by degree of weight loss in patients with upper
gastrointestinal cancer (UGC) cachexia.
Methods: Fifty-four patients (n=35 men) with UGC were recruited. Mean
(SD) age was 65(11)years and average weight loss was 8.4(9.4)%. LLEP
of the dominant limb was measured using a Nottingham Power Rig
(highest of five measurements) and timed-up-and-go (TUG) and sit-to-
stand (STS) times (fastest of three efforts) were measured as indicators of
functional ability. Statistical analysis was by Pearson’s product moment
using SPSS v 15.0.
Results: Mean LLEP was 1.29 (0.55)W kg
−1 (1.45 (0.60)W kg
−1 men,
0.99 (0.26) kg
−1 women). Mean TUG was 7.28 (1.80)s (7.24(1.83)s men,
7.37 (1.81)s women) and mean STS time was 0.66 (0.20)s (0.65 (0.20)s
men, 0.68 (0.19)s women). There was a significant negative correlation
between LLEP and both TUG (r=−0.51, p<0.001) and STS (r=−0.58, p<
0.001). Furthermore, percentage weight loss was significantly negatively
correlated with muscle power (r=−0.32, p=0.021) and significantly
positively correlated with STS (r=0.38, p=0.011) but not with TUG (r=
0.26, p=0.089).
Conclusions: We have shown evidence of an association between lower
limb power, functional ability, and weight loss. This supports a rationale
for developing multimodal anti-cachexia interventions to improve power
output in patients with cancer.
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Background and aims: Although muscle wasting in cancer cachexia is
thought to arise from an imbalance between synthetic/proteolytic path-
ways, direct evidence in human cancer cachexia is limited. This study
examined the transcriptional profile of quadriceps muscle in patients before
and after potentially curative surgery for upper gastrointestinal cancer
(UGIC).
Methods: Baseline quadriceps muscle biopsies were performed on 12
UGIC patients undergoing curative resection (mean weight loss 7.4%) and
6 healthy controls (HC). UGIC patients had a follow-up biopsy an average
of 260 days post-surgery (clinically disease-free, weight-stable preceding
2 months). The global transcriptome of these biopsies was analysed using
J Cachexia Sarcopenia Muscle (2011) 2:209–261 231microarrays. Significance analysis of microarrays (SAM), gene
ontology (GO) and ingenuity pathway analysis (IPA) were carried
out. Muscle function (quadriceps strength/lower limb power/hand grip
dynamometry) and physical activity (step count/24 h) were measured
in UGIC patients.
Results: SAM analysis of baseline compared with follow-up UGIC patient
biopsies identified 1,747 downregulated and 121 upregulated genes (false
discovery rate (FDR)≤6%; fold change ≥30%). RT-qPCR validated
selected genes. GO analysis showed downregulation of genes at baseline.
IPA revealed enrichment for skeletal and muscle disorders, PPARα/RXRα
activation, IL-6 signalling and glucocorticoid receptor signalling. Nine
hundred fourty-one genes had lower expression (FDR<10%) in baseline
UGIC patients’ compared with HC muscle. Of theses downregulated
genes, 558 were also regulated between baseline and follow-up UGIC
patient samples. All except one (TFDP2) were higher at follow-up.
Comparison between HC and UGIC follow-up samples revealed a
transcriptomic profile indistinguishable from healthy muscle. Muscle
function and physical activity were not different at follow-up compared
with baseline indicating transcriptomic differences were due to tumour
removal rather than varying physical activity levels.
Conclusions: This study shows that cancer and weight-loss leads to a
suppression of transcriptional activity for genes involved in both anabolism
and catabolism supporting the idea that muscle turnover is suppressed in
cancer cachexia.
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Background and aims: MicroRNAs (miRNAs) represent powerful
mechanisms for regulating tissue phenotype. This study set out to
investigate the role of miRNAs in the skeletal muscle of patients with
cancer cachexia.
Methods: Eighteen upper gastrointestinal cancer patients (average weight
loss, 8.9%) undergoing potentially curative surgeries were recruited. Three
controls undergoing surgery for benign disease were also recruited. Rectus
abdominis muscle biopsies was taken at the time of surgery and RNA
extracts prepared. qPCR and microarrays (Exiqon LNA mercury platform)
were used to study expression level of miRNAs in cancer cachexia.
miRNAs differentially expressed in human muscle tissue and those that
changed with >10% weight loss were identified using significance analysis
of microarray. Differentially expressed miRNAs with a fold change of
≥30% and a false discovery rate <10% over ≥3 probes were chosen.
Results: Microarray revealed five miRNAs (miR-29b, miR-143, miR-100,
miR-193b, miR-768-3p) that were upregulated with >50% fold change and
one miRNA (miR-208a) which was downregulated with >50% fold
change. qPCR validation of selected differentially expressed miRNAs
indicated that miR-29b correlated with weight loss (R=0.5; p=0.03) and
miR-424 showed a trend (R 0.4; p=0.06). miR-195 was also related to
weight loss (R=0.4; p=0.08). Investigation of the ‘myomirs’ (miR-1, miR-
133a and miR-206), which are highly expressed in human muscle and play
a role in muscle development/physiological responses showed that weight-
loss significantly co-varied with mir-133a (R=0.6, p<0.01) but not with
miR-1 and miR-206.
Conclusions: This study has identified novel miRNAs involved in muscle
wasting in cancer cachexia which may represent potential biomarkers and
targets for future therapeutic intervention development.
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Expression profiles of regulatory and proteolytic pathways in skeletal
muscle of patients with non-small cell lung cancer cachexia
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Background: Experimental research has indicated that increased
muscular nuclear factor kappa B (NF-κB) and ubiquitin (Ub) protea-
some system (UPS)-mediated proteolysis plays a pivotal role in cancer-
induced muscle wasting. Currently, only limited data on these pathways
is available in clinical cachexia. This hampers progress in human
cachexia and therefore, translation to clinical cachexia is essential at this
moment.
Aim: The study aims to investigate NF-κB activity and expression of E3
Ub-ligases in skeletal muscle of cachectic patients with NSCLC.
Methods: Sixteen cachectic and 10 pre-cachectic patients with NSCLC
were compared to 22 healthy controls. Body composition was assessed by
DXA and plasma and quadriceps muscle biopsies were obtained.
Transcriptional levels of IkBa were determined as indirect measure of
NF-κB activity and ex vivo plasma transfer to stable NF-kB-luciferase
reporter muscle cells were used to assess NF-κB inducibility. Proteolytic
activity was evaluated by measurement of mRNA expression of four E3
Ub-ligases (NEDD4, Atrogin-1/MAFbox, TRIM32, MuRF1) and
autophagy-related markers (MAP1LC3B, BNIP3).
Results: Cachectic patients demonstrated significant weight loss (mean
13.1%) and decreased muscle mass (p<0.001), while mean weight loss
in pre-cachectic patients was limited (2.1%) and muscle mass was not
altered. Increased muscular mRNA expression of IkBa was evident in
cachectic but not in pre-cachectic patients. Interestingly, ex vivo
exposure to plasma of pre-cachectic and cachectic patients showed
induction of NF-κBl u c i f e r a s ea c t i v i t yi nc u l t u r e dm u s c l ec e l l s .E 3U b -
ligase expression was not significantly altered in both patients groups,
whereas transcript abundance of autophagy-related genes was increased
in cachectic patients.
Conclusions: This study reveals that NF-κB activity, as observed in
muscle tissue, is the consequence of a factor contained within the
circulation of cachectic patients. The absence of Ub-ligase transcriptional
activity suggests that decreased protein synthesis or other proteolytic
systems, such as autophagy as found here, may contribute to muscle
atrophy in human cancer cachexia.
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Background and aims: Cancer cachexia, observed in 80% of advanced
cancer patients, is a multifactorial syndrome characterized by anorexia,
body weight loss, loss of adipose tissue, and skeletal muscle accounting
for at least 20% of deaths in cancer patients. Cancer cachexia is
232 J Cachexia Sarcopenia Muscle (2011) 2:209–261responsible not only for a poor quality of life (QOL) but also poor
responses to chemotherapy. Therefore, development in the treatment and
amelioration of cancer cachexia is required for the improvement of the
decreased QOL and effective chemotherapy. It has been reported that
patients with gastric cancer have the highest frequency (83%) of weight
loss. The aims of the present study are to establish cancer cachexia model
by transplantation of human gastric cancer cell and examine the effects
of rikkunshito, which is a traditional Japanese medicine that prescribed
to treat various gastrointestinal tract disorders, on the cancer cachexia
models.
Methods: Novel two cell lines (MKN45clone85 and 85As2) were
originally established from human gastric cancer cell line MKN45 by
repeated transplantation followed by sorting of the clones causing
significant weight loss in mice. These cells (1×106–107 cells) were
subcutaneously transplanted into nude rats, and then body weight, food
intake, body composition and plasma inflammatory makers were mea-
sured. The effects of oral administration of rikkunshito into rats trans-
planted with 85As2 cell were also examined.
Results: In nude rats transplanted these cell lines, weight loss, anorexia,
low fat-free mass and increased plasma inflammatory makers were
observed (the degree of cachexia:85As2>MKN45clone85). Oral adminis-
tration of rikkunshito significantly ameliorated severe symptoms of cancer
cachexia–anorexia in rats transplanted with 85As2 cells.
Conclusions: These findings suggest that the novel animal models
established here are useful for the study of cancer cachexia including the
pathogenesis and development of potential therapies. Further, rikkunshito
would contribute to the improvement of QOL of patients with cancer
cachexia.
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Background and aims: The aim of the Animal CAchexia SCOre
(ACASCO) is to overcome the problem of cachexia staging in experimen-
tal animals.
Methods: The score considers five main different factors: body weight
and lean body mass loss (BWC), anorexia (ANO), inflammatory,
immunological and metabolic disturbances (IMD), physical performance
(PHP) and quality of life (QoL). The score’s scale goes from 0 to 100:
mild cachexia (less than 25), moderate (more than 25 and less than 50),
severe (more than 50 and less than 75) and terminal phase (more than 75
and up to 100).
Results: In the study, we analyzed the aforementioned factors in tumour-
bearing rats (Yoshida AH-130 ascites hepatoma) at different days after the
tumour inoculation in order to validate the ACASCO. The parameters
analyzed were the following: body and muscle weights (BWC); plasma
levels of tumour necrosis factor-α, serum amyloid A, albumin, lactate,
urea, hematocrit and lymphocyte proliferation assay (IMD); food intake
(ANO); grip strength test and total physical activity (PHP); signs of
distress (temperature alterations, closed eyes, piloerection, diarrhea,
constipation, chomodacryorrhea, lack of movement); and the intruder-
resident paradigm and forced swim tests (QoL).
Conclusions: The present score facilitates cachexia staging in experimental
animals bearing tumours and therefore will allow for a more approppiate
measurement of the degree of cancer wasting.
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The cancer cachexia is frequently seen in patients with advanced cancer
and is characterized by anorexia and weight loss. It is well-known that
such advanced cancer stages are scarcely responsive to available
pharmacological treatments, suggesting that once a critical point is
reached, improvement of the metabolism and availability of nutrients
may be hard to achieve. The central melanocortin system directly controls
nutrient intake and energy metabolism. In the present study, we
investigated the changes in the expression of melanocortin 3 and 4
receptors (MC3R and MC4R) and pro-opiomelanocortin (POMC), which
encodes α-melanocyte-stimulating hormone, within the rat hypothalamus
in both early- and late-stage of cancer cachexia. A tumor xenograft model
was prepared in F344/N-rnu rat using human gastric cancer cells, 60As6.
At 8 weeks after tumor inoculation, when rats exhibited slight
anorexia and weight loss, both MC3R and MC4R expressions in the
hypothalamus were significantly reduced compared to control rats. In
contrast, the dramatic increases in the expression of those receptors
were observed in the hypothalamus of tumor-bearing rats 16 weeks
after tumor inoculation, when rats exhibited severe wasting associated
with significant reduction of both adipose tissue and muscle mass.
Further, under the same conditions, remarkable decrease in POMC
expression in the hypothalamus of tumor-bearing rats was also
observed. These findings suggest that the dramatic upregulations of
MC3R and MC4R possibly caused by downregulation of POMC in
the hypothalamus may contribute to the metabolic alterations and
reduced availability of nutrients under late-stage of cancer cachexia.
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Background: Cancer cachexia is a devastating wasting syndrome that
affects up to 50% of patients, and accounts for >20% of cancer-related
deaths. Wasting results from depletion of adipose tissue and skeletal
muscle. We tested the hypothesis that inactivation of myostatin, a potent
inhibitor of skeletal muscle mass, would prolong survival and attenuate
muscle atrophy and adipose tissue loss.
Methods: Fourteen-month-old C57Bl/6 J wild-type (WT) mice and
myostatin knock-out mice (KO) received a subcutaneous injection of 5×
10
6 Lewis lung carcinoma (LLC) cells to induce cachexia or vehicle alone
J Cachexia Sarcopenia Muscle (2011) 2:209–261 233(n=10 per group). A second cohort was used for a survival analysis on WT
and KO mice injected with LLC cells as described above.
Results: Five weeks later, myostatin gene inactivation significantly
increased food intake (p<0.01; WT-LLC: −9.3% and KO-LLC: +6.52%).
WT-LLC mice had a greater tumor weight than KO-LLC mice (+30%; p<
0.05). Adipose tissue loss was partially prevented in KO mice, with a fat
loss that reached 80% in WT-LLC mice vs. 60% in KO-LLC mice (p<
0.05). LLC injection induced skeletal muscle atrophy in WT mice as
evidenced by the decrease in tibialis anterior and soleus muscle weights
(TA and SOL; −25%), extensor digitorum longus (EDL; −30%) and
gastrocnemius (GAS; −20%) compared to control WT. Myostatin gene
inactivation significantly reduced the magnitude of this loss. Skeletal
muscle mass was only reduced by 10% in TA and EDL muscles (p<0.05
and p<0.001; WT-LLC-injected mice vs. KO-LLC-injected mice) and 6%
both in SOL and GAS muscles (p<0.01 and p<0.05; WT-LLC-injected
mice vs. KO-LLC-injected mice). Finally, myostatin gene inactivation
prolonged lifespan from 32 to 41 days (p<0.001).
Conclusion: Myostatin gene inactivation potently prolongs animal survival
together with attenuating skeletal muscle atrophy and protecting adipose
stores, while increasing food intake and reducing tumor growth. These
findings highlight the therapeutic potential of myostatin inhibition for
cancer cachexia.
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Despite recent consensus definitions of cancer cachexia, lack of specific
diagnostic biomarkers remains a major hurdle towards more accurate
diagnosis of cancer cachexia, but also towards the understanding of
cachexia as a separate entity from other wasting syndromes. In a previous
pilot study, we have shown that cancer-cachectic mice have a unique
metabolic fingerprint with distinct glucose and lipid alterations when
compared to healthy controls. Further, 1H NMR-based metabolomics
studies were carried out to investigate the differences in metabolic profiles
of cancer-cachectic mice when compared to tumor-bearing non-cachectic
mice, calorie-restricted mice, and surgically treated cancer-cachectic mice.
Male CD2F1 mice were divided into five groups: (1) cachexia group
received cachexia-inducing C26 undifferentiated colon carcinoma cells; (2)
tumor-burden group received, non-cachectic, P388 lymphoma cells; (3)
starvation group remained cancer-free but were subjected to caloric-
restriction; (4) surgery group was similar to cachexia group but tumors
were resected mid-experiment; and (5) control group was left to age intact.
Baseline, mid-experiment and final serum samples were collected for 1H-
NMR spectroscopic analysis. After data reduction, unsupervised principal
component analysis and orthogonal projections to latent structures
demonstrate that the unique metabolic fingerprint is independent of tumor
burden and distinct from profiles of starvation and aging. Furthermore,
mice that underwent surgical tumor removal have a metabolic profile that
differentiates itself from that of cachectic mice, seemingly reverting to a
profile more congruent with healthy controls, indicating a return to a
normal state with cure in murine models. Hyperlipidemia, hyperglycemia,
and reduced branched-chain amino acids, distinguish the metabolomic
profile of cachexia from other groups. The findings that metabolomic
analysis of murine serum is able to completely differentiate cachexia from
tumor burden and caloric-restriction warrant similar translational inves-
tigations in patients to better understand cancer cachexia’s unique disease
progression and treatment response.
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Background: Cardiac or respiratory failure is responsible for death in
approximately 30% of advanced cancer patients with cachexia. Signif-
icant reduction in contractile function has been observed in mouse
models of cancer cachexia. The reversal of this cardiac weight loss
increased their longevity. These findings imply the importance in
maintaining cardiac structure and function during cancer progression.
The characterisation of structural and molecular changes in cardiac
muscle during cancer cachexia would allow improved diagnosis and
identification of potential therapeutic targets to improve quality of life
and survival in cancer.
Aims: This study aims to investigate cardiac ultrastructure and gene
expression of the myogenic transcription factor MEF2C and gene targets in
cancer-bearing mice.
Methods: The colon 26 (C26) carcinoma mouse model of cachexia was
established and whole hearts were isolated for gene and protein expression
studies using real-time qPCR and Western blotting. Ultrastructure was
studied with transmission electron microscopy.
Results: Significant weight loss (15–20%) was evident in hearts from C26
mice. Loss of structural integrity and altered mitochondrial morphology
was seen in electron micrographs of cachectic cardiac muscles. Gene and
protein expression of myocyte enhancer factor 2C, an important transcrip-
tion factor in muscle maintenance and regeneration, was found to be
downregulated in hearts from cancer bearing mice with concurrent
suppression of downstream target gene transcription i.e. myoglobin and
myomesin.
Conclusion: The distorted morphology observed in cardiac muscle of
cancer bearing mice suggests compromised oxygen transport capacity and
function. This deterioration of cardiac function due to cancer may
contribute to other complications observed in cancer cachexia. The
alterations in MEF2C gene expression in cardiac muscle due to cancer
has not previously been described and may play an important role in the
underlying pathogenesis of the disruption of cardiac sarcomeric integrity
and energy homeostasis in cachectic hearts.
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Background and aims: Patients suffering from heart failure or
advanced cancer share several clinical features including limitation in
exercise capacity, shortness of breath, early fatigue, and the develop-
ment of cachexia. In both populations, cachexia is a major factor that
reduces quality of life and is associated with an unfavorable
234 J Cachexia Sarcopenia Muscle (2011) 2:209–261prognosis. The underlying mechanism of cancer-mediated cardiac
cachexia is poorly understood. Here, we evaluated the expression of
genes involved in fatty acid oxidation in a mouse cancer model
associated with cardiac cachexia.
Methods and results: A solid pertioneal tumor was induced through
intraperinoneal implantation of melanoma cells (10
6 B16-F10 cells).
Tumor-bearing mice revealed markedly reduced heart weight/body weight
(HW/BW: Cntr.: 5.1±0.2 vs. tumor: 3.7±0.2 mg/g; p<0.001) and heart
weight/tibia length ratio as compared to control mice (HW/TL: Cntr: 12.6
vs. tumor: 5.0 mg/cm; p<0.001) 3 weeks after cell implantation.
Echocardiographic analysis showed reduced systolic function of tumor
bearing mice as measured by fractional shortening (FS: Cntr: 38.9±10.4%,
n=12 vs. tumor: 23.1±5.1%, n=9; p<0.001) and overall thinning of the
wall thickness. This was associated with a high mortality in cancer animals
(66%, n=25 vs. 0% in control, n=17; p<0.001). QRT-PCR revealed
increased mRNA expression of three peroxisome proliferator-activated
receptor isoforms (PPAR α, δ and γ and their co-factor PGC1 α (PPARα:
+71.4±19.2%; p=0.02; PPARδ: +17.3±10.1%, p<0.04; PPARγ:+ 7 0 ±
20.6%, p=0.04; PGC1 α: +36.1±23.1%, p=0.01)). Moreover, the mRNA
levels of carnitine palmitoyltransferase-1, the rate-limiting enzyme that acts
in β-oxidation, was significantly increased (CPT1α: 114.2±29.4, p<0.001;
CPT1β:1 6 4 8 ± 2 1 9 ,p=3).
Conclusion: These findings demonstrate that cancer-induced cachexia is
associated with upregulation of components of the PPAR pathway
involved in muscle fatty acid oxidative gene transcription. This observation
suggests that cancer-mediated cardiac cachexia differs at the molecular and
potentially also at the metabolic level form cardiac cachexia in endstage
heart failure where this pathway has been reported to be upregulated.
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Background and aims: Due to an aging population, cardiovascular and
cancer diseases become an increasing problem. The morbidity and
mortality of cancer and/or chronic heart failure patients is not only
characterized by the progression of the disease-specific process, but also by
cachexia which results in dramatic loss of lean mass and body fat. Despite
the clinical importance, critical molecular mechanisms in cachexia
development and potential common denominators between cardiovascular
and cancer diseases remain unknown, prompting us to explore potential
links between these two disease entities.
Methods: To induce cahcexia, we transplanted Colon26 adenocarcinoma cells
subcutaneously in Balb/c mice. Subsequently, mice were metabolically
monitored by MRI technology and body weight and food intake were
determined. Additionally, we investigated cardiac function by weekly
echocardiography and PV-loop measurement. The heart weight/tibia length
ratio, cardiac morphology, cardiomyocyte size and the degree of cardiac
fibrosis were determined. Furthermore, the gene expression of the heart was
analyzed by Taqman analysis and Affymetrix GeneChips.
Results: Cancer cachexia was induced in experimental mice as shown by
significantly lower body weight, loss of adipose and skeletal muscle
masses and anorexia. Analysis of gene expression pattern revealed a switch
from an adult to a fetal gene program in the heart. Monitoring of heart
function demonstrated a significantly reduced heart rate as well as impaired
fractional shortening in tumor bearing mice. Additionally, the heart weight/
tibia length ratio was lower in mice with cancer. This atrophic phenotype
was correlated with increased autophagy but not with the activation of the
ubiquitin-proteasome system like in skeletal muscle.
Conclusions: We show that cancer cachexia causes an impairment of
cardiac function and energy balance, leading to cardiac atrophy and
insufficiency. Ongoing experiments will now address the molecular
signaling pathways which induce the observed cardiac phenotype in
response to tumor growth.
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Altered circadian rhythm and inflammatory signaling in white adipose
tissue and lipid metabolites in cancer cachexia syndrome
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Involuntary weight loss among patients with cancer is often attributed
to the cancer cachexia syndrome. The aetiology is multifactorial
involving loss of skeletal muscle, adipose tissue and high systemic
levels of inflammatory cytokines such as IL6. In the present study, we
investigated the impact of the murine cachectic Colon 26 (C26)
adenocarcinoma on white adipose tissue (WAT) and lipid metabolites
in plasma and liver. Morphological analysis of WAT by light
microscopy showed reduced size of white adipocytes in cachectic C26
tumour-bearing mice. Alterations in the mRNA levels, as well as
diurnal rhythmic expression of REVERBα,B M A L 1 ,P P A R δ,P P A R γ,
C/EBPα and target genes PBE, ATGL, FAS, LPL and PERILIPIN,
indicate perturbed diurnal pattern in circadian regulation of lipid
metabolism. Furthermore, lipid mobilisation did not appear to be
stimulated through classical hormone-induced PKA activation. These
changes in WAT are accompanied by activation of IL6 signaling
mediated primarily through phosphorylation of STAT3 rather than
ERK1/2 and p38 MAP kinases. Additional Western analysis showed
that the key mediator of metabolic homeostasis and sensor of low
energy state AMPK is activated while downstream mTOR/4EBP1
signalling cascade, which has been implicated in the suppression of
lipolysis, is inhibited. Lipid mobilization was evident in plasma with
increased total free fatty acids. Extensive MS-based lipidomic analysis
of liver and plasma of cachectic mice revealed distinctive changes in
numerous lipid species including ceramides, sphingomyelins, phospho-
lipids, cholesterol, TAGs and DAGs that were unaltered or opposite to
levels apparent in pair-fed mice.
Conclusion: The dramatic depletion of adipose tissue in cachectic tumour-
bearing mice is accompanied by aberrant lipid mobilization and metabo-
lism that cannot be attributed to anorexia.
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Activation of brown adipose tissue in cancer cachexia: an energetically
wasteful process
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Background: Cancer cachexia/anorexia is a complex syndrome involving
profound metabolic imbalance leading to muscle wasting and fat depletion
and is the direct cause of death in 20–30% of all cancer patients. Brown
adipose tissue (BAT) plays a key role in thermogenesis and energy balance
J Cachexia Sarcopenia Muscle (2011) 2:209–261 235and may contribute to the physiological perturbations associated with
advanced cancer including hypermetabolism, fever and cachexia. There-
fore, we investigated the impact of the IL-6 producing cachectic Colon 26
(C26) tumour on BAT in mice.
Results: EM and light microscopy revealed profound delipidation and
smaller brown adipocytes in cachectic C26 tumour-bearing mice. Circadian
expression profiling of key regulators of lipid accumulation and fatty acid
β-oxidation and their corresponding target genes revealed dramatic
molecular changes indicative of active BAT. Increased Ucp1, Pbe and
Cpt1α expression at specific timepoints coincided with higher BAT and
body surface temperatures during the dark cycle, indicative of tight
temporal stimulation of thermogenesis in cachexia. Deiodinase 2,
adenylate cyclase 3 and PGC1α were increased at all diurnal timepoints.
These changes persisted when cachectic mice were acclimatized to 28oC,
confirming inappropriate stimulation of BAT despite thermoneutrality.
Activation of BAT was accompanied by elevated levels of circulating IL-6
and enhanced cytokine signaling in BAT, shown by increased phospho-
STAT3 and SOCS3 mRNA. Activation of BAT did not occur in mice
bearing a non-cachectic variant of the C26 tumour that neither releases IL-
6 into circulation nor elicits IL-6 signaling in BAT. While cachectic mice
do reduce food intake, pair-feeding experiments demonstrated that
activation of BAT could not be attributed to restricted nutrients. Indirect
calorimetry via Oxymax showed that cachectic mice do not correspond-
ingly reduce energy expenditure despite restricted calorie intake.
Conclusion: Our findings highlight a role for thermogenic activation of
BAT associated with tumour-derived IL-6 as an energetically wasteful,
maladaptive response to anorexia during the development of cachexia.
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Depot modulation of interferon-γ in rat white adipose tissue
by cancer-associated cachexia
Alex S. Yamashita, José C. Rosa Neto, Rodrigo X. Neves, Miguel L Batista
Junior, Marília C Seelaender (Department of Cell and Developmental
Biology, Institute of Biomedical Science, São Paulo, São Paulo, Brazil)
Background and aims: Cancer-associated cachexia is a progressive
wasting syndrome characterized by an extensive loss of white adipose
tissue (WAT) and skeletal muscle, which is regulated by inflammatory
mediators produced by tumour and host. The WAT has been
recognized as a source of many endocrine and inflammatory factors,
which could contribute to cachexia-related inflammation. The WAT is
a heterogeneous tissue, and therefore we sought to understand the role
of inflammation in different WAT depots during cachexia progression.
Methods: Male Wistar male (210–230 g) were inoculated with Walker-256
tumour cells (2×107 cells) and sacrificed on days 0 (T0), 4 (T4), 7 (T7), 10
(T10) and 14 (T14) (n=6–10/group), after inoculation. Retroperitoneal
(RPAT), epididymal (EAT), mesenteric (MEAT) adipose tissue depots and
serum of the tumour-bearing rats were collected. Total-cholesterol (Cho),
triglycerides (TG), high density lipoprotein (HDL), and glucose were
measured with enzymatic commercial kits, IFN-γ, TNF-α, and IL-1β
concentration were measured with ELISA and normalized by total protein.
Results: Tumour-bearing rats significantly decreased food intake on T10
(−8.7%; p<0.05) and T14 (−10.7%; p<0.05). A progressive decrease in
serum glucose concentration was found starting on day 4 (−7%; p<0.05)
after tumour inoculation, and the higher reduction was observed on T14
(−16%; p<0.001). Serum HDL concentration decreased (−6%; p<0.05)
and TG concentration augments on T14 (+63%; p<0.001). No modulation
was found in regard to TNF-α and IL-1β in WAT. A progressive increase
of INF-γ concentration was found in MEAT reaching the peak on T14
(+88%; p<0.05). On the other hand, in RPAT INF-γ concentration
decreased progressively with the lowest concentration on T14 (−46; p<
0.05) and no alteration in INF-γ levels was observed in EAT.
Conclusion: IFN-γ was up-regulated in MEAT, suggesting a depot-
specific of WAT regulation under cachexia. In addition, IFN-γ mediated
inflammation in MEAT may favour the inflammatory milieu observed in
cachexia progression.
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Cancer cachexia modulates the expression of lipases in the epididymal
adipose tissue of rats
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Background and aims: Increased fat cell lipolysis and hormone-sensitive
lipase (HSL) overexpression are key factors underlying the loss of adipose
tissue in cancer cachexia. However, the importance of novel lipolysis-
related proteins [adipose triglyceride lipase (ATGL), comparative gene
identification-58 (CGI-58) and perilipin A] on adipose tissue depletion in
cachexia is still controversial. It was our aim to characterise the expression
of these proteins during the progression of cachexia.
Methods: Animals were divided into: control (CTR), tumour-bearing
(Walker 256-carcinosarcoma) studied on the seventh day (TB7) and
tumour-bearing studied on the fourteenth day (TB14) after tumour
inoculation. We examined the gene (real-time PCR) and protein expression
(Western blotting) of HSL, ATGL, CGI-58 and perilipin A in the
epididymal adipose pad. Morphometrical analysis of adipocytes, plasma
free fatty acids concentration (ELISA) and in vitro rates of lipolysis in
isolated adipocytes were also determined.
Results: Adipocyte size was dramatically reduced in TB7 and TB14 (60%
and 72% respectively), compared with control (P<0.001). HSL gene
expression was higher in TB7, while other proteins were unaffected. At the
end-stage of cachexia (TB14) HSL gene expression was similar to control
values and the other proteins mRNA levels were reduced. However,
protein expression showed a different pattern: ATGL and CGI-58 were
reduced, while perilipin A presented a tendency for reduction (P=0.06 vs.
CTR) in TB14. Plasma free fatty acids were increased in TB14 (P<0.001
vs. other groups). A decrease in isoproterenol-stimulated lipolysis was
observed in isolated adipocytes from TB14 rats.
Conclusion: ChronicexposureoffatcellstoTNF-αorsustainedactivationof
the PKA pathway results in increased basal lipolysis and a markedly blunted
response to stimulated lipolysis. We found a high plasma free fatty acid
concentration in TB14, even with a reduction on ATGL and CGI-58
expression, suggesting the importance of basal lipolysis in terminal cachexia.
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Adipokine expression in tumour-bearing rats during the progression
of cachexia
Renata Silvério, Felipe Fedrizzi Donatto, Marília Seelaender (Cancer
Metabolism Research Group, Institute of Biomedical Sciences, University of
São Paulo, Brazil)
Background and aims: Cancer cachexia markedly affects the adipose
tissue, an important endocrine organ, secreting the adipokines. Some
authors suggest that the impaired response of adipokines to body weight
loss may play a role in the pathogenesis of cancer-induced cachexia.
However, the association between adipokine level and cancer-induced
cachexia has not yet been fully elucidated. Therefore, it was our aim to
examine adipokine expression during cachexia progression.
Methods: Animals were divided into three groups: control (CTR, n=10),
tumour-bearing (Walker 256-carcinosarcoma) on the seventh day (TB7, n=6)
and tumour-bearing on the 14th day (TB14, n=9) after tumour inoculation.
236 J Cachexia Sarcopenia Muscle (2011) 2:209–261We examined the protein expression (ELISA) of adiponectin and leptin in the
epididymal adipose tissue (EAT), and evaluated plasma concentration of
those factors. TNF-alpha content assessment in EAT was also carried out.
Results: Plasma leptin concentration was decreased in TB7 and TB14 (P<
0.05 vs. CTR). Adiponectin plasma concentration was diminished only in
TB14. There was a decrease in leptin and adiponectin tissue content (P<
0.05 vs. CTR), in TB7. At the end-stage of cachexia (TB 14) the response
was different: leptin tissue concentration was maintained and adiponectin
showed an even more pronounced decrease (P<0.001 vs. CTR and TB7).
TNF-alpha tissue concentration was 2.0-fold higher in TB7 (P<0.05 vs.
CTR) and 2.5-fold higher in TB14 (P<0.05 vs. CTR and TB7). Moreover,
adiponectin was inversely correlated with TNF-alpha in EAT (P<0.01).
Conclusions: Our results suggest that adiponectin has an important anti-
inflammatory role in cancer cachexia and we conclude that modified
adipokine tissue expression during cachexia progression may contribute to
the aggravation of systemic inflammation viewed in this syndrome.
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Erythropoietin administration counteracts adipose tissue deplation
in murine cancer cachexia models
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Background/aims: While the relevance of adipose tissue depletion to the
pathogenesis of cancer cachexia is controversial, recent reports show that
mice genetically lacking triglyceride lipase are protected against cancer-
induced cachexia [1] and that in lung cancer patients, obesity positively
correlates with survival [2]. The aim of the present work was to test
whether erythropoietin (EPO) administration could prevent fat wasting in
mice bearing the Colon26 (C26) or the Lewis Lung carcinoma.
Methods: C26 mice received 5×10
5 tumor cells s.c. in the back, while LLC
mice were injected i.m. in one hind leg with 5×10
5 cells. EPO (100 IU) was
administered i.p. every 3 days. Animals were sacrificed 14 days after tumor
implantation; blood and several tissues were collected for further analyses.
Results: Tumor growth in both C26- and LLC-bearing mice resulted in
marked muscle and fat depletion, reduced food intake and anemia. In the
C26 hosts, EPO treatment reversed the hematocrit reduction and partially
prevented white adipose tissue (WAT) wasting, without affecting food
intake or skeletal muscle mass. As for the LLC bearers, both the marked
anemia and WAT depletion were only partially corrected by EPO, while no
effects on muscle wasting and anorexia could be observed. EPO effect on
WAT is likely exerted directly, as suggested by the increased levels of EPO
receptor. The mechanism accounting for EPO-induced WAT preservation
could rely on an increased clearance of circulating triglyceride, as
suggested by the higher lipoprotein-lipase (LPL) activity found in the
WAT of treated vs. untreated mice.
Conclusions: EPO administration might be beneficial in the treatment of
cancer cachexia for its ability to counteract anemia and adipose tissue
depletion.
1. Das SK et al., Science. 2011; 333(6039):233–8
2. Yang R et al., J Surg Res. 2011;170(1):e75–83
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Background and aims: Cachexia is a wasting syndrome observed in severe
clinical conditions such as neoplastic diseases, trauma, and infections. Loss
of adipose tissue, which occurs primarily due to increased lipolysis, is a key
feature of weight loss in cancer patients. Specific proteins located at the
surface of lipids droplets, i.e. the perilipin family, have an important role in
the control of lipolysis. In this study we verified perilipin A (PLIN)
expression in the subcutaneous adipose tissue of cancer cachectic patients.
Methods: Samples were obtained from weight-losing tumour-bearing
patients (Cx), weight-stable tumour-bearing patients (TB) and weight-
stable non-tumour-bearing patients (CTR). The mRNA content (by
real-time PCR) and protein expression (by Western blotting) of PLIN,
as well as its tissue distribution (by immunohistochemistry) were
studied. Data are presented as means±SE. Comparisons were made
by one-way analysis of variance (ANOVA) followed by a post hoc
test (Tukey). Differences were statistically significant at P<0.05.
Results: PLIN gene expression was identical among the studied groups (P>
0.05). Cx patients presented a protein content 54.8% lower than CTR, but it
was not statically significant (p=0.07; CTR=93.15±18.91, Cx=54.81±10.34,
TB=93.87±34.94 arbitrary units). Immunohistochemistry analysis showed that
the distribution of PLIN in the adipose tissue was not modified by cachexia.
Conclusions: Loss of adipocyte perilipin content, with the concomitant
loss of the protection of stored triacylglycerol from cytosolic lipases, is part
of the mechanism by which TNF-α increases lipolysis. Our results suggest
that a decreased PLIN content in subcutaneous adipose tissue may have a
role in the higher lipolysis rate present in cachexia.
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Background and aim: Several studies have demonstrated that cancer
cachexia induces loss of fat mass that accounts for a large part of the
dramatic weight loss observed both in humans and in animal models. To
evaluate the onset of cancer cachexia in adipose tissue (AT) at morphological
and molecular level, we evaluated the different WAT depots in cancer
cachexia animal model at three different time-points after tumour implantation.
Methods: Male Wistar rats, 8 weeks old, were subcutaneously inoculated
with 1 mL (2×107) of tumour cells (Walker 256). Samples of different AT
depots were collected at days 0, 4, 7 and 14 and stored at −80°C (five
animals per each day/group). Morphometric alterations were evaluated by
light microscopy, and PPARγ gene expression was quantified by RT-PCR
(real time-PCR), and protein expression (PPARγ) by Western blotting.
Results: In MEAT, sectional areashowedan increaseof 52%(p<0.05) and 1.3-
fold (p<0.001), respectively, on day 14. Conversely, from RPATand EATwere
reduced (54% and 27%, p<0.05), respectively, on day 14 compared to day 0.
Gene expression of PPARγ-2 fell significantly during cancer cachexia
development in all three adipose tissues depots evaluated: MEAT 75.1% (p<
0.001) and TARP 57.4% (p<0.01), respectively, on day 4. On day 14 (MEAT,
86.2%, RPAT, and 72.6% EAT, 81.9%, p<0.01), all depots compared to day 0.
J Cachexia Sarcopenia Muscle (2011) 2:209–261 237PPARγ-2 protein and mRNA expression levels decreased on day 14 in all fat
depots evaluated (MEAT, 76.1%, RPAT, and 56.5% EAT, 43.8%, p<0.01).
Conclusion: In the present study, we demonstrated several changes at the
morphological and molecular levels in AT of tumour-bearing animals resulting
in depot-dependent adipose dystrophy. Down regulation of the master regulator
of adipogenesis, PPARγ, seems to have started earlier than any detectable
morphological disruption, indicating the importance of PPARγ in this setting.
Financial Support: FAPESP 2007/52782-1, 2008/51094-9 and 2010/51078-1.
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Background and aims: Profound loss of adipose tissue is a hallmark of
cancer cachexia. During the progression of this syndrome, the morpho-
logical and biochemical characteristics of the adipose tissue are markedly
modified. Nevertheless, the changes caused by cancer cachexia regarding
adipose tissue extracellular matrix have not yet been fully described. The
aim of the study was to evaluate the effects of cancer cachexia upon the
expression of collagen VI α1 (COL6A1), fibronectin (FN1) and metal-
loproteinase 2 (MMP2) in the subcutaneous adipose tissue (SAT) of cancer
patients, by real-time PCR and immunohistochemical analysis.
Methods: Patients of the University of São Paulo Hospital submitted to
surgery were divided into two groups: cancer cachexia (CCx)—gastrointestinal
cancer—and Control (C)—incisional hernia—(n=14 and 8, respectively). The
fresh sections of SAT from CCx and C were fixed in paraformol 4% and
embedded in paraffin. The paraffin sections of 5 μm were processed for
immunostaining. All slides were incubated with primary antibodies overnight
at 4°C. The slides were incubated with DAB and counterstained with Meyers
hematoxylin. Gene expression analysis was carried out by real-time PCR.
Results: The immunostaining for COL6A1 was dramatically modified in
CCx, as the strong presence of collagen fibrils was evident in the interstitial
space mostly in the fibrotic areas, but solely in CCx. The expression levels of
COL6A1wereincreasedinCCx(p<0.05). FN1 showed increased expression
after immunostaining as well as augmented mRNA levels in CCx in
comparison with the control. However, the expression of MMP2 was
decreased in CCx, as evaluated by PCR and by immunostaining.
Conclusions: Cancer cachexia deeply affects the adipose tissue. The
accumulation of components of the extracellular matrix in the adipose pad
leadsto remodeling.The increase of COL6A1may be directlyrelatedwiththe
emergence of tissue fibrosis
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Background and aims: Cachexia associated with cancer can be defined as a
multifactorial syndrome in which there is continuous loss of muscle mass
(with a loss or no loss fat mass), which cannot be fully reversed by
conventional nutritional support, leading to progressive functional impairment
of the body. Over the last decade, WAT has been recognized as an important
endocrine organ for its ability to synthesise and secrete adipokines such as
TNF-α, IL-6, adiponectin or leptin. The aim of this study was to analyse the
gene expression of inflammatory cytokines and their plasma profile in two fat
depots (subcutaneous and visceral) of patients with cancer cachexia.
Methods and results: Cytokine concentration was assessed in plasma by
ELISA and the gene expression in the subcutaneous and visceral adipose
pads by real-time PCR obtained from cachectic patients, weight-stable
cancer patients, and non-cancer patients, eight per group, CEP HU/USP:
752/07. TNF-α plasma levels in cachectic cancer patients were higher (42-
fold, p<0.01) than in weight-stable cancer patients and non-cancer
patients. TNF-α (12-fold, p<0.01) and CD68 (50-fold, p<0.001) gene
expression was increased in the subcutaneous adipose tissue of the
cachectic group compared with the non-cancer group. However, gene
expression in the visceral depot was unchanged.
Conclusion: Cancer-associated cachexia markedly affects the adipose tissue,
inducing local and systemic inflammation.
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Background and aims: Colorectal cancer is the third most common cancer
in the developed world. Advanced colorectal cancer is characterized by
malnutrition and cachexia, which includes loss of muscle and adipose tissue.
Mechanisms underlying fat loss are not well understood, and knowing the
types of fat being lost from adipose tissue will enhance our understanding of
aberrations of lipid metabolism in cancer and help define interventions to
circumvent wasting. The aim of this study is to explore the differences in fatty
acid composition between visceral adipose tissue (VAT) and subcutaneous
(SAT)depotsandrelatethistobodycompositionaswellaschangesinfatmass
assessed using CT images in colorectal cancer patients.
Methods: Adipose tissue (VATand SAT) was obtained intraoperatively from
CRC patients (n=18) and frozen at −80°C until analysis. Patient information
including age, gender, weight, height, liver metastases, stage of disease, date
of sample collection, types and dates of chemotherapy were obtained from
patient records. To investigate amounts and types of fatty acids stored in
adipose depots, adipose tissue triglyceride and phospholipid were isolated
using Folch immediately followed by thin layer chromatography and gas
liquid chromatography. CT image analysis was used to quantify SAT, VAT
and intramuscular adipose tissue areas.
Results: The findings indicate that the majority of patients were overweight or
obese at the time of diagnosis. VATcontained less saturated fatty acids than SAT,
whereas mono-unsaturated fatty acids were higher in VAT than SAT. PUFAs
amount did not significantly differ between depots. Subjects were stratified into
normal and overweight/obese categories and no significant differences were
observed in the fatty acid composition of the adipose tissue in these two groups.
Conclusions: The results demonstrated that there might be a relationship
between the rate of adipose tissue loss and changes in fatty acid status during
disease progression.
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External validity of the European consensus on sarcopenia: mortality
predictor
Mario U. Perez Zepeda, Luis Miguel Gutierrez-Robledo, Victoria Eugenia
Arango-Lopera (Instituto de Geriatria, Mexico City, Mexico)
238 J Cachexia Sarcopenia Muscle (2011) 2:209–261Sarcopenia has an important impact in elderly. Recently, the European
Working Group on Sarcopenia in Older People (EWGSOP) defined
sarcopenia as the loss of muscle mass plus low muscle strength or low
physical performance. Lack of clinical sounding outcomes (i.e., external
validity), is one of the flaws of this algorithm. The aim of our study was to
determine the association of sarcopenia and mortality in a group of Mexican
elderly. Three hundred fourty-five elderly were recruited in Mexico City and
followed up for 3 years. The EWGSOP algorithm was integrated by: gait
speed, grip strength and calf circumference. Other covariates were assessed in
order to test the independent association of sarcopenia with mortality. Of the
345 subjects, 53.3% were women; with a mean age of 78.5 (SD 7)years.
During the 3-year follow-up, a total of 43 (12.4%) subjects died. Age, MMSE
score,Katzscore,Lawtonscore,healthself-perception,ischemicheartdisease,
and sarcopenia were associated in the bivariate analysis with survival, with an
statistical significance of <0.1 (see table). Negative predictive value for
sarcopenia regarding mortality was of 90%. Kaplan–Meier curves along with
their respective log-rank test were significant for sarcopenia.The components
of the final Cox regression multivariate model were age, ischemic heart
disease, ADL and sarcopenia. Adjusted HR for age was 3.24 (CI 95% 1.55–
6.78, p=0.002), IHD 5.07 (CI 95% 1.89–13.59, p=0.001), health self-
perception 5.07 (CI 95% 1.9–13.6, p=0.001), ADL 0.75 (CI 95% 0.56–0.99,
p=0.048) and sarcopenia 2.39 (CI 95% 1.05–5.43, p=0.037).
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Sarcopenia, low muscle mass, is an increasing problem in our aging
society. The prevalence of sarcopenia varies extremely between elderly
cohorts ranging from 7% to over 50%. Without consensus on the definition
of sarcopenia, a variety of diagnostic criteria are being used. We assessed
the degree of agreement between seven different diagnostic criteria for
sarcopenia based on muscle mass and handgrip strength, described in
literature. In this cross-sectional study, we included men (n=325) and
women (n=329) with complete measurements of handgrip strength and
body composition values as measured by bioimpedance analysis within the
Leiden Longevity Study. Prevalence of sarcopenia was stratified by gender
and age. In men (mean age, 64.5 years), the prevalence of sarcopenia with
the different diagnostic criteria ranged from 0% to 20.8% in the lowest age
category (below 60 years), from 0% to 31.2% in the middle (60 to
69 years), and from 0% to 45.2% in the highest age category (above
70 years). In women (mean age 61.8 years), the prevalence of sarcopenia
ranged from 0% to 15.6%, 0% to 21.8%, and 0% to 25.8% in the lowest,
middle, and highest age category respectively. One participant (0.3%) was
identified having sarcopenia according to all diagnostic criteria that marked
prevalence above 0%. We conclude that the prevalence of sarcopenia is
highly dependent on the applied diagnostic criteria. It is necessary to reach
a consensus on the definition of sarcopenia in order to make studies
comparable and for implementation in clinical care.
Figure: Number of participants identified as having sarcopenia according to
various definitions, represented by letter codes
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Muscle age-related expression of two transcriptional repressors,
BHLHB2 and BHLHB3, reveals that BHLHB2 is increased
in the oldest healthy subjects
Anne-Cécile Rouveure, Vanessa Euthine, Christine Durand, Michel Fessy,
Marc Bonnefoy, H. Vidal, Etienne Lefai (Laboratoire CarMeN, INSERM,
U1060, Université Lyon, Faculté de Médecine Lyon-Sud F-69921 Oullins
Cedex, France)
Background: Sarcopenia is a muscle aging process, characterized by a
loss of skeletal muscle mass, quality and performance. This physiological
process affects 13–25% of the over 60 years population, and can become
pathological when it is exacerbated.
Aim: The aim of this study is to follow in human muscle from different
age subjects, BHLHB2 and BHLHB3 expressions, two transcriptional
repressors involved in muscle atrophy mechanisms.
Method: Muscle samples (Gluteus Maximus) from 41 subjects were divided
into three groups (less than 60 years, 60–75yearsandmorethan75years).We
measured mRNA and protein levels of BHLHB2 and BHLHB3, and two of
their targets genes MyoD and Myogenin. We also studied two atrogenes
involved in muscle atrophy, MuRF1 and Atrogin1.
Results: We observed an increase in the level of BHLHB2 protein in the
muscle from the oldest group compared to the youngest, while the
expression of MuRF1, and Atrogin1 remains constant. However, this
increase in BHLHB2 seems to have no consequence on the MRF
expression, particularly MyoD.
Conclusion: These first results on the expression of BHLHB2 and
BHLHB3 factors in the muscle of a healthy population are reference data
essential to a further study of a sarcopenic aged population.
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Frailty in Mexican community-dwelling elderly
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Objectives: The study aims to determine the prevalence of frailty
syndrome in Mexican elderly people, as well as describing socio-
demographic features and the health status implicated with it.
Design: This is a cross-sectional study involving 60 years and older
beneficiaries Mexican Social Security (IMSS) of Mexico City.
Measurements: Socio-demographic features, geriatric rating scales (Katz
Index, Lawton and Brody Index, Mini-Mental State Examination, CES-D
scale, body mass index, Charlson Index), and usage of the health service in
the last 6 months were utilized. We used the modified frailty phenotype of
Fried et al.
Results: Prevalence of frail was 15.7%, pre-frail of 33.3%, and non-frail of
51.0%. The factors associated with pre-frail elder were: women (OR=
0.64), 60–64 years old (OR=0.51), and 65–74 years old (OR=0.56), 1–
6 years of education (OR=0.91), 7–12 years of education (OR=1.14),
singles (OR=1.03), living alone (OR=1.27), limitations in basic activities
of daily living (OR=1.36), and instrumental activities of daily living (OR=
1.70),cognitiveimpairment(OR=1.13),depression(OR=3.44),underweight/
malnutrition (OR=1.46), and overweight/obesity (OR=0.75), moderate
comorbidity (OR=1.33), and serious co-morbidity (OR=1.46). The factors
associated with frail elderly were: 60–64 years old (OR=0.17), and 65–
74 years old (OR=0.20), none year of education (OR=1.52), singles (OR=
1.08), living alone (OR=0.92), limitations in basic activities of daily living
(OR=2.35), and instrumental activities of daily living (OR=3.77), cognitive
impairment (OR=1.84), depression (OR=8.95), overweight/obesity(OR=
0.43), moderate co-morbidity (OR=2.17), serious co-morbidity (OR=1.11),
and using health services (OR=1.83).
Conclusion: The socio-demographic features and changes in the health
status have a stronger force of association with frail elderly rather than with
pre-frail elderly compared with non-frail elderly.
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Oxidative parameters as biomarkers of frailty
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Background: Frailty has been defined as a physiological state of
vulnerability to increased morbidity and mortality; hence, it is regularly
studied in older adults. Oxidative stress may contribute to frailty in part
through inflammation and aerobic metabolic changes. Intracellular oxida-
tive stress promotes the formation of oxidized cellular components.
Methods: In the current study, we evaluated the enzymatic response to
oxidative stress in a cohort composed by 157 participants of 60 years
and older as oxidative parameters for frailty. Frailty status was
determined from Fried’s criteria. Hence, the cohort was determined
as follow: fails (F); 25.8% (23) pre-fails (PF); 56.2% (50) non-frails
(NF). M: 13.2% (9) frails; 30.9% (21) pre-Frails; 55.9% (38) NF.
Results: Our findings showed an increase in lipid and protein oxidation in
F and PF elderly as follows: 145% more lipoperoxidation (LPX) in frail
elderly and 84% more LPX in pre-fail when compared with NF elderly. As
well as an increase of 153% and 131% of oxidized proteins in frail and pre-
frail population respectively, when compared with NF elderly. GSH levels
also decreased in the same groups (75% F and 69% PF). The above was
confirmed by a decrease in the expression of the enzyme γ-GCS, which
has been described to regulate the levels of GSH. However, catalase
activity showed no significant changes among the different groups
analyzed.
Conclusion: Our findings regards the oxidative parameters may be related
with frailty as a part of a chronic inflammatory state or as part of the
decline in physiological processes associated with aerobic metabolism. The
mechanism to explain how the oxidative stresses increase during frailty has
not been fully clarified. However, it would be interesting to explore the
possible relationship between the inflammatory processes and the
oxidative stress through the involvement of pro-inflammatory molecules such
as NF-κB.
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Mean corpuscular haemoglobin concentration (MCHC): a marker
for metabolic stress and immune activation in immobilisation
and chronic fatigue?
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240 J Cachexia Sarcopenia Muscle (2011) 2:209–261Background: Chronic fatigue syndrome (CFS) is a disabling condition
characterised by severe fatigue, exhaustion, and myalgia that results in
very low physical activity levels. Unduly immobilisation may affect
metabolic balance and muscle functional capacity but this has not been
studied in detail. The aetiology of CFS is unknown but immune activation
is discussed to be involved in the pathophysiology. Increased mean
corpuscular haemoglobin concentration (MCHC) has been suggested as a
global marker of metabolic stress secondary to strenuous energy
demanding work load. Elevated MCHC in relation to exercise may
indicate impaired intracellular glucose availability, disturbed osmotic
regulation and cellular swelling. The aim of this study was to investigate
the characteristics of MCHC as a global metabolic marker in relation to
cellular immune activation in patients presenting with chronic fatigue.
Methods: We evaluated full blood count and immunological profile
(CD4+, CD8+, CD11a+, CD28+, CD57+, HLADR+ T-cells) of 190
patients (mean age±SD: 44±12, 64% female) presenting with fatigue
symptomatic in our outpatient clinic. The T-cell cytokine profile of
inflammatory activation (IL-2, IL-4, IL-5, IL-10, IFN-γ, TNF-α)w a s
assessed in the supernatant of ConA-stimulated blood cells.
Results: MCHC of the assessed population was 34.14±1.0 g/dl. Fourty-
seven patients (25%) had an elevated MCHC value above the upper
normal. Patients showed upregulated T-cells activity (CD57+CD8+ T-
cells). Elevated MCHC was positively associated both with chronic T-cell
activation (CD57+; r=0.17, p=0.035) and a type 2 IL-5high profile (r=
0.22, p=0.028).
Conclusions: Increased MCHC is highly prevalent among patients with
chronic fatigue indicating metabolic stress. As these patients usually have
low activity levels, chronic immune activation is likely to contribute to this
metabolic imbalance. It needs to be studied whether these imbalances
account for abnormal muscle catabolism in patients with chronic fatigue.
5-07
Adiposity to muscle ratio predicts incident physical limitation in a cohort
of 3,153 older adults—an alternative measurement of sarcopenia
and sarcopenic obesity
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Background and aims: Conventionally sarcopenia is defined by muscle mass
alone. We hypothesized that the disability caused by sarcopenia and sarcopenic
o b e s i t y( S O )w a sr e l a t e dt ot h ea m o u n to fa d i p o s i t yo rb o d yw e i g h tb e a r i n go na
unit of muscle mass, or the adiposity to muscle ratio. We therefore examined
whether this ratio could predict physical limitation.
Methods: We have recruited 3,153 community-dwelling adults aged
>65 years and their body composition were measured by dual-energy X-
ray absorptiometry (DXA). Assessment of physical limitation was
undertaken at baseline and 4 years later. The relationship between baseline
adiposity to muscle ratio and incident physical limitation was examined by
logistic regression.
Results: In men having BMI<23, muscle mass could predict physical
limitation before (p<0.01) but not after (p=0.82) adjustment. When the
BMI was >23, the adiposity to muscle ratios, namely body fat to lower
limb muscle mass, body fat to fat-free mass (FFM) and body weight to
FFM, were predictive of physical limitation before and after adjustment
(all p values <0.001). In women, throughout the entire BMI range, all three
adiposity to muscle ratios were associated with physical limitation 4 years
later both before and after adjustment (all p values <0.05). In women
having BMI less than 21, muscle mass alone could not predict physical
limitation both before (p=0.4) and after (p=0.5) adjustment.
Conclusions: Sarcopenia and sarcopenic obesity as measured by either the
body weight or fat mass bearing on a unit of muscle mass (the adiposity to
muscle ratio), is a valid predictor of incident or worsening physical
limitation in older women throughout the entire BMI range and in older
men having BMI>23. This ratio can serve as a measurement of both
sarcopenia and SO in women and SO in men.
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Accomplishing and maintaining locomotor gains in a group of elderly
for a follow-up time of 7–10 years after implementation of a home-
based exercise program
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Background: Ageing is associated with progressive decline in muscle
mass and muscle function. Regular exercise training is thought to
counteract these processes. We sought to establish the effects of a
clearly defined daily exercise program (www.fuenfesslinger.de)o n
usual gait speed, maximal gait speed, chair-rise test, and force plate jump
test in a cohort of adults aged 58 years or above.
Methods: We conducted a prospective single-center cohort study at the
outpatient department of a geriatric clinic. Sixty-one healthy elderly
subjects were enrolled in 2000 and instructed to adhere to a home-based
exercise program. Subjects were free of chronic disabling diseases and
physical disabilities. Follow-up visits were performed monthly over the
first 4 months, bi-annually until 2 years of follow-up, and annually
thereafter up to 10 years. Assessments at each visit included usual gait
velocity (UGV) and maximal gait velocity (MGV), chair rising test (CRT)
performed by rising five times from sitting at a height of 45 cm as quickly
as possible, and total power output on counter jumping, measured on the
force plate Leonardo mechanography system (FPJ).
Results: Forty-eight subjects (mean age 66.4±5.1 years, body mass
index 25.3±5.1 kg/m
2, 35 female) completed the follow-up visits up to
at least 7 years. Forty of these 48 subjects completed more than 80% of
follow-up visits. Whilst significant improvements were maintained over
10 years for CRT, there was a significant decrease in FPJ at 7 years
(repeated measures analysis of variance, all p<0.0001). UGV at baseline
was 1.43±0.26 m/s, then increased to 1.56±0.22 at 4.5 months (p<
0.0001 vs. baseline) to decrease again to 1.41±0.0.25 at 7 years, and
1.37±0.27 m/s at 10 years (p=0.06). The respective values for MGV
were 1.94±0.32, 2.13±0.33 (p<0.0001), 1.93±0.35, and 1.87±0.42 m/s
(p=0.06). Time required in CRT decreased from 7.40±1.73 s at baseline
to 5.96±1.33 at 4 months, 6.22±1.45 at 7 years to 6.26±1.72 s at
10 years (all p<0.001 vs. baseline). FPJ increased from 30.4±6 W/kg
body weight at baseline to 31.6±5.7 at 4.5 months to decrease again to
27.7±5.6 at 7 years and 26.3±5.7 W/kg at 10 years (all p<0.002 vs.
baseline).
Discussion: A home-based daily exercise training was effective in
improving UGV, MGV, CRT and FPJ after 4.5 months. The improve-
ments in CRT could be maintained over 10 years of follow-up in
motivated healthy elderly subjects. After 7 years of follow-up, UGV and
MGV were still at baseline level. FPJ was found significantly decreased
after 7 years. It appears likely that the decline in neuromuscular
function, measured by CRT or gait velocity, is counteracted by this
program. Limitations of our study include its uncontrolled design.
Further studies in larger cohorts of patients are required to confirm
these findings.
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Is body mass index or weight loss more important in survival? A
9-year prospective study in 1,816 nursing home residents
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Background and aims: Weight loss has been considered predictive of
early mortality in nursing home residents. Lower body mass index,
irrespective of weight loss, has also been considered detrimental for
survival in community-dwelling older persons. We examined which of the
two is more important for survival in nursing home residents.
Method: Of the nursing home residents, 1,816 were assessed by the Mini-
Dataset (MDS) 2.0 at baseline and mortality status was assessed at
6 months, 1, 2, 4 and 9 years later. Relationship between mortality and
significant weight loss (≥5% over 30 days or ≥10% over 180 days), and
body mass index (BMI), was studied by Cox regression with both variables
in the same model, adjusted for age, gender, medical conditions (cancer,
renal failure, heart disease, dementia, hip fracture, diabetes mellitus), tube-
feeding, left 25% food uneaten, swallowing problem, and the activities of
daily living hierarchy scale.
Results: Of the residents, 1,816 residents (67.7% female) with mean age
83.5±8.4 years and mean BMI 21.7±4.8 were studied. Mortality rate were
7.4% (6 months), 15.6% (1 year), 28.6% (2 years), 48.6% (4 years), and
78.5% (9 years). Significant weight loss was not associated with higher
mortality at all follow-up durations, whereas higher BMI was significantly
protective: hazard ratio per standard deviation increment 0.58 (6 months),
0.58 (1 year), 0.66 (2 years), 0.80 (4 years) and 0.74 (9 years), all p<0.001.
Having ≥25% of food uneaten (50.4% of participants) persisted to have no
relationship to survival at all follow-up durations.
Conclusion: Significant weight loss as defined by the MDS 2.0 was not
associated with short- or long-term survival in Chinese nursing home
residents. BMI however is predictive of short- and long-term survival
irrespective of weight loss in this population. Low body mass index,
detectable at a single point of time, may be another readily available
alternative check-point for possible reversible mortality risk factors.
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Muscle loss in patients with chronic heart failure: results
from the SICA-HF study
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Background: The term sarcopenia describes age-related loss of muscle
mass and strength. A debate exists whether this term should be used in
patients with chronic disease. Using the criteria defined for the diagnosis of
sarcopenia, we sought to assess muscle mass and other relevant clinical
variables in patients with chronic heart failure (CHF) as part of the Studies
Investigating Co-morbidities in Heart Failure (SICA-HF).
Methods: We prospectively enrolled 153 patients with symptomatic,
clinically stable CHF (male sex 78%, New York Heart Association
[NYHA] class [mean±SD] 2.4±0.6, age 67±10 years, creatinine 1.2±
0.4 mg/dl). Appendicular skeletal muscle mass was assessed by dual-
energy X-ray absorptiometry (DEXA) and compared with a healthy
reference group of young adults aged 18–40 years from the previously
published Rosetta study. In addition, we analysed muscle strength by hand
grip, and all patients underwent 6-min walk test and spiroergometry.
Muscle wasting was defined as appendicular muscle mass 2 SD below the
mean of the young reference group.
Results: Muscle wasting was detected in 29 (19%) subjects. Patients with
muscle wasting were older (69.5±8.0 vs. 66.1±10.3 years, p=0.1009), had a
lower body mass index (26.7±12.4 vs. 29.7±4.9 kg/m², p=0.0383), and a
lower left ventricular ejection fraction (33.7±11.7% vs. 40.4±13.9%, p=
0.0271) than patients without. Total fat mass was significantly lower in
patients with muscle wasting than in those without (22.1±11.9 vs. 29.9±
9.5 kg, p=0.0002). Furthermore, patients with muscle wasting presented with
lower exercise time (7.4±4.1 vs. 10.4±3.0 min, p=0.0004) and lower total
peak oxygen consumption (absolute peak VO2, 1,163.9±478.2 vs. 1,622.5±
472.9 ml/min, p=0.0002) and had lower hand grip strength than patients
without muscle wasting (33.2±9.0 vs. 38.1±11.8 kg, p=0.0453). In addition,
a significant difference was detected for 6-minute (368.5±140.3 vs. 440.4±
141.2 m, p=0.0248) and 4-m (4.6±2.0 vs. 3.9±1.0 s, p=0.0218) walk
distance. No difference was detected for NYHA class, creatinine or bone
mineral density (p>0.1).
Conclusions: This single-center experience from the multi-national SICA-
HF study shows that muscle wasting using the criteria defined for
sarcopenia assessment is a frequent co-morbidity among patients with
CHF. The presence of muscle wasting may have serious impact on
mobility, quality of life, frequency of falls, and overall morbidity. Our
preliminary findings warrant further study in larger cohorts of patients.
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Factors influencing exercise performance in people with thoracic
cancer
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Background and aims: Patients with thoracic cancer often complain of a
reduced ability to exercise which can impede levels of independence and
quality of life. Several factors may be responsible but there is little formal
study in this group. We have explored how various physiological and
psychological factors relate to performance in a test of exercise capacity.
Methods: Inspiratory muscle strength, peripheral muscle power, lung
function and mastery over breathlessness were assessed using sniff nasal
inspiratory pressure, leg extensor power, simple spirometry and the
mastery domain of the Chronic Respiratory Disease Questionnaire,
respectively. Exercise performance was assessed using the Incremental
Shuttle walk Test (ISWT) during which patients wore a K4 b2 system
allowing continuous measurement of heart rate, minute ventilation (VE)
and oxygen uptake (VO2). Relationships between ISWT distance and
independent factors were determined using Pearson’s correlation coeffi-
cient and β regressions coefficients.
Results: Forty-one patients (21 male, mean (SD) age 64 (8) years) took
part. They walked a median [IQR] 320 [250–430] metres and reached 76
(10)%, 48 (14)% and 77 (25)% of their predicted maximal heart rate, VE
and VO2, respectively. Exercise performance was significantly associated
only with inspiratory muscle strength (r=0.42, P<0.01) and peripheral
muscle power (r=0.39, P=0.01). These factors were also significant
determinants of exercise performance (β coefficients [95% CI] 1.77 [0.53,
3.01] and 1.22 [0.31, 2.14]).
Conclusion: Both inspiratory and peripheral muscle performance appear
to influence exercise performance in people with thoracic cancer.
242 J Cachexia Sarcopenia Muscle (2011) 2:209–261Interventions aimed at maintaining or slowing down the decline in
exercise performance should include components targeting muscular
performance.
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Background: Cancer and aging are both associated with metabolic
alterations, including insulin resistance, that may lead to muscle loss. This
may result in increased use of amino acids for gluconeogenesis (GNG) via
the tricarboxylic acid cycle and phosphoenolpyruvate (PEP).
Methods: We measured the fractional contributions (%) of glycogen,
glycerol and GNG from PEP to 17-h fasting endogenous glucose
production (EGP), using oral
2H20 and the positional deuterium enrich-
ment of plasma glucose, by NMR spectroscopy. Whole-body protein and
glucose kinetics were measured (
13C-leucine and
3H3-glucose) in the
postabsorptive state and during a hyperinsulinemic, euglycemic, isoami-
noacidemic clamp to determine insulin resistance in: young (n=11; 27±
3 years old), older (n=9; 65±2 years old) and older men with lung cancer
(CA; n=9; 66±2 years old).
Results: Men with CA had higher serum CRP levels and resting
energy expenditure (REE) than young and older groups, and a lesser
clamp glucose disposal (p<0.001) indicating insulin resistance. EGP
was elevated with aging and cancer with greater contribution from
GNGPEP: 37±2, 43±2 and 48±4% in young, older and CA (ANOVA p<
0.05), whereas percentage contribution from glycogen and glycerol did
not differ. This resulted in greater GNG flux (EGP×%GNG) in older and
CA groups, but no difference between the two. Elevated GNG flux
correlated positively with REE (R=0.61, p<0.001) and negatively with
fat-free mass index (R=−0.41, p<0.05). Surprisingly, postabsorptive
protein net balance (synthesis-breakdown) was less negative in older and
CA groups (ANOVA, p<0.001). However, GNG flux was also related to
lesser glucose uptake and protein anabolic response (R=−0.54, p=
0.001; and greater protein oxidation) during the subsequent hyper-
insulinemic, isoaminoacidemic clamp.
Conclusions: These findings suggest that greater production of glucose
from GNG in the fasting state might predict postprandrial responses
resulting in lesser protein retention in response to insulin and upon feeding
small amounts of protein (isoaminoacidemia). (Supported by the CIHR.)
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In vivo progression of muscular defects throughout the lifespan
in Caenorhabditis elegans
Thomas Milne, Nathaniel J. Szewczyk, Timothy Etheridge (University of
Nottingham, Derby, England)
Background: The deterioration of muscle mass and function with
increasing age is a major challenge to the health services within ageing
societies. To date, little is known of the onset and progression of defects in
the various muscle subcellular processes, and if a temporal relationship
exists between them. Such information may provide important information
as to the initiating events that induce muscle defects with age, and thus
assist in designing diagnostics and therapeutics.
Methods: Here, we used transgenic Caenorhabditis elegans worms to
study the progression of defects in ageing muscle. These transgenic
animals allowed us to study onset of protein degradation and impairment
of the maintenance of myofibres and mitochondria in vivo.
Results: In ageing animals grown at 20°C, we found loss of
mitochondrial maintenance occurred first (at mid-adulthood), followed
by disruption of myofibrillar maintenance and, finally, increased
cytosolic protein degradation. As C. elegans is a poikilotherm its
lifespanvarieswithtemperatureinanegativelinearfashionbetween15°Cand
25°C. We therefore also examined whether the progression of muscle defects
are affected by temperature. The order of onset of defects in muscle
maintenance was similar between temperatures. However, at lower temper-
atures where lifespan is increased there was a delayed onset and decreased
severity of muscle defects versus 20°C. Conversely at higher temperatures
where lifespan is decreased, muscle defects occurred earlier and with greater
severity.
Conclusion: Our data provide in vivo evidence that there may be an
ordered decline of muscle with age at least in C. elegans.
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immobilization—effects of ageing
Charlotte Suetta
1,4, Ulrik Frandsen
2, Line Jensen
1,2, Lars G. Hvid
2,J a k o b
G. Jespersen
1, Mette Munk Jensen
2, SJ Petersson
3, Henrik D. Schrøder
3,P e r
Aagaard
2,PS c h j e r l i n g
1, Michael Kjaer
1 (
1Institute of Sports Medicine and
Center of Healthy Aging, Faculty of Health, University of Copenhagen,
Bispebjerg Hospital, Denmark;
2Institute of Exercise Physiology and
Clinical Biomechanics, University of Southern Denmark, Denmark;
3Department of Clinical Pathology, Odense University Hospital, Odense,
Denmark;
4Department of Clinical Physiology and Nuclear Medicine,
Bispebjerg Hospital, University of Copenhagen, Denmark)
Background: Important insights concerning the molecular basis of skeletal
musle disuse atrophy and age-related muscle loss have been obtained in
cell culture and animal models. However, little is known about the
underlying mechanisms in humans.
Purpose: Muscle atrophy was induced by short-term immobilization in
healthy young and old human individuals to study the effect of aging on
transcriptional regulatory signaling pathways involved in the regulation of
muscle cell size in vivo.
Methods: Myofiber atrophy was induced by application of a knee-brace
for a period of 4 days in young (Y, ∼20 years, n=11) and aged (O,
∼70 years, n=11) individuals. Muscle biopsies of the VL muscle were
collected pre and at 1, 2, and 4 days of immobility. Changes in mean
muscle fiber area (MFA) and maximal voluntary muscle strength (MVC)
wasmeasuredpreandafter4daysofimmobility.ExpressionlevelsofMuRF1,
Atrogin-1, MGF, IGF-1Ea, PGC-1α, and PGC-1β mRNA were determined
using real-time RT-PCR and normalized to the Ribosomal Protein Large P0
(RPLP0) mRNA. Protein levels of phosphorylated Akt (P-Akt) and Akt were
measured by western blotting of whole muscle protein isolates.
Results: In both age groups, there was a decline in MFA (Y: 10.6%; O:
9.0%, p<0.05) and MVC (Y: 13.0%; O: 14.3%, p<0.05) at 4 days, along
with an increase in expression levels of Atrogin-1 and MuRF at 1 day and
2 days. In contrast, MGF mRNAwas upregulated at 1 and 2 days primarily
in O, while western blotting of Akt and phosphorylated Akt showed a
decrease in phosphorylated Akt in Y after 2 and 4 days and an increased
phosphorylation in O at 4 days. In contrast, expression levels of PGC-1α
mRNA were down regulated at 1 and 2 days primarily in Y and in both Y
and O at 4 days. PGC-1β mRNA was downregulated at 1 day primarily in
Y and at 2 and 4 days in both Y and O.
Conclusion: The present data demonstrates parallel activations of the
ubiquitin-proteasome and IGF/Akt pathways, respectively, and a dimin-
ished activation of PGC-1α and PGC-1β pathways during the first 4 days
of immobility, indicating that proteolyses plays an important role in the
J Cachexia Sarcopenia Muscle (2011) 2:209–261 243initiation of human disuse atrophy in both young and old muscle. In
contrast, the regulation of protein synthesis and mitochondrial function
appears to be more age-dependant.
Supported by Lundbeck Foundation, the Danish National Research Council,
the Danish Rheumatology Association, and the Nordea Foundation
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TET inducible myostatin overexpression inhibits muscle growth during
postnatal development and induces muscle atrophy in aged mice
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Myostatin is a potent negative regulator of muscle growth during the prenatal
and postnatal fast-growth period as deletion of myostatin in adult mice leads to a
moderate increase in muscle mass, while developmental knockout causes a
double muscle phenotype. Little is known of the effect of myostatin on muscle
mass during aging. Here we describe the effect of myostatin overexpression on
muscle mass in young, adult and aged mice using a doxycycline-inducible
myostatin transgenic mouse model. Myostatin mRNA and protein were
significantly higher in skeletal muscle, and serum myostatin levels were
increased ∼15 fold in young transgenic animals after doxycyline induction. In
young growing mice (3-week-old), myostatin overexpression significantly
decreased body weight (−24%), lean mass (−21%), quadriceps (−49%), and
gastrocnemius (−42%) mass over a 9-week period of doxycycline treatment.
Grip strength, in situ hind limb and ex vivo EDL muscle tetanic force were also
significantly reduced by myostatin overexpression (p<0.05). In both mature (7-
month-old) and aged (18-month-old) mice, myostatin overexpression also
resulted in significant loss of quadriceps (mature: -38%; aged:-18.6%) and
gastrocnemius (mature: −33%; aged: −16.8%) over a 2-month period of
doxycyline treatment. Interestingly, muscle mass and strength returned to
control levels after doxycycline withdrawal. These findings identify a novel
role for myostatin in regulation of muscle mass at different ages, and suggest
that the effects of myostatin on muscle mass diminish with advancing age.
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Upregulation of new pro-inflammatory cytokine/TAK-1/p38/ActivinA/
SMAD3 skeletal muscle signaling pathway in rat sarcopenia
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Pro-inflammatory cytokines have been shown to cause skeletal muscle
atrophy, differentiation inhibition and also to be upregulated in age-
related muscle wasting, called sarcopenia, a condition with impaired
muscle regeneration. However, their mode of action, upstream and
downstream of NFkappaB activation, is not completely understood. In a
human skeletal muscle cell system (skMC), we describe here that IL-
1alpha and TNF-alpha block differentiation, and that these effects are
counteracted by ActRII/Alk/Smad2/3 pathway inhibitors. The inhibitory
effect of IL-1alpha and TNF-alpha on skMC differentiation can be
subdivided into immediate and delayed signaling events. IL-1alpha and
TNF-alpha induce the release of Activin A into supernatants (SN) and
subsequently releasaed Activin A inhibits skMC differentiation. TAK-1,
p38 and NFkappaB pathway inhibitors prevent immediate cytokine-
induced Activin A release into SN and inhibition of skMC differenti-
ation, whereas blockade of ActRII/Alk/Smad2/3 pathway using siRNA
to Smad2/3 (siSmad2/3) has no influence on Activin A release.
Although, inhibition of differentiation is blocked by ActRII/Alk/
Smad2/3 inhibition, establishing that activin A released by cytokines
inhibits skMC differentiation in an autocrine fashion via ActRII/Alk/
Smad2/3. In accordance with this pathway, IL-1alpha and TNF-alpha
induce phosphorylation of immediate signaling events (TAK-1/p38/
NFkappaB) very rapidly (10 min after stimulation) and these phosphor-
ylation events are all blocked by TAK-1 inhibition.In contrast, IL-1alpha
and TNF-alpha do not induce phosphorylation of Smad2/3 after 10 min
stimulation when no Activin A is detectable in SN, but do so after 24 h
stimulation, when Activin A is found in SN. Moreover, delayed IL-1alpha-
and TNF-alpha-induced Smad2/3 phosphorylation is blocked by TAK-1/
p38/NFkappaB inhibition confirming that these pathways are upstream of
Activin A release and Smad2/3 signaling. Analysis of this new pathway in a
rat sarcopenia model showed that Smad3 as well as TAK-1 and p38
phosphorylation significantly increased from 6 to 24 months. Moreover,
expression of TAK-1, Activin A beta and serum TNF-alpha level also
increased with age confirming upregulation of the TNF-alpha/TAK-1/p38/
Activin A/Smad3 pathway during aging.
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The mitochondrial and neuromuscular systems are severely dysregulated
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Background and aims: Age-related loss of skeletal muscle mass and
strength (termed sarcopenia) occurs in most mammalian species and
adversely affects quality of life and survival. The etiology of sarcopenia is
believed to be multifactorial but the specific initiating molecular
mechanism(s) has not been elucidated, in part, because of dearth of non-
invasive methods for such studies in humans and of suitable rodent
models. Here, we describe a rat model and applied it to elucidate the
genomic and proteomic changes associated with sarcopenia.
Methods: Male Harlan Sprague–Dawley (SD) rats aged 6, 12, 18, 21, 24,
and 27 months were characterized for clinical phenotype, skeletal muscle
weight and histo-morphometry; evoked muscle strength was assessed in a
separate group of 6-, 12-, 18- and 24-month-old rats. Muscle samples were
subjected to microarray and proteomic analysis to identify systems and
pathways perturbed during sarcopenia as distinct from aging.
Results: Male Harlan SD rats exhibited sarcopenia as determined by
progressive loss of muscle mass after 18 months of age. Sarcopenia was
associated with atrophy of types 1, 2A and 2B muscle fibers and a decline
in fiber oxidative enzyme activity. Gene set enrichment analysis of
microarray data revealed that mitochondrial energy metabolism pathways
(tricarboxylic acid cycle and oxidative phosphorylation) were the most
down-regulated while genes associated with the neuromuscular (NM)
junction were the most up-regulated. Pathways involved with protein
synthesis and translation were also enriched. Proteomic analysis also
revealed depletion of proteins associated with mitochondrial energy
metabolism and enrichment of proteins associated with translation of both
cytosolic and mitochondrial proteins.
Conclusions: The phenotypic, genomic and proteomic features of
sarcopenia in these rats are similar to those of human sarcopenia and
suggest that these rats may be a suitable model for mechanistic studies of
sarcopenia. That the mitochondrial and NM were the most perturbed
systems suggest that interventions that rescue these systems may be
beneficial for preventing or treating sarcopenia.
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Loss of ex vivo muscle function with preserved muscle mass may be
indicative of sarcopenia onset in aging mice
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Background and aims: Sarcopenia is the decline of muscle mass and
function with ageing. The relationship between loss of muscle mass
and strength is not fully clear, since part of the decline in muscle
strength is independent of muscle mass decline. The aim of this study
was to characterize these aspects in mice of increasing age.
Methods: Male C57BL6/6 J mice of 7, 10, and 13 months of age (m7,
m10, m13; n=5/group) were characterized for their body composition by
DEXA. Extensor digitorum longus muscle (mEDL) was weighted and its
function determined according to an ex vivo force–frequency stimulation
protocol (10–167 Hz). Statistics were performed using a one-way ANOVA
with LSD post-hoc testing.
Results: Total and lean body weight of m7 was lower (p<0.05; one-way
ANOVA) than of m10 and reached a plateau thereafter. Muscle function
declined in m13 (157±18 mN*) compared to m7 (210±31 mN) and m10
(234±21 mN), as characterized by a lower maximal force (p<0.05; one-way
ANOVA). Simultaneously, maximal contraction and relaxation velocity
decreased. mEDL mass, however, was not reduced in m13 versus m10.
Conclusions: In 13-month-old mice, a decline in muscle function precedes
age-related changes in muscle mass. This coincides with a decrease in bone
mineral density. The data suggest that loss of muscle function in an ex vivo
protocol is a potential indicator for loss of muscle quality and the onset of
sarcopenia in this mice model. These observations offer potential to
explore the effect of interventions targeting sarcopenia in the future.
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Lack of apoptotic myonuclei during the initial phase of atrophy in young
as well as old human skeletal muscle
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Several animal models have demonstrated that muscle atrophy is initiated
by apoptotic loss of myonuclei.
Purpose: To investigate apoptotic signaling in myonucli during the initial
phase of muscle atrophy in healthy young as well as old human individuals.
Methods: Myofiber atrophy was induced by application of a knee-brace for a
period of 4 days in young (Y, ∼20 years, n=11) and aged (O, ∼70 years, n=
11) individuals. Muscle biopsies of the VL muscle were collected pre and at
1, 2, and 4 days of immobility. Changes in gene expression levels of BAX
and p53 mRNA was determined using real-time RT-PCR and normalized to
the Ribosomal Protein Large P0 (RPLP0) mRNA. Fragmented DNA was
analyzed by TUNEL labeling on histological sections.
Results: Muscle atrophy was demonstrated by a decline in (MFA) (Y: 10.6%,
O:9 . 0 % ,p<0.05) and MVC (Y: 13.0%, O: 14.3%, p<0.05) at 4 days. Gene
expression analysis revealed an age-specific (old subjects only) upregulation
of the pro-apoptotic markers Bax and p53 after only 2 days of immobility,
with further increasing levels after 4 days in both young and old muscle.
These data were supported by a concomitant increase in TUNEL+nuclei (p<
0.05). No TUNEL positive myonuclei were, however, observed in neither
young nor old muscle. TUNEL positive nuclei were localized in the
interstitial space between muscle cells. Double immunohistochemical
staining for TUNEL and the endothelial marker CD-31, the macrophage
marker CD-68 or the satellite cell marker Pax7 did not reveal any TUNEL
positive endothelial cells, macrophages or satellite cells.
Conclusion: The present data indicates that disuse atrophy, in young as well
as old human skeletal muscle, is not initiated by a degenerative process
involving loss of myonuclei.
Supported by Lundbeck Foundation, the Danish National Research Council,
the Danish Rheumatology Association, and the Nordea Foundation.
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Assessment of sarcopenia in geriatric dogs
Dana Hutchinson
1, James Sutherland-Smith
1, Adrian L. Watson
2, Lisa M.
Freeman
1 (
1Department of Clinical Sciences, Tufts Cummings School of
Veterinary Medicine, North Grafton, MA, USA;
2WALTHAM Centre for
Pet Nutrition, Leicestershire, UK)
Background and aims: Sarcopenia is a common problem in aging people
but it has not been well-described in dogs. The aim of this study was to
evaluate clinically applicable methods of assessing lean body mass in dogs,
and to compare muscle mass, inflammatory markers, and insulin-like growth
factor (IGF-1) in healthy young and geriatric dogs.
Methods: Healthyyoung(1–5yearsold)andgeriatric(>8yearsold)Labrador
Retrievers of optimal body weight were eligible for the study. Lumbar muscle
measurements at the level of T13-L1 were performed by radiography,
ultrasound, and computed tomography (CT). Temporal (CT and ultrasound)
and quadriceps muscles (ultrasound) also were measured. Serum C-reactive
protein (CRP), tumor necrosis factor-á (TNF), and IGF-1 were measured, and
dogs’ activity for 14 days was assessed using an activity monitor.
Results: Nine young dogs (five female, four male; mean age=2.4±1.0 years)
and 11 geriatric dogs (nine female, two male; mean age=9.4±1.7 years) were
enrolled. Body weight was not different between groups nor was any measures
ofbodysize(e.g.,length,height)orcalorieandproteinintake.Musclecondition
scoresindicatedsignificantlymoremusclelossinthegeriatricgroup(p<0.001).
The mean area of the lumbar muscles was significantly smaller in geriatric
compared to young dogs when measured by ultrasound (p=0.005) and by CT
(p=0.02). Differences between groups were not detected for quadriceps or
temporal muscles by either technique. Activity was lower in the older dogs (p
=0.02) but muscle area was more significantly related to age than to activity.
TNF, IGF-1, and CRP concentrations were not different between groups.
Conclusions: Muscle loss occurs in both aging dogs and humans. Additional
studies evaluating functional changes in this canine model are warranted, as are
studies to evaluate potential benefits of exercise and nutritional modifications.
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A molecular predictor of the human ageing biological program
James A. Timmons (University of London, London, UK)
The ability to monitor the progression of the ageing process requires the
identification of mechanisms which also take into account confounding
environmental factors. To discover the gene networks that define ageing, we
hypothesised that it would be critical to incorporate detailed physiological
phenotyping into the analysis, in order to rule out false associations. First, we
produced a molecular classifier able to discriminate between healthy young
(<30 years, n=30) and healthy old (>60 years of age, n=30) human skeletal
muscle; one that is unrelated to aerobic, strength, metabolic fitness or
exercise status. The ∼40 gene expression programme is ∼90% accurate at
classifying age in multiple independent human and murine muscle data sets,
including human kidney and human superior frontal gyrus. The ageing
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longevity or pathways that alter longevity in multiple species. The remaining
genes represent novel associations, including proteins involved in WNT
signalling and RNA binding proteins. Cause-effect analysis using a drug
connectivity map identified ∼40 candidate drugs that regulated the ageing
expression programme in human cells. We found that Rapamycin (mTOR
inhibitor) and LY-294002 (PI3K inhibitor) induce the ageing gene network
and both drugs inhibit genes which extend lifespan. Finally, we applied the
age classifier to 150 middle-aged subjects (40–59 years). As expected only
5% of subjects were defined as having a ‘youthful’ middle-aged profile.
While both groups had the same chronological age (∼50 years) and
cardiovascular and metabolic fitness, remarkably the ‘youthful’ middle-
aged human subjects had a significantly lower resting heart-rate, a long-
established correlate of longevity in the animal kingdom. The ageing gene
network therefore represents not only the first accurate predictor of muscle
ageing, but an excellent resource to develop small-molecule drugs and an
excellent toxicology biomarker for future drug-safety screening.
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Background and aims: Dementia is a neurological disease mainly
characterized by clinically significant cognitive deficit which includes
memory. Behavioral changes may occur and lead to an autonomy loss and a
decreasedcapacity toperform daily professional and socialactivities.Disease-
related undernutrition leads to an increased number of clinical complications
as with a negative outcome in the physical and psychological status.
Hospitalization can worsen the status. The Mini-Nutritional Assessment
(MNA) is the golden standard for nutritional status evaluation and it is
validated for Alzheimer’s disease. This study aims to evaluate the Nutritional
Status of the hospitalized elderly people in the Geriatric Ward of the Hospital
de Magalhães Lemos–Porto and its relation with calf circumference.
Methods: Thisanalyticalcross-sectionalstudywasmade between the periods
of February to May of 2011. The Mini Nutritional was applied. Furthermore,
the patients were subjected to weight, height, calf circumference and mid-arm
circumference measurements and the body mass index was calculated.
Results: This study was built with a sample of 22 elderly dementia people, of
which 31.8% were male and 68.2% female. The Mini Nutritional Assessment
revealed that 45.5% of the elderly dementia people were at risk for
undernutrition, 4.5% did not show nutritional risk and 50% was undernour-
ished. The calf circumference equal or superior to 31 cm showed to be more
representative with 54.5%, while inferior to 31 cm showed 45.5%.
Conclusions: This study revealed the major importance of assessing the
nutritional status and the need to use the calf circumference as a parameter for
that evaluation.
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Accuracy of food intake assessment is influenced by body fatness
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Background and aims: The accurate measurement of energy intake is
essential in patients with cachexia and other diseases causing wasting,
which are highly prevalent among older persons. However, there are no
accurate methods for the assessment of food intake in older populations,
underreporting of intake being highly prevalent. There are reports that
obesity is associated with higher prevalence of underreporting of energy
intake, but few studies have measured body fatness itself. It is possible that
older people with lower body fat underreport less, so that food intake
inquiries would be more precise in patients with cachexia and other
conditions that promote loss of fat mass. This research aimed to assess the
correlation between underreporting of energy intake and different
percentages of body fat in independent older people.
Methods: Fourty-one volunteers (21 female) were evaluated, representing
the four quartiles of fat percentage of a representative sample of 100
volunteers from the community. Resting energy expenditure was measured
by indirect calorimetry, total energy expenditure (TEE) was measured by
the doubly labeled water method (DLW) and energy intake (EI) was
assessed by three 24-h recalls and a food frequency questionnaire (FFQ).
Regression and analysis of variance were employed to compare TEE and
energy intake values, energy intake-to-TEE ratios and energy intake-TEE
values between dietary assessment methods. Bland and Altman analysis
were performed for each method.
Results: TEE, as measured by DLW was 2,220±601 kcal, while the EI,
measured respectively by the 24 h recall and FFQ, was 1,919±602 and 2,119±
670 kcal. Under-reporting was less frequent in subjects with lower percentage of
body fat and men (p<0.05). In conclusion, underreporting was less frequent
among older persons with lower percentage of body fat.
Conclusion: It is possible, therefore, that undernourished patients report
more precisely their energy intake. This finding needs confirmation in
further studies including patients with cachexia.
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Mechanisms underlying anorexia in adjuvant arthritis: Focus on IL-
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Background and aims: Adjuvant arthritis (AA), a rat model of
rheumatoid arthritis induces anorexia–cachexia syndrome. Pro-
inflammatory cytokine interleukin (IL)-1beta serves as a potent anorexi-
genic agent that interacts with hypothalamic neuronal circuits regulating
appetite. In this study, we tested whether the loss of appetite and body
weight during AA is associated with alterations in the expressions of IL-
1beta and anorexigenic/orexigenic neuropeptides in the hypothalamic
arcuate nucleus (ARC) or paraventricular nucleus (PVN).
Methods: AAwas induced in rats by complete Freund’s adjuvant injection.
On day 18 of AA, mRNA expressions of neuropeptide Y (NPY), agouti-
related protein (AgRP), cocaine and amphetamine regulated transcript
(CART), pro-opiomelanocortin (POMC), melanocortin-4 receptor
(MC4R), and IL-1beta in ARC or PVN were determined by quantitative
TaqMan PCR. Plasma levels of leptin, insulin, ghrelin and corticosterone
were determined by immunoassays.
Results: Arthritic rats displayed a 50% reduction in food intake and a 26%
reduction in body weight compared to controls at the end of the
experiment. Plasma levels of anorexigenic leptin were lower, insulin
unchanged, and orexigenic ghrelin and corticosterone higher in arthritic
rats than in controls. This was associated with increased ARC mRNA
expressions of orexigenic NPY and AgRP in arthritic rats. The ARC
mRNA expressions for anorexigenic CART were decreased, for POMC
unchanged, and for IL-1beta increased in arthritic rats. In PVN, mRNA
246 J Cachexia Sarcopenia Muscle (2011) 2:209–261expressions of IL-1beta and MC4R were also enhanced in the arthritic
group.
Conclusions: The anorexia–cachexia syndrome in AA is not mediated by
increased ARC mRNA expressions of anorexigenic neuropeptides or sup-
pressed expressions of orexigenic ones. Reduced leptin and increased ghrelin
and corticosterone levels indicate normal physiological response to starvation
during AA. The failure of this response to increase food intake in arthritic rats
can be ascribed to the anorexigenic effect of IL-1beta which over-expresses in
the ARC and PVN.
Supported by: MSM 0021620816
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Association of the surrogate measures of dietary protein intake and survival
in 100,088 chronic hemodialysis patients
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Background: Decreased dietary protein intake may be associated with
increased mortality risk in individuals with kidney failure undergoing
maintenance hemodialysis (MHD).
Objectives: We examined 8-year (7/2001-6/2009) all-cause mortality in
100,088 MHD patients from DaVita dialysis clinics across the nation. We
hypothesized that survival would improve across increased levels of
normalized protein nitrogen appearance (nPNA), also known as protein
catabolic rate (nPCR) and that this trend would be consistent even in
hypoalbuminemic patients and in Blacks, Caucasians, and Hispanics.
Methods: Time-averaged Cox models were used to estimate death hazard
ratios for quarterly averaged nPCR categories controlled for case-mix,
comorbidity, dialysis dose (Kt/V), and available markers of malnutrition-
inflammation-complex syndrome (MICS).
Results: In all patients, the best survival was associated with an nPCR
between 1.2 and 1.3 g/kg/day, while nPCR <1.0 or ≥1.4 g/kg/day was
associated with higher mortality. Adjustment for MICS attenuated the
associations considerably, indicating that protein intake may be related to
survival via the MICS axis as intermediary. Subgroup analyses revealed
similar trends for hypoalbuminemic patients and in Blacks, Caucasians,
and Hispanics, with Black and Hispanic subjects experiencing higher
mortality rates than Caucasians at low nPCR levels.
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Conclusions: A low daily protein intake is associated with increased risk
of death in MHD patients, esp. in Blacks and Hispanics, with likely
mechanism of modulating the MICS axis. Trials of dietary intervention to
improve survival in MHD patients are indicated.
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Nutritional status in patients with chronic obstructive pulmonary
disease (COPD)
Barbara Kuznar-Kaminska, Halina Batura-Gabryel (Department of Pulmonology
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Poznan, Poland)
Background and aims: COPD is chronic inflammatory disease with
systemic symptoms. The most often extrapulmonary manifestation is loss of
lean body mass named cachexia. Study aim was: (1) Evaluation of body
composition and frequency of cachexia in COPD patients in comparison with
healthy subjects. (2) Assessment the relation between some parameters of
cachexia and COPD stage, as well as subtype of the disease.
Methods: Fifty-five COPD patients—43 males, 12 females (mean age 62.31±
11.08) and 32 healthy controls (mean age 57.43±8.79) was enrolled to the
study. Body composition was measured using analyser based on bioimpe-
dance. Percentage of ideal body weight (PIBW), body mass index (BMI), fat
free mass index (FFMI), and fat mass index were assessed. Spirometry with
evaluation of: forced vital capacity (FVC), forced expiratory volume in the first
second (FEV1), FEV1/FVC (Tiffeneau ratio) was performed in each COPD
subjects. Subtype of disease: empysematous or chronic bronchitis was assessed
on the base on clinical symptoms and parameters of emhysema evaluated in
bodypletysmography or computer tomography.
Results: PIBW,BMI,andFFMIindicatedmalnutritionwereconfirmedin5.45%,
3.64%, 18.18% of COPD patients and 3.12%, 0%, 3.12% of control group,
respectively. Average BMI did not differ between groups. FFMI was significant
J Cachexia Sarcopenia Muscle (2011) 2:209–261 247lower among COPD patients (19.05±3.44 vs. 20.55±3.19 kg/m
2). FFMI, but no
BMI, correlated with stage of disease. In COPD patients with predominant
emhysema, FFMI was lower than in patients with chronic bronchitis.
Conclusions: (1) Cachexia is frequent problem of COPD patients—it
concerns about 20% of subjects. (2) Analysis of body composition with
FFMI assessment is essential for evaluation of nutritional status—BMI is
not sufficient indicator. (3) Cachexia appears more often in advance stages
of COPD and in phenotype with emphysema
6-06
Mini nutritional assessment score predicts rehospitalisations in patients with
chronic obstructive pulmonary disease
Barbara Benedik
1,J e r n e j aF a r k a s
2, Mitja Kosnik
1, Sasa Kadivec
1, Mitja
Lainscak
3,4 (
1University Clinic or Respiratory and Allergic Diseases Golnik,
Golnik, Slovenia;
2Chair of Public Health, Faculty of Medicine, University of
Ljubljana, Ljubljana, Slovenia;
3Division of Cardiology, University Clinic or
Respiratory and Allergic Diseases Golnik, Golnik, Slovenia;
4Applied
Cachexia Research, Division of Cardiology, Charite–Campus Virchow-
Klinikum, Berlin, Germany)
Background: Limited information about nutritional status and risk of malnutri-
tion is available in patients with chronic obstructive pulmonary disease (COPD).
We have conceived this analysis to study the associations between malnutrition,
body composition, and rehospitalisations in patients with COPD.
Methods: This prospective study recruited COPD patients during
hospitalisation for acute exacerbation. In addition to routine assess-
ment, we performed pulmonary function testing, nutritional assessment
with Mini Nutritional Assessment (MNA) questionnaire, body compo-
sition measurement, and dyspnoea evaluation. We recorded hospital-
isations during 6-month follow-up. Same investigations were performed
in control group.
Results: We recruited 22 healthy controls (71±5 years, 59% men) and 108
COPD patients (71±10 years, 75% men, 85% severe or very severe
COPD). Control subjects had significantly higher MNA score than COPD
patients (27.0±1.7 vs. 21.2±4.9, p<0.001). MNA score indicated
malnutrition in 14% of patients, and further 55% were at risk of
malnutrition. With increasing severity of COPD per GOLD stage the
MNA score decreased (p=0.02). Body mass index but not body
composition parameters was higher in control subjects when compared
to COPD patients (29.1±3.8 vs. 27.0±6.3, p=0.041). A positive
correlation between MNA score, body fat content (p=0.001), and lean
body mass (p<0.001) was observed. During 6-month follow-up, 45
(41%) patients were rehospitalised. Malnourished patients had higher
risk of rehospitalisation (Figure), which was maintained after adjustment
for age, gender, GOLD stage, and body compositon parameters (HR
2.93, 95% CI 1.05–7.32).
Conclusions: Malnutrition and risk of malnutrition is frequent in patients
with COPD. Malnutrition predicted rehospitalisations at 6 months inde-
pendently of body composition parameters.
Figure.
6-07
Application of bioelectrical impedance analysis in nutritional
assessment of COPD patients
Alessia Fumagalli
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Background and aim: Chronic obstructive pulmonary disease (COPD) is
characterized by a range of pathophysiologic changes contributing to a
progressive loss of skeletal muscle mass. Body composition can be
analysed by bioelectrical impedance analysis (BIA), a noninvasive,
inexpensive and portable method. Phase angle (PA), a ratio obtained by
BIA, has been interpreted as an indicator of membrane integrity and
function and reflects body cell mass. Low values of PA could be
interpreted as malnutrition, defined as decreased body cell mass. We
investigated whether PA could be a useful indicator of nutritional status in
COPD patients and whether it would reflect disease severity.
Methods: One hundred thirty-two stable COPD patients were evaluated for
BMI, parameters measured by BIA, airway obstruction (FEV1, FEV1/FVC),
exercise capacity (6-min walkdistance), chronic dyspnea using Medical
Research Council (MRC) scale, blood gases (pO2, pCO2), biochemical blood
tests (albumin) and for all patients we calculated BODE index.
Results: PA shows a good significant correlation with FEV1 (r=0.521, p<
0.01) while BMI and FFM are weakly but significantly correlated with
FEV1 (respectively. r=0.329 and r=0.262). PA is statistically different
among patients in the four stages of COPD. PA values are higher in first
and second stage characterized by a smaller airflow limitation and
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248 J Cachexia Sarcopenia Muscle (2011) 2:209–261obstruction. PA is significantly associated with BODE index too: PAvalues
are higher in patient with lower BODE score.
Conclusion: PA seems to be representative of body cell mass and therefore
it could be used as a nutritional marker in COPD patients in which the BIA
assumptions are not fully valid. The quite strong correlation between PA
and FEV1 allow us to speculate that the decrease of PA reflects the
progression of disease. In our population the good association found
between PA and BODE confirm the possibility that PA should be evaluated
as a prognostic indicator.
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Background: Patients having cancer cachexia and mild to severe bowel
obstruction sometimes might benefit from parenteral nutrition. However
current guidelines (e.g. ESPEN) do leave many decisions to the treating
team, and therefore practices seem to vary substantially. We aim to
systematically collect expert opinions and together with results of a
systematic literature review provide information for further development of
clinical practice and research.
Methods: Based on systematic literature review on parenteral nutrition in
advanced incurable cancer patients, having mild to severe bowel obstruction
(presented at ESPEN 2011) and expert opinions, a group consisting of
physicians (oncologists, palliative medicine specialists, surgeons, others) and
nutritionists composed a survey to be distributed to different professional
societies (ESPEN, ESMO, EAPC). The survey is provides an introduction to
thetopic,followedbyintroductoryquestions onhealthcare providers’view on
the indications for parenteral nutrition in the population, describing patient
characteristics and views on current oncological palliative management to be
able to make decisions for parenteral nutrition, on outcomes for parenteral
nutrition in the setting and whether guidelines are used and are helpful for the
practice.Then,basicdemographicsofthehealthcareproviderarequeried(age,
gender, profession, working setting). Then inclusion criteria for in-depth
survey are requested, defined level of experience with this specific patient
population (exposure last years with defined number of patients, defined
setting of interdisciplinary decision making). In the following part, three
carefully described case reports, detailing all necessary components for
decision making, the practice of the responding experts is asked in terms of
patient population (important variables to make decisions; opinions about
current oncological and palliative management, which need to be available to
make decisions for or against parenteral nutrition; outcomes that respondents
believe to be important and should be measured in the specific case; opinions
about practices in terms of products components used; monitoring for safety
and efficacy; conditions for delivery at home etc.). In the final part, generic
questions about indications, outcomes and current practice are requested.
Analyses will be mostly descriptive, hypothesis might be tested based on
professions, countries and reimbursement system.
Results: The Survey will be launched in October 2011 and will be open for
4 weeks, therefore late braking results will be available by end of
November 2011.
Discussion: This international survey on indications, outcomes and
practices of parenteral nutrition in cancer cachexia patients having bowel
obstruction, based on the careful design and the inclusion criteria for
experts will provide solid informations to identify priorities and develop
clinical trial design for guideline development.
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What do patients eat when living with advanced cancer: findings
from an exploratory trial of the Macmillan Approach to Weight loss
and Eating (MAWE)
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Background: Evidence, although limited, suggests that advice on what to eat
when living with refractory cancer cachexia syndrome should include (1) take
a nutrition dense diet, (2) eat small amounts often, and (3) take nutritional
supplements
1. Following this advice, within the confines imposed by disease,
is important to minimising the malnutrition component of the syndrome.
Aim: To discuss the potential for nutritional counseling to benefit patients
living with involuntary weight loss, poor appetite and advanced cancer.
Methods: In the UK in 2006–2007, 50 patients were recruited into an
exploratory trial of a psycho-educational intervention for weight- and eating-
related problems in patients with advanced cancer. A baseline interview invited
self-report of food and fluid intake both the day before the interview and prior to
receiving a cancer diagnosis. Framework analysis enabled evaluation of
adherencetooptimal foodandfluidintakeforsomeonewithrefractorycachexia.
Results: Forty-sixpatientsreportedpoor appetitewith27admittingtofoodand
fluid intake half or less than half of pre-illness. As pre-illness, the majority took
a main meal, comprising meat and vegetables (n=30), even though many were
experiencing taste/smell changes that made this difficult. This led to
comments like ‘I can’t eat much.’ Only one person was taking their main
meal at the time of day they found easiest to eat. Few were snacking (n=5),
fortifying foods (n=5) or taking a nutritional supplement (n=13).
Conclusion: There is potential for nutritional counseling to support improve-
ment in nutritional intake in patients with refractory cachexia. Work is needed to
establish how best to support these patients in changing eating behaviours.
1. Hopkinson et al. (2011) What to eat when off treatment and living with
involuntary weight loss and cancer: a systematic search and narrative
review. Supportive Care in Cancer, 19(1): 1–17.
Funding body: Macmillan Cancer Support, UK
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Prognostic role of nutritional factors and C-reactive protein (CRP)
in locally advanced head and neck carcinoma (LAHNC) treated
with definitive or postoperative chemoradiation (CRT)
Cristiana Bergamini
1, Paolo Bossi
1, Laura Locati
1, Aurora Mirabile
1,
Roberta Granata
1, Carlo Resteghini
1, Ester Orlandi
2, Simona Barlera
3,
Cecilia Gavazzi
4, Lisa Licitra
1 (
1Head and Neck Head and Neck Medical
Oncology, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy;
2Radiotherapy, Fondazione IRCCS, Istituto Nazionale Tumori, Milan,
Italy;
3Biostatistics Istituto Mario Negri;
4Nutrition Unit, Fondazione
IRCCS, Istituto Nazionale Tumori, Milan, Italy)
Background: Head and neck cancer patients experience nutrition problems
due to the disease itself and/or to the effects of CRT and surgery.
Malnutrition can impact on clinical outcome and reduce treatment efficacy.
We reviewed the prognostic role of clinical and laboratory nutritional
factors and acute-phase protein CRP in a consecutive series of LAHNC
patients treated with definitive or postoperative CRT.
Patients and methods: From 2004 to 2010, 305 patients with LAHNC were
treated with definitive CRT (82%) or surgery plus postoperative CRT (18%).
J Cachexia Sarcopenia Muscle (2011) 2:209–261 249Baseline and 3 months after therapy values of body mass index (BMI),
haemoglobin (Hb) and lymphocytes (Ly) were collected; CRP was considered
only at baseline. Weight loss, the highest CRP and the lowest Hb level reached
during CRT were reviewed. All these parameters were analysed as prognostic
factors. Survival was calculated according to Cox multivariate analysis.
Results: Median age was 56 years, M/F ratio 231/74 (76%/24%), median
ECOG 0. Site of primary cancer was oropharynx (33%), nasopharynx (27%),
larynx-hypopharynx (14%), oral cavity (12%), and other (14%); stage IV was
most represented (79%). Median follow-up time was 28 months (range, 1–
138). Low BMI (<18.5), Hb (<12 g/dL), Ly (<900/mmc) were present
respectively in 5%, 18% and 14% of the patients at baseline and in 10%, 43%
and58%3monthsaftertherapy.HighvalueofCRP(>5mg/dL)wasidentified
in 27% of the patients at baseline. Thirty-seven percent experienced a high
weight loss (>10%) during CRT. A prognostic role was identified for baseline
CRP (p=0.0114) and for low Ly (p=0.0026) 3 months after CRT.
Conclusions: Nutritional factors and acute phase proteins have an impact
on LAHNC patients prognosis and could help in stratifying patients for
better therapeutic intervention and surveillance.
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Relationship between nutritional assessment, Glasgow Prognostic
Score and tumor staging in patients with breast cancer: preliminary
report
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Background and aims: Malnutrition in cancer patients is associated with
increased morbidity and mortality as well as higher medical expenses and
longer hospital stay. Tumor-derived agents and the systemic response to the
tumor, such as the presence of pro-inflammatory cytokines and hormones,
have been associated with the pathogenesis of malnutrition and cachexia
which impact on outcomes and functionality.Therefore, it is important to
assess the nutritional and the inflammatory status of these patients.
Methods: Patients with breast cancer were evaluated between September
2010 and August 2011. Subjective Global Assessment (SGA) was used to
assess nutritional status. Albumin and C-reactive protein (CRP) were
determined for classification of the Glasgow Prognostic Score (GPS). Disease
stage was determined according to the TNM classification. Patients were
divided according to the stage (1 and 2; 3 and 4) to assess the association
between GPS and tumor stage. The data were analyzed by Fisher’s exact test.
Results: This study enrolled 49 patients with breast cancer, mean age of
52.8±12.4 years. Patients were divided into malnourished and well
nourished according to SGA. The first group comprised patients with
moderate malnutrition (16.3%) and the second group encompassed the
nourished patients (83.7%). There was no significant relationship between
nutritional (SGA) and inflammatory status, classified by GPS (Fisher’s
exact test, p>0.05). There was a significant association between GPS and
tumor state (Fisher’s exact test, p<0, 05). No associations were observed
between stage and SGA, SGA and albumin and between SGA and CPR.
Conclusions: Higher GPS values are found in patients with advanced
breast cancer. GPS is not an indicator of patients’ nutritional status.
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Security hunger: an understanding of cancer cachexia-related distress
in families
Jane B. Hopkinson
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Background and aims: Weight loss and anorexia are symptoms of
cancer cachexia syndrome that can be experienced as distressing by
patients and their family members. This study aimed to develop a
theoretical understanding of cachexia-related distress that can underpin
family focused psychosocial interventions for the problem.
Methods: A novel understanding of cachexia-related distress was
generated from a secondary analysis of in-depth, semi-structured inter-
views conducted in the South of England in 2006–2007 with 31 advanced
cancer patient–family carer dyads (a total of 62 interviews). The two stages
of analysis comprised a discourse analysis followed by thematic analysis
and interpretation, which enabled the identification of interdependency in
patient and family carer experience and the construction of a conceptual
model. The analysis was critical in that pre-existing theory was then used
to explain the model and to generate an understanding of how cachexia-
related distress might be alleviated. Emergent concepts, propositions and
theory were tested through engagement with the study User Involvement
Group comprising healthcare professionals, academics and patients.
Findings: Our food habits are a taken-for-granted behaviour that can
communicate connection with and separation from those around us.
Interactional patterns between patient and family carer are disrupted by
weight loss and changing eating habits. Dyads can either adapt to this
change (dual acceptance) or resist (dual resistance or mismatched
resistance). Resistance can be understood as an indicator of threat to
emotional security and driven by security hunger. Cachexia-related distress
in both patients and their family members is symptomatic of unstable
connections and difficulty adapting relationships as disease progresses.
Conclusion: This theory challenges researchers and clinicians to seek ways
of aiding not only with the physical changes of weight loss and anorexia,
but also with adaptation to the inevitable relationship disruption in families
affected by cancer cachexia syndrome.
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PTHrP and cachexia
Akihiro Asakawa, Akio Inui (Division of Psychosomatic Internal Medicine,
Kagoshima University Graduate School of Medical and Dental Sciences,
Kagoshima 890–8544, Japan)
Cancer cachexia is reported to be a major cause of cancer-related death. Its
pathogenesis remains unclear. For that reason, few effective therapies have
been established. Myriad tumors produce parathyroid hormone-related
protein (PTHrP) and, consequently, plasma level of PTHrP is increased in
cancer cachexia syndrome. Peripherally administered PTHrP induced
negative energy balance by decreasing food intake and gastric emptying,
while not producing conditioned taste aversion. The mechanism involved
activation of hypothalamic urocortins 2 and 3 through vagal afferent
pathways, and the suppression of gastroduodenal motor activity. Contin-
uous administration of PTHrP reduced food intake and body weight gain
with a concomitant decrease in fat and skeletal muscle. These findings
suggest that PTHrP influences food intake and body weight and may be a
therapeutic target for cancer cachexia syndrome. We will summarize the
relationship between PTHrP and cachexia.
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Providing nutritional support to patients with thoracic cancer:
findings of a dedicated rehabilitation service
Cheryl Percival, Asmah Hussain, Sonja Zadora-Chrzastowska, Matthew
Maddocks, Gillian White, Andrew Wilcock (Nottingham University
Hospitals NHS Trust, Nottinghamshire, UK)
Background and aims: UK guidelines recommend screening patients
with thoracic cancer to identify those requiring nutritional support.
250 J Cachexia Sarcopenia Muscle (2011) 2:209–261To help quantify this area of need, the associated workload and
explore its impact, we report findings from a dedicated rehabilitation
service.
Methods: Patients were screened soon after diagnosis to determine the
prevalence of malnutrition and various aspects compared between
malnourished and not malnourished groups. A nutritional care plan
was instigated and all contacts recorded, together with follow-up body
weight.
Results: Of 243 patients seen, 84 (35%) were malnourished which was
associated with advanced disease (P=0.02) and a reduced survival (median
52 days less, P<0.01). About one-third of these were being considered for,
or receiving treatment with curative intent. Overall, about two thirds were
failing to meet their daily recommended energy intake. The dietitian
provided over 870 episodes of care, with a median [IQR] of 3 [2–5]
contacts per patient. More of the malnourished group received oral
nutritional supplements, but also experienced problems tolerating them.
After one month, weight was stable or increased in 69% and fell in 31%.
Neither the pattern nor magnitude of the change in weight differed between
groups.
Conclusion: All patients with thoracic cancer require a dietetic assessment
if those who are malnourished, or at risk of malnutrition, are to be reliably
identified and receive appropriate nutritional support. Our data provide a
pragmatic insight into the implications of following UK national guidance
on nutritional screening and support in this patient group.
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Background and aims: Patients with metastatic lung cancer frequently
develop anorexia–cachexia syndrome which is characterized by loss of
lean and fat body mass. However, in obese patients progressive loss of
musculature may be obscured due to the abundance of fat leading to
misdiagnosis of the syndrome. In the present study, we evaluated the
prevalence and prognostic value of nutritional depletion in obese patients
with metastatic lung cancer.
Methods: Newly diagnosed metastatic lung cancer patients accrued in
two University Hospitals in Greece were eligible. Obese patients,
defined as those with body mass index (BMI) ≥30 were analyzed. The
Mini Nutritional Assessment (MNA) score was used for the evaluation
of nutritional status and patients were classified into three groups:
adequately nourished (group A), at nutritional risk (group B) and
malnourished (group C). The prognostic significance of MNA was
also assessed.
Results: From an original cohort of 421 patients, 75 (17.8%) patients
were obese and were subsequently selected for analysis. Mean age
(±SD) was 64.2 (±10.6) and 58 (77.3%) patients were males. Mean
BMI (±SD) was 32.8 (±3.3). According to MNA, 32 (43.2%) patients
belonged to group A, 39 (52.7%) to group B and 3 (4.1%) to group
C. Median survival (±SD) for the aforementioned groups was 10
(±10.9), 7 (±6.7) and 2 (±1.7)months, respectively, and this difference
was statistically significant (p<0.001).
Conclusions: Obese cancer patients represent a heterogeneous cohort in
terms of nutritional adequacy and this may impact on survival. These
patients should not be spared from nutritional evaluation and should be
offered specialized counseling and/or nutritional support.
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Background and aims: Lung cancer patients frequently develop malnu-
trition and/or acute phase response in the context of cachexia and may
present defects in their immune system. Our aim was to evaluate the
association between nutritional status and chemokine-induced response of
lipopolysaccharide (LPS)-stimulated, ex vivo cultured peripheral blood
monocytes (PBMCs) in metastatic lung cancer patients. The correlations of
the recorded parameters with clinical outcomes were also evaluated.
Methods: Patients with metastatic lung cancer were eligible. Demograph-
ics and other baseline characteristics were recorded. Mini Nutritional
Assessment (MNA) protocol was used for nutritional assessment. PBMCs
were isolated and cultured in vitro for 2 h in the presence of autologous
serum and LPS. Interleukin (IL)-8 levels were measured in plasma before
and after LPS-stimulation, as an indicator of immune reactivity after
exposure to a high immunogenic stimulant. MNA was correlated with
“folds of IL-8 production” after LPS stimulation. Correlations with clinical
outcomes were also evaluated.
Results: Totally, 143 patients (89.5% males) [median age 67 years (range,
32–84)] were enrolled. The distribution of patients across MNA groups A,
B and C was: 40 (28%), 67 (46.9%) and 36 (25.1%), respectively, while
the median stimulation times for IL-8 (±SD) was 27.5 (±126.8). The
correlation between MNA groups and IL-8 stimulation times was
significant (p<0.05). MNA was further correlated with the development
of infections during first-line chemotherapy (p<0.05) as well as hospital-
izations (p<0.05), although this was not the case for IL-8 stimulation
times. MNA score and IL-8 stimulation times were further correlated with
time to tumor progression after first-line chemotherapy (rho=0.318, p<
0.01 and rho=0.321, p<0.01) and overall survival (rho=0.506, p<0.01 and
rho=0.298, p<0.01), respectively.
Conclusions: Immune reactivity may be impaired in cachectic lung cancer
patients and this may impact on their quality of life and survival.
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Endocrine abnormalities in advanced cancer patients with anorexia
Rony Dev, Eduardo Bruera, Edigio Del Fabbro (Department of Symptom
Control and Palliative Medicine, University of Texas M D Anderson
Cancer Center, Houston, TX, USA)
Background: We investigated the frequency of endocrine abnormalities in
patients with advanced cancer with poor appetite.
Methods: Retrospective review of 80 consecutive patients with an appetite
score of ≥4 referred to a supportive care clinic. We screened patients for
abnormalities in the following abnormal serum levels: 25(OH) vitamin D<
20 ng/ml, cortisol <4 mcg/dl, vitamin B12 <211 pg/ml, thyroid stimulating
hormone >5.5 μIU/ml and bioavailable testosterone <50 ng/mL.
Results: Male gender 51 (64%), white 53 (66%) with a median age of 60
(range, 27–91). Gastrointestinal 24 (30%) and lung 16 (20%) were
predominant. Average appetite score was 6.26 (SD 2.0). Sixteen patients
(20%)hadabodymassindex≤20.While67/80patients(84%)hadahistoryof
>5% weight loss, of which 26/37 patients (70.3%) were hypogonadic and 29/
63 patients (46%) were vitamin D deficient. No patients with anorexia had
J Cachexia Sarcopenia Muscle (2011) 2:209–261 251deficiency of vitamin B12, only 1/73 patients (1.4%), not on steroids, had low
cortisol, while 9/73 patients (12.3%) had abnormal thyroid studies.
Discussion: The majority of advanced cancer patients with an appetite
score ≥4 had a significant history of weight loss. Vitamin D deficiency and
hypogonadism, in males, were highly prevalent among advanced cancer
patients with chachexia, while thyroid dysfunction, adrenal insufficiency,
and low vitamin B12 were uncommon.
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Nutritional impact symptoms and management in patients with cancer
cachexia
Egidio Del Fabbro, David Hui, Ronz Dev, Shalini Dalal, Zohra
Noorhuddin, Eduardo Bruera (Palliative Care, MD Anderson Cancer
Center, Houston, TX, USA)
Background: Nutrition impact symptoms (NIS) such as nausea may contribute
to weight loss in patients with cancer by decreasing nutrient intake. We determined
the frequency and type of contributors to poor appetite and weight loss, and the
effect of their management on outcomes such as weight and symptoms.
Methods: The study is a review of 150 cancer patients referred to an
outpatient supportive care clinic for involuntary weight loss. All patients
received dietary counseling and exercise recommendations. Assessments
included weight, body mass index (BMI), assessment of nutritional impact
symptoms, and resting energy expenditure by indirect calorimetry.
Results: Median weight loss in the 100 days before referral was 9% (4–
13%) and median BMI at presentation was 20.8. Median number of NIS
was 3 (2–4). NIS were most commonly treated with metoclopramide (early
satiety in 62% of patients and nausea in 44%), laxatives (constipation in
52%), antidepressants (depression in 42%), zinc sulphate (dysgeusia in
28%), speech therapy or endoscopy evaluation (dysphagia in 14%)
artificial saliva (dry mouth in 9%), and opioids (mucositis in 7%). Poor
appetite and weight loss before referral (r=0.18, p=0.036) were associated
with increased NIS (r=0.22, p=0.008). Forty-one percent (24/59) of
patients were hypermetabolic appetite improved (p<0.001) and 31/92
(34%) of patients returning for a second visit gained weight.
Conclusions: Patients had a high frequency of multiple NIS, and hyperme-
tabolism. A combination of inexpensive pharmacological and nonpharmaco-
logical interventions improved appetite significantly, and increased weight in
one third of patients who were able to return for follow-up.
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One of main goals of in vitro research is to develop efficient methods for drug
delivery. Effective delivery of genetic material into cells is crucial for application
in clinical environment for gene therapy or genetic vaccination. The tissue of
choice for gene therapy or DNA vaccination are skeletal muscles, representing
40%ofthebodymassandwhichareknowntoactivelyparticipateintheimmune
response. Here we compared the efficiency of two different methods for transfer
of plasmid DNA: electroporation, where electric pulses are used to permeabilize
cell membrane; and lipofection which uses liposomes as carriers. Electroporation
ispromisingforclinicalapplicationwhilelipofectionisauspiciousfordeveloping
strategies for gene therapy. Plasmid pEGFP-N1 coding for green fluorescent
protein was transfected into primary human myoblasts with lipofection
(Lipofectamine 2000) or by applying high-voltage pulses. Our results
demonstrate that efficient transfection of human myoblasts with DNA in vitro
can be obtained both methods. The highest transfection ratios were similar
(40.9% with lipofection versus 41.4% with electroporation). However, the main
difference was in cytotoxicity of both methods. Less than 40% of cells were
viable after the electroporation under conditions that give comparable
transfection results with lipofection. On the other hand, by lipofection, almost
80% of myoblast were viable after the treatment. Due to lower cytotoxicity, more
suitable method for transfection studies on myoblasts in vitro is lipofection.
Electroporation has advantage over lipofection in in vivo environment due to
simplicity of protocol and lack of need for using additional chemicals.
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Resistance exercise modulates testoterone levels in tumour bearing
rats
Felipe Fedrizzi Donatto, Rodrigo Xavier, Fernando Rosa, Marilia
Seelaender (Cancer Metabolism Research Group, Institute of Biomedical
Sciences, University of São Paulo, São Paulo, Brazil)
Introduction: Hypogonadism is a frequent symptom of cancer patients
and the decrease in testosterone may aggravate muscle mass loss. Exercise
is a simple, low-risk intervention and is associated with positive effects on
lean mass. Therefore, it could play a relevant role in counteracting the
effects of cancer cachexia on muscle wasting.
Aim: We carried out a study to assess the effects of a resistance exercise
program on Walker 256 tumour-bearing rats testosterone profile.
Methods: Forty rats were randomly assigned to one of the three experimental
groups: control (C), tumour-bearing (TB), resistance training (RT) and tumour-
bearing RT (RTTB). During the 8 weeks of resistance training, climbing
sessionswereperformedonce every3 days.Trainingsessions consisted of three
ladder climbs with 75%, 90%, and 100% of their maximal carrying capacity,
determined in the previous session. At the sixth week of resistance training,
tumour cellswere inoculatedintumourgroups subcutaneouslyin the right flank
(2×107 Walker 256 carcinosarcoma cells). Plasma testosterone was determined
with a commercial radio assay kit and expressed in nanogram per milliliter.
Results: Testosterone levels were higher 55% (p<0,042) in RTTB group
when compared with CT group and 63% (p<0,03) compared with TB group.
Table 1. Hormone and muscle protein profile
Parameters Control TB RT RTTTB
Testosterone (ng/ml) 254±41.3 221±23.1 734±88.2
a,b 577±131
a,b
Gastrocnemius
Protein (ug/ul)
4.7±0.1 4.5±0.08 5.9±0.03b 5.1±0.3
a=compared with control
b=compared with TB
Conclusions: Theresistanceexercise protocolshoweda markedeffecteffects
on testosteroneprofileinthe plasma oftumourbearing rats, preserving muscle
protein.
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252 J Cachexia Sarcopenia Muscle (2011) 2:209–261Background and aims: Tumour growth is associated with weight loss
resulting from both adipose and muscle wasting.
Methods: Administrationof L-carnitine (1 g/kg body weight) was given to rats
bearing the AH-130 Yoshida ascites hepatoma, a higly cachectic rat tumour.
Results: L-Carnitine treatment resulted in a significant improvement of food
intake and in muscle weights (gastrocnemius, extensor digitorum longus
(EDL) and soleus). These benefitial effects are directly related with improved
physical performance (total physical activity, mean movement velocity and
total travelled distance). Administration of L-carnitine decreases proteasome
activity and expression of genes related with this activity, such as ubiquitin,
C8 proteasome subunit and MuRF-1. Interestingly, L-carnitine treatment also
decreases caspase-3 mRNA content therefore suggesting a modulation of
apoptosis. Although some of the effects of L-carnitine on muscle tissue could
be indirect, addition of a 50 μMo fL-carnitine to isolated EDL muscles
results in a significant decrease in the proteolytic rate.
Conclusions: The reportedresults clearly demonstrate forthefirsttime that L-
carnitine supplementation increases food intake and can prevent muscle
wasting in animals with cancer cachexia. L-carnitine is a natural compound
free from toxicity up to 7 g/day in human subjects and since it is readily
excretated, supplement ingestion is well tolerated. Further clinical trials are
needed to clarify its efficacy in the cancer patient; however, the results
presented here suggest that L-carnitine may be an essential component for a
multi-targeted approach of nutritional intervention in cancer cachexia.
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Curcumin supplementation attenuates lean body mass loss during
the progression of cancer cachexia in the Lewis lung carcinoma-tumor-
bearing mouse
Kandy T. Velazquez
1, Reilly T. Enos
1, Aditi Narsale
1, Johannes Aartun
1,
Melissa Puppa
1, Angela Murphy
2, Mark Davis
1, James Carson
1 (
1Depart-
ment of Exercise Science, University of South Carolina/Columbia, SC,
USA;
2Department of Pathology, Microbiology and Immunology, School
of Medicine, University of South Carolina/Columbia, SC, USA)
Background and aims: The interest in understanding and treating
cachexia has intensified over the past decade as a result of the high
mortality index associated with cancer and other chronic diseases that also
involve muscle wasting. Thus, interventions that can improve or maintain
muscle mass should provide favorable outcomes for the health of cachectic
patients. Nutraceutical compounds, including the natural phenol curcumin,
have been the center of significant research recently due to their anti-
inflammatory, antioxidant, and anticarcinogenic properties. The purpose of
this study was to determine if curcumin supplementation could improve
body composition and physical function in the Lewis lung carcinoma
(LLC) mouse model of cancer cachexia.
Methods: C57BL6 mice injected with LLC cells were supplemented daily
with 10 mg of curcumin (C) (n=7) or vehicle (V) (n=11) over a 3-week
period and C57BL6-V (n=8) mice served as controls. Body weight, body
composition, strength, and neuromuscular performance were assessed over
the course of the experiment.
Results:L L C - Vm i c el o s t7 %( p=0.010) of their body weight, and DEXA
analysis revealed a 6% (p=0.046) loss of lean mass, while there was no
significant change in fat mass. Curcumin supplementation significantly attenuated
body weight loss (p=0.025) without affecting tumor growth. Curcumin
supplementation significantly increased lean mass compared to LLC-V mice (p
=0.050). Related to physical function, voluntary grip strength in LLC-V mice
was significantly decreased during the study, and curcumin supplementation did
not alter this change. RotoRod performance, a measure of neuromuscular
function, was not affected by cachexia or curcumin supplementation.
Conclusion: In the LLC model of cachexia, curcumin supplementation can
attenuate body weight loss and maintain lean body mass independent of
strength loss during the progression from pre-cachexia to cachexia.
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Elevated fatty acid content in muscle is reversed by fish oil
in an animal model of colorectal cancer receiving irinotecan/5FU
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Colorectal cancer is associated with significant weight loss characterized by
depletion of skeletal muscle and altered lipid metabolism. Using computed
tomography (CT) images, our research revealed a high degree of fat in the
muscles of patients with advanced cancer. Fat deposition into skeletal muscle
is associated with poor function and strength. Irinotecan (CPT-11) combined
with 5-fluorouracil (5-FU) are the most commonly used chemotherapy drugs
to treat colorectal cancer; however, these drugs are highly toxic and lead to
altered lipid metabolism. Clinical studies suggest that fish oil (FO)
supplementation increases muscle mass, improves chemotherapy efficacy,
however, the effect of neither chemotherapy nor fish oil on intramuscular
adiposetissueisnotknown.Ourstudyaimedtoassesstheamountandtypesof
lipids in skeletal muscle in the Ward colon tumor rat model undergoing CPT-
11 and 5-FU with or without fish oil. Throughout the study, female fisher 344
rats were fedeithera control diet (CON; n=8) or fish oil diet (FO; n=9).Rats
either received CPT-11/5-FU treatment (CMO; n= 8 )o rn ot r e a t m e n tw a s
provided (CON). Rats without tumor served as a reference group (REF; n=8).
A Folch method was used to extract lipid from muscle tissue. Phospholipid
(PL) and triglyceride (TG) were separated by thin layer chromatography. Fatty
acids (FAs) were determined by gas liquid chromatography. Rats receive
chemotherapy exhibited more fat in muscle tissue (P=0.02); however, FO was
not different from REF group. CON and CMO had low omega-3 FA in
muscle tissue (P=0.01) and more saturated FA (P=0.05) than REF. Rats fed
FO had lower saturated FA (P=0.06) and more omega-3 FA than CMO. Our
study suggests that omega-3 fatty acids might be useful to decrease fat in
muscle which would affect muscle function and quality of life in cancer
patients.
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Oxypurinol and eicosapentaenoic acid in the treatment of muscle
wasting in cancer cachexia
Vanessa C. Vaughan, Edward Hinch, Melanie J. Sullivan-Gunn, Paul A.
Lewandowski (Molecular Nutrition Unit, School of Medicine, Deakin
University, Waurn Ponds 3216, Australia)
Background: Cancer cachexia (CC) is a profound wasting condition,
driven by systemic inflammation and oxidative stress. This study
investigated oxypurinol (xanthine oxidase (XO) inhibitor) in combination
with eicosapentaenoic acid (EPA; anti-inflammatory) as a treatment to
attenuate muscle wasting in a mouse model of CC.
Methods: Mice with CC were randomised into four treatment groups (EPA
(0.4 g/kg/day), oxypurinol (1 mmol/L ad libitum), combination, or
control), and euthanized after 29 days of treatment. Gene expression and
enzyme activity analyses were completed on gastrocnemius muscle.
Results: The oxypurinol and combination groups displayed weight loss
significant from control for an extended duration (9 and 10 days) compared to
EPA (19 days), while oxypurinol indicated a trend toward increased rate-of-
decline in condition. Expression of CuZnSOD and MnSOD decreased in the
combination compared to oxypurinol, MnSOD increased with oxypurinol
compared to control, and combination decreased EcSOD compared to all
groups. Catalase expression increased with oxypurinol compared to combina-
tion and control, and in EPA compared to control. EPA and oxypurinol showed
increased expression of GPx-1 compared to combination and control.
Oxypurinol increased XDH expression compared to all groups. EPA and
J Cachexia Sarcopenia Muscle (2011) 2:209–261 253oxypurinol increased expression of UbB, MURF-1 and MAFbx compared to
combination and control. SOD activity increased in oxypurinol compared to all
groups. Activity of GPx was reduced by EPA group compared to control and
combination. Catalase activity was reduced by combination treatment
compared to oxypurinol and control. There was no significant difference in
XO activity between groups.
Conclusion: Whilst several antioxidant genes were upregulated by oxy-
purinol,sotoowereXDHandproteolyticsubunits,andthoughfurtherstudyis
required,mayshedlightonthepathwaysthatleadtotheexacerbateddeclinein
condition observed. In combination with EPA, there was little significant
improvement from control, indicating oxypurinol is unlikely to be a viable
candidate for multimodal therapy in CC.
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Wai W. Cheung
1, Michal Ayalon-Soffer
2, Robert H Mak
1 (
1Division of
Pediatric Nephrology, University of California San Diego,
2 BioLine
Innovations, Jerusalem, Israel)
Background and aim: We have previously shown that elevated circulating
levels of cytokines such as leptin may be an important cause of chronic
kidney disease (CKD)-associated cachexia (Cheung et al., JCI 2005). BL-
5040 is a recently developed pegylatedleptin antagonist, which binds leptin
receptor with high affinity but does not activate it. BL-5040 has been
previously shown to increase appetite and weight gain in normal mice
(Elinav et al., Endocrinology 2009).We tested whether BL-5040 would be
effective in attenuating CKD-associated cachexia.
Methods: CKD was induced by 5/6 nephrectomy in 8-week-old c57BL/6 J
mice. CKD and Sham (S) mice received either BL-5040 (7 mg/kg, i.p.) or
vehicle (V) once daily for 28 days. All mice were fed ad libitum during
this period. Metabolic rate was measured by Oxymax, body composition
by Echo-MRI and muscle function by rotarodactivity and grip strength.
Results: BL-5040 reverses anorexia in CKD. The food intake of the CKD/
BL-5040 mice was significantly increased compared with CKD/V mice
(3.7±0.0 vs. 3.1±0.1 g/mouse/day; p<0.001). CKD/BL-5040 micegained
more weight than CKD/V mice (15.1±0.4% vs. 3.0±0.3%; p<0.001).
CKD/BL-5040 mice gained fat mass (gain of 0.4±0.1 g) and lean mass
(gain of 0.2±0.1 g) while CKD/V mice continued to lose fat mass (loss of
0.2±0.0 g) and lean mass (loss of 1.3±0.1 g; p<0.001). Basal metabolic
rate was increased in CKD/V mice (3,845±62 mg/kg/h) compared with S/
V mice (3,369±43 mg/ml/h; p<0.001) and was normalized in CKD/BL-
5040 mice (3,246±79 mg/ml/h). Rotarod activity and grip strength was
decreased in CKD/V mice (130.3±5.8 s, 1149.6±49.2/100 g; p<0.001)
compared with S/V mice (187.0±12.0 s, 1643.3±28.2/100 g) and was
normalized in CKD/BL-5040 mice (175.8±3.8 s, 1,568.2±46.0/100 g).
Conclusions: BL-5040, a peripheral leptin antagonist, reverses anorexia,
ameliorateslean body mass losses and normalizes muscle function in a
mouse model of CKD-associated cachexia.
7-08
Peptidic agonists of ghrelin with a prolonged orexigenic effect
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Ghrelin originates mainly from the stomach where it increases acid secretion
and motility. In the adenopituitary, ghrelin acts as a growth hormone
secretagogue, and in the hypothalamus as an orexigenic hormone. Ghrelin is
theonlyfood intake stimulatingpeptide bornin the peripheryandacting inthe
brain. Physiological effects of ghrelin are mediated through its growth
hormone secretagogue receptor GHS-R1a. Ghrelin, a single peptide of 28
amino acids, has its serin in position 3 (Ser
3) acylated with octanoic acid
which is crucial for ghrelin activity but prone to hydrolysis by esterases. In
this study, ghrelin analogues with octanoic acid coupled to diaminopropionic
acid (Dpr) replacing Ser
3 were synthesized in order to make ghrelin resistant
to esterases. Beyond using Dpr(N-octanoyl) in position 3, ghrelin analogs
were stabilized replacing phenylalanine in position 4 (Phe
4) with noncoded
bulky hydrophobic Phe derivatives and/or using sarcosine instead of glycin
in position 1. The stabilized derivatives had a similar binding affinity to cell
membranes with transfected GHS-R1a as ghrelin, but showed a longer-
lasting orexigenic effect in lean mice and a higher stability in the blood
compared to ghrelin. Replacement of the ester bond for the amide ones plus
using non-coded amino acid(s) instead of natural ones resulted in effective
ghrelin agonists with a prolonged stability that could be efficient for a long-
term application at cachexia accompanying cancer or chronic inflammatory
diseases where ghrelin anti-inflammatory effect could also be beneficial.
This study was supported by grant of Grant Agency of the Czech Republic 303/
09/0744 and Z40550506 of the Academy of Sciences of the Czech Republic.
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Dln101 a naturally occuring ghrelin splice variant for the treatment
of cachexia
Liat Mintz (DiaLean, Ltd., East Brunswick, USA)
Unexplained weight loss is a common and vexing problem in many chronic
diseases and can lead to the development of cachexia. There are currently no
approved medications for cachexia or frailty. Three therapies are approved
for treatment of AIDS-related cachexia (megestrol acetate, somatropin, and
dronabinol), but adverse effects and questionable efficacy render them poor
choices in many cases. Ghrelin is a 28-amino acid hormone secreted by the
stomach that has been extensively studied since its discovery in 1999. It is
the natural ligand of the growth hormone (GH)–secretagogue receptor in the
pituitary gland, and it is also the only known circulating orexigen (appetite
stimulant) to date. In humans, endogenous ghrelin secretion rises before
eating and falls afterward, and exogenous ghrelin stimulates hunger and
food intake, inducing weight gain. Ghrelin has been administered
successfully to over 400 men and women, to date, including patients with
cancer, pulmonary disease,diabetes,renalfailure,andheartfailure.Dln101is
a proprietary 24 amino acid, acylated peptide that can be easily manufactured
at low cost. Extensive preclinical studies have shown that Dln101 acts
similarly to ghrelin in increasing food intake, promoting weight gain, and
increasing GH release. These extensive preclinical studies also suggest
beneficial effects on lean body mass, cholesterol, and glucose that are specific
to Dln101. These positive unique metabolic effects of Dln101 make it a better
candidate for the chronic treatment in diabetes, renal failure, heart failure,
cancer, and COPD-related cachexia. Dln101 has also successfully completed
the requisite preclinical toxicology, pharmacokinetic, and pharmocodynamic
testing and has received approval to start phase 1 clinical trials.
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Leveraging the myostatin signaling pathway with small molecules:
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Background and aims: Inhibition of myostatin signaling has the potential to
beaneffectivetreatmentformusclewastingandosteoporosis.Knockoutofthe
activin receptors as well as treatment with the soluble extracellular domain
protein of ActR2B show muscled phenotypes in the mouse. While
biologicals have the potential to treat muscle wasting disorders, small
molecules targeting the myostatin signaling pathway may also have potential.
Methods: Protein and cell-based screening assisted by structure-based
drug design were used to identify small molecule kinase inhibitors of the
activin receptors ActR2A and B. Compounds were profiled in in vitro
assays to determine their potency and selectivity and to elucidate their true
mode of action. Molecules with suitable pharmacokinetic profiles were
investigated in vivo for muscling effects.
Results: Two highly selective and potent ActR2B kinase inhibitor series of
molecules were developed. Dual ActR2B and 2A kinase inhibitors were also
discovered. Despite their promising profiles, both subtype selective and dual
ActR2 kinase inhibitors showed only modest muscling effects.
Conclusions: The failure of potent and selective activin receptor kinase inhibitor
tools to directly influence myostatin signaling demonstrates a significant gap in
the accepted dogma surrounding TGFbeta family member signaling.
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Acute anabolic effects of β-hydroxy-β-methylbutyrate (HMB) in
human skeletal muscle
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Background: The leucine metabolite β-hydroxy-β-methylbutyrate (HMB)
has shown promise as an anabolic (e.g. enhancing resistance exercise
training-induced hypertrophy) and anti-catabolic (e.g. reducing immobili-
zation, AIDS and cancer-associated atrophy) supplement in humans and
animal models. However, there have been no investigations into its
mechanism(s) of action: viz., the acute anabolic effects of HMB on skeletal
muscles of otherwise healthy animals/humans.
Methods: We studied eight healthy young men (18–35 years old) over a 5-
h period during which we gathered baseline ‘pre-HMB’ measurements for
2.5 h before subjects’ consumed a single oral HMB bolus (∼3 g as free-
acid form), such that the subsequent 2.5 h represented the ‘post-HMB’
measurement period. Muscle protein synthesis (MPS) was measured in
biopsies of the vastus lateralis by incorporation of 1,2[13 C2]-leucine into
myofibrillar proteins, plasma HMB by GC-MS, plasma insulin by ELISA,
leg [femoral] blood flow (LBF) by Doppler ultrasound and intramuscular
signalling proteins regulating MPS by immunoblotting.
Results: Oral HMB was rapidly absorbed with increases in plasma HMB
peaking 30 min post-ingestion (basal, 5±1 μmol l
−1 vs. 30 min: 408±
27 μmol l
−1; P<0.001) and remaining significantly elevated throughout the
study (275±12 μmol l
−1 2.5 h post HMB; P<0.001 from basal). HMB
robustly stimulated MPS with baseline fractional synthetic rates (FSR) of
0.039±0.004%h
−1 compared to 0.073±0.01%h
−1 (P<0.01) in the period
following HMB ingestion. HMB also increased LBF (baseline: 0.55±0.03
vs. post-HMB: 0.73±0.05 lmin
−1; P<0.01). Temporal resolution of
intramuscular signalling (sampling 30–120 min post-HMB) revealed that
HMB likely exerts its anabolic effects via mammalian target of rapamycin
complex 1 (mTORc1). All these changes occurred in the absence of
alterations in plasma insulin (mean for study: 5.87±0.45 mU l
−1; P>0.05).
Conclusions: HMB increases MPS and LBF even in the absence of
exogenous nutrients or increases in plasma insulin. These findings
highlight novel mechanisms of HMB action which likely underlie its
efficacy/promise for countering human muscle wasting.
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Metabolic modulators might have a key role in enhancing muscle
differentiation and contrasting atrophy: possible application
in the treatment of cachexia and sarcopenia
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Background: Metabolic modulators have been found to improve cardiac
energy metabolism. Their beneficial effect in patients with ischaemic cardiomy-
opathy has been well established. Trimetazidine (TMZ), for example, inhibits
fatty acid oxidation thereby increasing glucose oxidation, which results in a
cytoprotective activity of trimetazidine. It has been recently reported that TMZ
might also improve exercise capability in patients suffering from angina, which
suggests that TMZ improves muscle performances. We therefore decided to test
the effect of trimetazidine on myotube function and morphology and to evaluate
its potential protective effect against stressors causing myotube atrophy.
Methods: C2C12 myotubes were treated with TNF and the protective role
of TMZ was evaluated. In particular, we analyzed myotube morphology by
means of actin and myosin immunofluorescent staining and by transmis-
sion electron microscopy (TEM). We also studied the expression of
atrophy/hypertrophy/autophagy proteins. Moreover, we wanted to deter-
mine the effect of TMZ on myogenic differentiation; for this purpose
C2C12 cells were induced to differentiate in presence of TMZ and
expression of myogenic markers was evaluated.
Results: We observed, in presence of TMZ, a reduction of TNF-induced
atrophy as evidenced by MuRF-1 and Atrogin-1 expression decrease. We also
observed that TMZ was capable of inducing cytoprotection tophagy. Static
cytometry and TEM analyses also suggested (1) thatcytoskeletalintegrity and
function was preserved by TMZ administration and (2) that TMZ was capable
of bolstering protein synthesis and metabolic pathways exerting a powerful
“trophic” activity on myotubes. Finally, very strikingly we also found that
TMZ increases myogenic differentiation and myoblast fusion.
Conclusions: Our experiments suggest that TMZ protects from muscle
atrophy, enhances myogenic differentiation and bolsters cell response to
stress. We are also testing these effects on mouse models of cachexia and
sarcopenia. Our results clearly suggest a reappraisal of TMZ in the
treatment of muscle wasting disorders.
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Muscle mass loss in ageing rats is restricted to hindlimb
and can be restored by formoterol
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Ageing is a word wide concern and it is estimated that 25% of the
population in 2025 will be constituted of elderly (60 years old or more).
The loss of muscle mass and function in the senior, namely sarcopenia,
is one of the main causes of the disability, loss of autonomy and
increase risk of falls and frailty. The etiology is multi-factorial and
includes intrinsic factors such as altered hormonal levels, high level of
inflammatory cytokines, neural remodeling (alteration of NMJ number
J Cachexia Sarcopenia Muscle (2011) 2:209–261 255and function), deficiencies of satellite cells for muscle regeneration, or
includes extrinsic factors such as poor nutritional status or physical
activity. Actually, there is no clinical treatment for this symptom.
Formoterol is a long-acting β2-adrenoceptor agonist used extensively in
clinic to supplement prophylactic corticosteroid therapy for the treatment
of asthma and also known to have muscle anabolic effects when
administered at millimolar doses. The objective of the study was to
determine whether formoterol could reverse the age-related changes in
skeletal muscle in rats assessed longitudinally by MRI. Compound-treated
aged Wistar rats (21 months) received a continuous administration by mini-
osmotic pump of formoterol (0.03 mg/kg/day) for 8 weeks and were
compared to saline-treated rats. From days 1 to 56, saline-treated 9 and
21 months rats exhibited little variation in body mass. Interestingly, muscle
mass loss in saline-treated 21-month rats was restricted to hindlimb
muscles (−20%) whereas forelimb muscles were not affected (e.g.
pectoralis). Muscle mass of Formoterol-treated 21-month rats increases
graduallyduringtheexperimentationandwascomparableorevengreaterafter
8 weeks of treatment to saline-9 Mo treated rats. These findings demonstrate a
putative therapeutic potential of formoterol for sarcopenia but further studies
are needed in order to determine the optimum design to prevent age-related
loss of muscle mass and function.
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Background and aims: Tumour growth in cancer patients is associated
with weight loss resulting from both adipose and muscle wasting; this
constitutes the cachexia syndrome. Moreover, the contribution of chemo-
therapeutic agents aimed to reduce tumour growth in the pathogenesis of
cachexia remains uncharacterized.
Methods: The study presented involved rats bearing the Yoshida AH-130
ascitestumourmodel—whichinduces a highdegreeof cachexia—treatedwith
the beta-2 agonist Formoterol and with the chemotherapeutic agent
sorafenib—a multi-kinase inhibitor which targets receptor tyrosine and serine/
threonine kinases involved in tumor progression and tumor angiogenesis.
Results: The results obtained clearly show that administration of the
beta-2 agonist formoterol, significantly contributes to improve the
anti-tumoural treatment by decreasing its adverse effects on muscle
wasting. The beta-2 agonist contributed to not only improving muscle
size but also in increasing physical performance.
Conclusions: Further clinical trials are needed to clarify its efficacy in the
cancer patient; however, the results presented here suggest that formoterol
should be an essential component for a multi-targeted approach of
intervention in cancer cachexia.
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Megestrol acetate treatment influences tissue amino acid uptake
and incorporation during cancer cachexia
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Background and aims: Tumour growth is associated with weight loss
resulting from both adipose and muscle wasting.
Methods: The aim of the present investigation was to study the effects of
megestrol acetate (MA) (100 mg/kg) on the rate of leucine incorporation
(
14C-leucine) into muscle tissue and on the uptake of α-amino-
3H-
isobutyrate (AIB, a non-metabolizable analogue of alanine) in both skeletal
muscle and liver tissue in cachectic tumour-bearing rats (Yoshida AH-130
ascites hepatoma).
Results: Administration of MA to tumour-bearing rats resulted in an
important reversal of the muscle wasting process, as reflected by
individual muscle weights. Treatment with the progestagen resulted in
a significant increase in the uptake of AIB in GSN (15%), tibialis
(20%) and soleus muscles (25%), together with an increased leucine
incorporation into GSN (43%), tibialis (50%) and EDL (23%) muscle
protein. MA treatment significantly decreased AIB uptake by the liver
(25%).
Conclusions: Altogether, the data clearly show that MA treatment is
able to influence tissue interorganic amino acid uptake by increasing
these parameters in muscle and decreasing them in the liver,
normalizing the pattern of amino acid uptake found in non-tumour
bearing rats. The results presented here clearly support those previously
described by our research group indicating the mechanisms involved in
the anabolic action of the synthetic progestagen drug upon muscle tissue
during cachexia.
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Low dose formoterol combined with megestrol: a potential therapeutic
use in cancer cachexia
Silvia Busquets
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Background and aims: Options for treatment of cancer cachexia are very
limited.Megestrolacetate,thoughunapprovedinmostcountries,issometimes
used to stimulate appetite but has no significant effect on muscle mass.
Formoterol fumarate has been found to limit muscle degeneration in rodent
cancer models, but also has the potential detrimental effects of reducing fat
mass and increasing heart weight (doses of 0.3 mg/kg/day and above) and
decreasing food consumption (doses of 1 mg/kg/day and above).The aim of
thisstudywastoexaminethe effectsoflowerdoses offormoterol alone and in
combination with megestrol using an experimental cancer cachexia model.
Methods: Individual muscle weights, adipose weights and organ weights,
along with body and carcass weights and food intake were measured in rats
bearing the Yoshida AH-130 ascites hepatoma, treated with low doses of
formoterol and/or megestrol over a 7 day period.
Results: Formoterol at 1 and 10 μg/kg/day sc produced significant
increases in gastrocnemius muscle weights compared with control animals.
These doses of formoterol had no significant effects on heart weight or
food consumption. Formoterol at 10 μg/kg combined with megestrol at
100 mg/kg (intragastric administration) produced greater increases in
skeletal muscle, carcass and body weights and food intake than either drug
given alone. The combination had no significant effect on the carcass
weight/heart weight ratio, whereas megestrol alone decreased this ratio,
reflecting a relative increase in heart size.
Conclusions: Formoterol given at low, therapeutically relevant doses
selectively increases skeletal muscle weight without increasing heart size
or reducing food consumption. Low dose formoterol and megestrol
when administered in combination have synergistic effects on some key
measures of cancer cachexia. These data support the clinical develop-
ment of formoterol combined with megestrol in the treatment of cancer
cachexia.
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Thalidomide for managing cancer cachexia: a systematic review
Joanne Reid
1, Moyra Mills
1, Michael Donnelly
2, Marie Cantwell
2, Chris
Cardwell
2, Liam Murray
2 (
1Nursing and Midwifery Research Unit, School
of Nursing, Queen’s University Belfast, Belfast, UK;
2Cancer Epidemiol-
ogy and Health Services Research Group, Centre for Public Health, School
of Medicine, Dentistry and Biomedical Sciences, Queen’s University
Belfast, Belfast, UK)
Background: Cancer cachexia is an important and common clinical
problem. Although reviews have examined different treatment modalities
for cancer cachexia, evidence has not identified an optimum treatment.
Preliminary studies of thalidomide for cancer cachexia have demonstrated
encouraging results. However the safety and efficacy of thalidomide for
cancer cachexia has not been systematically reviewed.
Aim: This study aims to evaluate the effectiveness of thalidomide for
cancer cachexia and identify and assess any adverse effects.
Method: Detailed search strategies have been developed for electronic
databases including MEDLINE, EMBASE, CINAHL, Web of Science and
clinical trials registers. Hand searching will also identify additional grey
literature. The results from the searches will be downloaded to a reference
management database (Reference Manager) and duplicates will be
removed. The remaining citations will be read by two review authors and
checked for eligibility. Studies that are deemed ineligible for inclusion will
have clear reasons for exclusion documented. Non-randomised studies
including quasi-experimental, cohort and case control studies will be
considered systematically after all eligible RCTs have been identified.
Independent data extraction will be performed and all studies which meet
the review inclusion criteria will be independently assessed for quality by
at least two review authors. A meta-analysis will be conducted on
comparative trials of adequate quality and a narrative analysis will be
conducted on studies that are not amenable to quantitative synthesis.
Conclusion: This systematic review will provide clinicians and researchers
with best available evidence about the use of thalidomide for the
management of cancer cachexia.
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Curcuma longa extract is effective in reducing blood levels of reactive
oxygen species (ROS) and increasing antioxidant enzyme glutathione
peroxidase (GPx) in patients with cancer-related cachexia and oxidative
stress
Roberto Serpe
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Background and aims: Curcumin (diferuloylmethane) is the biologi-
cally active compound of Turmeric (Curcuma longa) and has been used
for a long time in traditional Asian medicine to treat diseases ranging
from heartburn to arthritis: it is thought to have antioxidant and
antinflammatory properties. The aim of this study was to assess the
antioxidant capacities of a curcumin extract in advanced cancer patients
with cachexia.
Methods: In September 2011, 10 patients (M 5/F5; age range, 55–85 years)
with cancer at different sites were enrolled, all stage IV and cachectic.
Twenty-one age/sex-matched healthy controls were studied. All enrolled
patients had oxidative stress (high levels of ROS, low levels of blood
antioxidant enzymes GPx and SOD and low levels of total blood
antioxidant stasus, TAS, compared to controls). Patients received 6 tablets
(1.2 g)/day curcumin extract (Meriva, Indena, Milan, Italy). Treatment
duration was 10 days.
Results: A significant reduction of ROS levels (510±120 vs. 390±186
Fort U) and a significant improvement of circulating levels of GPx
(5,630±1,189 vs. 6,590±2,390 U/l) as well as a significant improve-
ment of TAS (0.61±0.23 vs. 0.69±0.4 mmol Trolox eq.) was
observed after treatment. No patient was withdrawn from the study
and the treatment was safe and well tolerated.
Conclusions: Curcumin extract at a dose of 1.2 g/day added to the
normal diet was shown to be able to significantly counteract some of
the key parameters of oxidative stress, such as ROS GPx and TAS,
found in advanced cancer patients with cachexia. Curcumin antioxi-
dant activity could be useful in a multi-targeted combined pharmaco-
nutritional approach to treat cancer-cachexia. Further phase III clinical
studies are warranted.
Table 1. Patients’ clinical characteristics
No.
Patients enrolled 10
Female 5
Male 5
Mean age (mean±SD) 65±21
Stage of disease
IV 10
Tumor site
Head and neck 3
Lung 2
Ovary 1
Pancreas 1
Breast 1
Colon 1
Stomach 1
ECOG PS
0 0
1 2
2 5
3 3
Table 2. Oxidative stress parameters in healthy controls and cancer patients before and after treatment
*p<0.05 in comparison to healthy controls. ROS reactive oxygen species, GPx glutathione peroxidase, SOD superoxide dismutase, TAS total antioxidant status
Parameters Healthy controls Cancer patients
Baseline After treatment p Value after treatment vs. baseline
ROS (U Fort) 332±118 510±120* 390±186 <0.001
GPx (U/l) 8,622±2,314 5,630±1,189* 6,590±2,390 <0.05
SOD (U/ml) 163.78±43.59 101±36* 112±62 n.s.
TAS (mmol Trolox eq.) 0.92±0.28 0.61±0.23* 0.79±0.4 <0.05
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Immunotherapy for cancer with polysaccharide of Maitake mushroom
Hiroaki Nanba (Kobe Pharmaceutical University, Immunology Section,
Kobe, Japan)
It is well-known that medical mushrooms contain polysaccharide which
demonstrated anti-tumor activity. The specific beta-glucan, designates as
the MD-Fraction, extracted from Maitake edible mushroom (Grifola
frondosa) was indicated to have strong anti-cancer effects by activating
antigen presenting cells (APCs), such as macrophage and dendritic cells,
and also T cell in C3H/Hev mice in which a Th-1 dominant response was
established. The study using BALB/C mice in which a Th-2 response was
genetically dominant, MD-Fraction reduced the expression of Th-2
cytokine interleukin (IL)-4 but markedly increased the expression of the
Th-1 cytokine interferon (IFN)-gamma in CD4+T cells and also increased
IL-12p70 production as well as IFN-gamma production by APCs,
suggesting that MD-Fraction promotes the differentiation into Th-1 cells
of CD4+T cell through enhancement of IL-12 by APCs. Also this
increasing IL-12 level could activate the cytotoxicity of Natural Killer
(NK) cells. Amounts of cachexia due to cancer-bearing were also
decreased. All these facts indicated by MD-Fraction, could challenge to
kill the cancer cells, respectively. The clinical trial with MD-Fraction for
human suffered with breast, lung, colon and pancreas cancer were done
in Japan and USA. Cachexia due to cancer was decreased and also the
each cancer was regressed to 40–60% when MD-Fraction was used as
complementally drug with chemotherapy treatment. Especially, Memo-
rial Sloan–Kettering Cancer Center (MSKCC, New York) as done the
Phase I and II study supported by the USA government for Beat Cancer
and result was already published on Jour. Cancer Res. Clin. Oncol.,
2009, 135 (9), 1215–1221. Daily dosage of 2 mg/kg MD-Fraction was
associated with the greatest increase of CD3+25+ or CD4+CD25+T
cell in the peripheral blood, and 6 mg/kg administration was indicated
with the most significant increase in IL-1 production by NKT cells.
MSKCC institute concluded that oral administration of MD-Fraction
was associated with measurable change in peripheral blood. The dose
associated with the most significant change varies by immunological
parameter. The 6 mg/kg MD-Fraction is selected as the dose in the
future studies with clinical endpoint.
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Glutamine-enriched immunonutrition in treatment of patients
with inflammatory bowel diseases
Sergey Ivanov
1, Igor Khoroshilov
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2 (
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Aims: The study effects of glutamine enriched oral nutritional supplements
on system inflammatory response in patients with acute inflammatory
bowel diseases.
Methods: Twenty patients with severe ulcerative colitis in acute phase
were observed. All patients were treated by corticosteroids and
mesalazine. In addition to drug therapy, four patients were received
glutamine enriched immunonutrition in dose 10 g glutamine (500 kcal
per day) during 2 weeks in addition to usual diet, five patients were
received polymeric formulas for enteral nutrition in the same dose and
duration, and three patients were received only drugs and usual diet.
The level of pro-inflammatory cytokines in the blood was studied
before and after 2 weeks of treatment.
Results: After treatment with glutamine, enriched immunonutrition were
detected significant decrease of TNF-alpha (up to 25%), IL-6 (up to 50%)
and IFN-gamma (up to 20%) in the blood in comparison with patients
received polymeric formulas for enteral nutrition and usual diet.
Conclusions: Glutamine-enriched immunonutrition in addition to drug
therapy may be to reduce the system inflammatory response in patients
with inflammatory bowel diseases.
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Randomised phase III clinical trial of a combined treatment
with carnitine+celecoxib±megestrol acetate for patients
with cancer-related anorexia/cachexia syndrome
Clelia Madeddu
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Background and aims: A phase III, randomized non-inferiority study was
carried out to compare a two-drug combination (including nutraceuticals, i.e.
antioxidants)withcarnitine+celecoxib±megestrol acetate for the treatment of
cancer-related anorexia/cachexia syndrome (CACS): the primary endpoints
were increase of lean body mass (LBM) and improvement of total daily
physical activity. Secondary endpoint was: increase of physical performance
tested by grip strength and 6-min walk test.
Methods: Sixty eligible patients were randomly assigned to: arm 1, L-
carnitine 4 g/day+Celecoxib 300 mg/day or arm 2, L-carnitine 4 g/day+
celecoxib 300 mg/day+megestrol acetate 320 mg/day, all orally. All
patients received as basic treatment polyphenols 300 mg/day, lipoic acid
300 mg/day, carbocysteine 2.7 g/day, vitamin E, A, C. Treatment duration
was 4 months. Planned sample size was 60 patients.
Results: The results did not show a significant difference between treatment
arms in both primary and secondary endpoints. Analysis of changes from
baseline showed that LBM (by dual-energy X-ray absorptiometry and by L3
computedtomography)increasedsignificantlyinbotharmsaswellasphysical
performance assessed by 6-min walk test. Toxicity was quite negligible and
comparable between arms.
Conclusions: The results of the present study showed a non-inferiority of
arm 1 (two drug combination) vs. arm 2 (two drug combination+megestrol
acetate). Therefore, this simple, feasible, effective, safe, low cost with
favourable cost-benefit profile, two-drug approach could be suggested in the
clinical practice to implement CACS treatment.
8-06
Safety and tolerability of LGD-4033, a novel non-steroidal oral
Selective Androgen Receptor Modulator (SARM) in healthy men
Shehzad Basaria
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5 (
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SARMs are tissue-selective androgen receptor (AR) ligands that are being
developed to treat muscle wasting associated with cancer, and acute and
chronic illness, as well as age-related muscle loss. LGD-4033 is a novel non-
steroidal, orally active SARM. In animal models, LGD-4033 demonstrated
anabolicactivityinmuscles,anti-resorptiveandanabolicactivityinbones,and
robust selectivity for muscle versus prostate. In a randomized, double-blind,
placebo-controlled phase I study, the safety and tolerability of LGD-4033 was
evaluated. Healthy men (aged 21–50 years) were randomized to oral daily
doses of 0.1, 0.3, or 1 mg LGD-4033 or placebo over 21 days. Safety,
258 J Cachexia Sarcopenia Muscle (2011) 2:209–261including lab tests was evaluated during the treatment period and a 5-week
observation period. Lean body mass (LBM) was measured using DXA scan,
maximal voluntary leg press strength using 1-RM method, and physical
performance using stair climb time and power. LGD-4033 was safe and well
tolerated at all doses including no effects on liver enzymes, displayed a long
elimination half-life of 24–36 h, and linear pharmacokinetics. There were no
drug-related serious adverse events and no subject was discontinued due to an
adverse event. Adverse events were mild to moderate with no
statistical difference between the LGD-4033 and placebo groups. No
clinically significant changes in PSA, hematocrit or ECG were seen at
any dose. Testosterone, LH, SHBG and HDL levels decreased dose-
dependently, consistent with an androgenic effect. LGD-4033 adminis-
tration was associated with dose-dependent increases in LBM (∼1.2 kg
increase at 1 mg dose). Positive trends towards an increase in maximal
voluntarylegpressstrength andinphysicalperformancemeasures(stair climb
power and speed) were also seen over the short treatment period. Phase II
studies with 12 weeks of treatment are planned to evaluate LGD-4033 in
conditions such as muscle wasting associated with cancer, acute illness, and to
promote rehabilitation.
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GTx-024, a selective androgen receptor modulator (SARM), improves
physical function in non-small cell lung cancer (NSCLC) patients
with muscle wasting
Shontelle Dodson
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Background: Muscle wasting in cancer patients leads to a decline in
physical function. At diagnosis, >50% of lung cancer patients have
substantial wasting, increasing to >80% prior to death. Data shows
that NSCLC patients with muscle wasting are less likely to tolerate
chemotherapy, have worse outcomes and shorter survival. This has
detrimental consequences early in a patient’s malignancy, underscoring
the importance of diagnosing and treating this condition at an early
stage. Literature shows that a 10% improvement in physical function
is a substantial clinically meaningful benefit. We conducted a
randomized, double-blind, placebo controlled, multi-center study to
evaluate the effect of GTx-024 on muscle wasting and physical function in
patients with cancer cachexia.
Methods: Subjects (n=159) were randomized to oral GTx-024 or placebo
for 16 weeks. Subjects were males >45 years and postmenopausal females,
with ≥2% weight loss in 6 months prior to randomization and diagnosed
with NSCLC, colorectal cancer, non-Hodgkin’s lymphoma, chronic
lymphocytic leukemia or breast cancer. The primary endpoint was change
in lean body mass with QOL and physical function as secondary endpoints.
For this analysis, clinical benefit is defined as 10% improvement in
physical function (stair climb).
Results: One hundred three subjects (MITT) had stair climb assessed at
baseline and week 16. GTx-024 subjects demonstrated clinical benefit
compared to placebo (P=0.03). Among NSCLC subjects, 28 were included
in the physical function analysis. Seventy-eight percent treated with GTx-
024 responded compared to 30% treated with placebo (P=0.02). Physical
function was positively correlated with QOL as assessed by the FAACT
questionnaire further substantiating clinical benefit (Spearman correlation
coefficient=0.60, P=0.001).
Conclusions: GTx-024 was well tolerated and showed a statistically
significantandclinicallyrelevantimprovementinphysicalfunctioninNSCLC
subjects. Clinical benefit in stair climb power correlated with a clinically
relevant improvement in quality of life. These data provide evidence
that GTx-024 may play an important role in the management of patients with
NSCLC by improving physical function and quality of life.
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In a phase IIb trial GTx-024 overcomes the negative impact of >8%
weight loss on overall survival in non-small cell lung cancer (NSCLC)
subjects
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Background: Non-small cell lung cancer (NSCLC) represents >80% of
newly diagnosed lung cancer. At diagnosis, >50% of lung cancer
patients have substantial weight loss, increasing to >80% prior to
death. Much of this weight loss is attributed to muscle wasting-
leading to a decline in physical function and other detrimental effects.
Studies show that NSCLC patients with wasting at diagnosis are less
likely to tolerate chemotherapy, have worse outcomes and shorter
survival. The negative impact of wasting underscores the importance
of preventing and treating this condition early. We conducted a phase
IIb, randomized, double-blind, placebo-controlled, multi-center study
to evaluate the effect of GTx-024 on muscle wasting and physical
function in patients with cancer.
Methods: Subjects (n=159) were randomized to oral GTx-024 or placebo
for 16 weeks. Subjects were males >45 years and postmenopausal females,
had experienced ≥2% weight loss in the 6 months prior to randomization,
and NSCLC, colorectal cancer, non-Hodgkin’s lymphoma, chronic
lymphocytic leukemia or breast cancer. The primary endpoint was change
in total lean body mass. We report on overall survival in the entire study
population and NSCLC cohort based on weight loss of > or ≤8% in the
6 months prior to randomization.
Results: In placebo subjects (ITT), overall survival was significantly (P=
0.003, log rank) reduced in subjects with >8% weight loss compared to
subjects with ≤8% weight loss. Among NSCLC subjects (n=61) placebo
subjects with >8% weight loss demonstrated a similar survival disadvan-
tage (P=0.04); 4 month Kaplan–Meier estimates 100% vs. 49%±14.8%. In
GTx-024-treated subjects in both the ITT and NSCLC groups, baseline
weight loss did not negatively affect survival.
Conclusions: Preceding weight loss among NSCLC patients not treated
with GTx-024 is predictive of decreased survival. NSCLC subjects
randomized to placebo with >8% weight loss at baseline were two times
more likely to die than subjects with ≤8% weight loss. In the GTx-024
group baseline weight loss was not predictive of survival. These data
suggest that GTx-024 may overcome the negative prognostic effect of
>8% weight loss. Further research is needed to assess the effect of
GTx-024 on overall survival.
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Phase I/II trial of formoterol fumarate combined with megestrol
acetate in patients with advanced malignancy
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Background and aims:Cancer cachexia is a debilitating condition with a
major impact on quality of life. We tested a novel combination of an
anabolic beta2-agonist and an appetite stimulant in cachectic cancer
patients.
Methods: Eleven patients to date (M/F, 3:8) with an advanced solid
tumour and involuntary weight loss have received oral formoterol fumarate
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8 weeks. We measured quadriceps size (MRI) and strength (dyna-
mometry), lower limb extensor power (Nottingham Power Rig) and
physical activity (accelerometry). Protocol defined response criteria
were ‘non-response’ (any decline); ‘minor response’ (0–2% increase
(size) and 0–5% increase (function)); ‘moderate response’ (>2% and
<4% (size) and >5% and <10% (function)) and ‘major response’ (≥4%
(size) and ≥10% (function)).
Results: Of the 11 patients, six did not reach 8 weeks due to disease
progression. Few adverse events were considered probably or possibly related
to the study drugs, the commonest being mild tremor (seven reports),
peripheral oedema (three), tachycardia (two) and heartburn/indigestion (two).
Of the five patients who completed 8 weeks, 5/5 had a muscle size response
(four major, one moderate) and 4/5 had a muscle function response (three
major,onemoderate).Physicalactivitymarkedlyimproved(averagedailystep
count >1,000) after 8 weeks in two patients. In those reaching 8 weeks (n=5),
mean quadriceps volume increased significantly (R leg 0.94 versus 0.98 l, p=
0.009; L leg 0.91 versus 0.97 l, p=0.04). Increases in mean values for the
other variables over the treatment period did not achieve statistical
significance.
Conclusions: In this frail cohort with advanced cancer and cachexia, MA
and FF in combination are well tolerated and appear to have a beneficial
effect on muscle size. Muscle function and physical activity are improved
in a proportion of individuals. This warrants further investigation in larger,
randomised trials.
Acknowledgements: We thank Claire Lamb and staff of the Clinical
Research Facility, Royal Infirmary Edinburgh
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The feasibility and acceptability of Neuromuscular Electrical
Stimulation (NMES) in patients with advanced cancer
Tamara Y. Windholz, Tara Swanson, Brandy L. Vanderbyl, R. Thomas
Jagoe (McGill Cancer Nutrition Rehabilitation Program Clinic, Jewish
General Hospital, Montreal, Quebec, Canada)
Background: The McGill Cancer Nutrition–Rehabilitation Program at the
Jewish General Hospital (CNR-JGH) addresses weight loss, nutritional
symptoms and impaired functional status in ambulatory patients with
advanced cancer. Exercise training is a central component of the
intervention plan for many patients. However, regular attendance for
hospital-based exercise training is difficult for patients with poor
performance status, or those that live far from the hospital. The objective
of this study was to assess the feasibility and acceptability of neuromus-
cular electrical stimulation (NMES) to facilitate improvements in physical
functioning in this patient population.
Methods: Patients who were unable to attend regular exercise training were
recruited from the CNR-JGH clinic. All assessment, instruction and follow-up
were performed by the study physiotherapist. Participants were asked to use
NMES at home on both quadricepses daily for 6 weeks (30 min, 200 ms
pulses, 50–100 Hz, with individually adjusted stimulation intensity, simulta-
neous active contraction). Compliance was measured using a patient-
completed diary. Acceptability and feasibility were assessed using compliance
scores and questionnaire. In addition, physical functioning was assessed at the
start and end of the study using performance status (PS), repeated sit-to-stand
(STS), 6-min walk test (6MWT) and SOBOE (Borg).
Results: Fifteen participants were recruited (9 (60%) male, mean (SD) age
68 (9)years) of whom 13 (87%) had PS 2–3. 5 (33%) patients did not
complete the study, four of these were for medical reasons and only one
patient dropped out because of discomfort using NMES. For patients
completing treatment, mean compliance was 57%, and NMES was well-
received with patients reporting 6 weeks’ treatment acceptable (mean score
3.9/5) and helpful (mean score 4/5). Assessment of physical functioning
also showed a general trend to improvement after NMES: PS (0.4, p=
0.03), STS (1.2 s), and breathlessness (1/10).
Conclusions: Home NMES is a feasible and acceptable exercise
intervention with potential beneficial functional impact even in advanced
cancer patients.
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Blocking interleukin-6 signal ameliorates inflammatory manifestations
and laboratories of cachexia in a patient with malignant mesothelioma: a
case study
Miho Murakami, Takaji Matsutani, Chieko Aoki, Hooi-Ming Lee, Y. Li,
Norihiro Nishimoto (Laboratory of Immune Regulation, Wakayama Medical
University, Ibaraki, 567–0085, Japan)
Background: Interleukin-6 (IL-6) is pathologically involved in cancer
cachexia especially in IL-6 producing cancers including malignant
mesothelioma (MM). Tocilizumab (TCZ) is a humanized anti-human
IL-6 receptor (IL-6R) antibody that specifically blocks IL-6 signaling.
In this study, we treated a patient with MM utilizing TCZ and
changes in the systemic manifestations and laboratories of cachexia
were examined.
Methods: A 76-year-old man with recurrent malignant pleural MM
refractory to combination chemotherapy and radiation therapy was treated
with TCZ (8 mg/kg body weight every 2 weeks) after obtaining approval
of ethics committee and patient’s informed consent. Cancer associated
manifestations were monitored including Eastern Cooperative Oncology
Group performance status (ECOG PS) scale and SF-36. Laboratories
including platelet counts (PLT), hemoglobin (Hb), CRP, albumin, rapid
turnover proteins such as prealbumin and retinol binding protein (RBP),
cholesterols, leptin, ghrelins, and vascular endothelial growth factor
(VEGF), as possible IL-6 dependent markers of cachexia, were measured
before and after TCZ treatment.
Results: During the TCZ treatment, low grade fever disappeared and ECOG
PS scale and patient’s assessment of fatigue using visual analogue scale
significantly improved, but SF-36 and face scale did not change. All the
laboratories improved within 2 weeks as shown in the table. Furthermore,
VEGF, which induces pleural effusions of MM and angiogenesis required
for the tumor growth, was also decreased into normal. Although
general status was considerably ameliorated, the patient suffered from
radiation pneumonitis caused by the previous treatment and TCZ was
discontinued, thereafter the tumor grew rapidly.
Baseline Week 1 Week 2
Parameter Unit 1st TCZ 2nd TCZ
Hb g/dL 9.4 10.4 11.1
PLT ×10
4/μL 38.7 40.4 23.7
CRP mg/dL 6.43 0.34 0.65
ALB g/dL 3 3.6 3.6
TCHO mg/dL 151 214 191
VEGF pg/mL 108 67 44
Prealbumin mg/dL 8.9 26.1 21.4
RBP mg/dL 1.6 3.6 3.2
Leptin ng/mL 1.7 1.9 1.9
Active ghrelin fmol/mL 33 21 15
Desacyl ghrelin fmol/mL 161 114 100
Conclusions: Blocking IL-6 action with TCZ ameliorates the inflam-
matory manifestations and laboratory markers of cachexia in a patient
with IL-6 producing MM, confirming that the important roles of IL-6
in MM associated cachexia. Further studies will be required to know
therapy targeting IL-6 indeed can improve cancer cachexia.
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Phase I/II study of IP-1510 a novel interleukin-1 receptor antagonist in
the management of cancer-related cachexia
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Background and objective: IP-1510 is a new synethtic peptide interleukin
1 receptor antagonist. Rat toxicity and tumor burden studies in rodents
with IP-1510 showed that this peptide had limited toxicity and suggestive
effectiveness for cachexia due to cancer. The objective of this study was to
determine whether there was any obvious toxicity in advanced cancer
patients with IP-1510 and whether any improvements were seen on their
appetite depression, performance status, and quality of life.
Methods: Eligible patients received 1 mg of IP-1510 in subcutaneous bidaily
injections. Patients underwent biweekly evaluations during the 28-day
treatment. Evaluations included full blood examination, physical check,
Karnofsky performance status, and Edmonton Symptoms Assessment Scale
(ESAS) and grip strength.
Results: Of 26 enrolled patients, 20 completed the course. Eighteen
patients chose to continue with IP-1510 treatment for another month.
Seventeen patients reduced the dose and frequency of their break-
through pain medication throughout the month. Subcutaneous adminis-
tration of IP-1510 at 1 mg bidaily was well tolerated with no serious
side effects reported. Weight stabilisation or gain was observed in 17 of
the patients. Appetite (P≤0.01) and depression (P≤0.01) scores improved
on ESAS. Performance scores also improved significantly on Karnofsky
scale (P≤0.01).
Conclusions: IP-1510 was well tolerated and safe in advanced cancer
patients. IP-1510 in the dosages reported mediated statistically significant
improvements in anorexia, physical performance, and depression in this
trial. Further larger trials are to be initiated on cachexia due to cancer and
COPD.
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